Original Article
Ipilimumab plus Dacarbazine for Previously Untreated Metastatic Melanoma
N Engl J Med 2011; 364:2517-2526June 30, 2011DOI: 10.1056/NEJMoa1104621
- Abstract
Background
Ipilimumab monotherapy (at a dose of 3 mg per kilogram of body weight), as compared with glycoprotein 100, improved overall survival in a phase 3 study involving patients with previously treated metastatic melanoma. We conducted a phase 3 study of ipilimumab (10 mg per kilogram) plus dacarbazine in patients with previously untreated metastatic melanoma.
Methods
We randomly assigned 502 patients with previously untreated metastatic melanoma, in a 1:1 ratio, to ipilimumab (10 mg per kilogram) plus dacarbazine (850 mg per square meter of body-surface area) or dacarbazine (850 mg per square meter) plus placebo, given at weeks 1, 4, 7, and 10, followed by dacarbazine alone every 3 weeks through week 22. Patients with stable disease or an objective response and no dose-limiting toxic effects received ipilimumab or placebo every 12 weeks thereafter as maintenance therapy. The primary end point was overall survival.
Results
Overall survival was significantly longer in the group receiving ipilimumab plus dacarbazine than in the group receiving dacarbazine plus placebo (11.2 months vs. 9.1 months, with higher survival rates in the ipilimumab–dacarbazine group at 1 year (47.3% vs. 36.3%), 2 years (28.5% vs. 17.9%), and 3 years (20.8% vs. 12.2%) (hazard ratio for death, 0.72; P<0.001). Grade 3 or 4 adverse events occurred in 56.3% of patients treated with ipilimumab plus dacarbazine, as compared with 27.5% treated with dacarbazine and placebo (P<0.001). No drug-related deaths or gastrointestinal perforations occurred in the ipilimumab–dacarbazine group.
Conclusions
Ipilimumab (at a dose of 10 mg per kilogram) in combination with dacarbazine, as compared with dacarbazine plus placebo, improved overall survival in patients with previously untreated metastatic melanoma. The types of adverse events were consistent with those seen in prior studies of ipilimumab; however, the rates of elevated liver-function values were higher and the rates of gastrointestinal events were lower than expected on the basis of prior studies. (Funded by Bristol-Myers Squibb; ClinicalTrials.gov number, NCT00324155.)
Media in This Article
Figure 1Kaplan–Meier Curves for Overall Survival, Progression-free Survival, and Duration of Response.Overall survival and progression-free survival in the intention-to treat population are shown in Panels A and B, respectively, and the duration of complete or partial response is shown in Panel C.
Figure 2Overall Survival According to Subgroup.ECOG denotes Eastern Cooperative Oncology Group, and ULN the upper limit of the normal range.
Article Activity
- Article
The survival rate for patients with metastatic melanoma is low, with an expected 2-year survival rate of 10 to 20%.1-3 Although dacarbazine has never been shown to improve survival in randomized, controlled studies, it has been the drug most frequently compared with new agents or combination therapies in randomized trials involving patients with melanoma.4,5 High-dose interleukin-2 is associated with durable, complete responses, with a survival benefit, in a small subgroup of patients with metastatic melanoma.6,7 Ipilimumab, a fully human, IgG1 monoclonal antibody, blocks cytotoxic T-lymphocyte–associated antigen 4 (CTLA-4), a negative regulator of T cells, and thereby augments T-cell activation and proliferation.8-12
Two separate phase 2 studies support the rationale for the current study. The first phase 2 study, involving 217 patients with previously treated metastatic melanoma, showed a dose-dependent response rate, with the highest rate of response seen in the group receiving ipilimumab at a dose of 10 mg per kilogram of body weight (11.1% in the group receiving 10 mg per kilogram vs. 4.2% and 0% in the groups receiving 3 mg per kilogram and 0.3 mg per kilogram, respectively; P=0.002).13 In the second, small, randomized, phase 2 study, involving 72 patients, treatment with a combination of dacarbazine (250 mg per square meter of body-surface area per day for 5 days every 3 weeks) and ipilimumab (3 mg per kilogram every 4 weeks for 4 doses) was associated with durable objective responses, with no new adverse events; the rationale for such combinations has been reviewed previously.14-16 We conducted a phase 3 study to determine whether ipilimumab (at a dose of 10 mg per kilogram) plus dacarbazine, as compared with dacarbazine and placebo, improves overall survival in patients with previously untreated metastatic melanoma.
Methods
Patients
Eligible patients were at least 18 years of age and had previously untreated stage III (unresectable) or stage IV melanoma with measurable lesions, an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 (with 0 indicating that the patient is fully active and able to carry on all predisease activities without restriction, and 1 indicating that the patient is restricted in physically strenuous activity but is ambulatory and able to carry out work of a light or sedentary nature, such as light housework or office work),17 and a life expectancy of 16 weeks or more. The baseline serum lactate dehydrogenase level did not affect eligibility. Patients were ineligible if they had received any prior treatment for metastatic disease. Patients who received prior adjuvant therapy were not excluded. Concomitant treatment with immunosuppressive agents or long-term use of systemic glucocorticoids (except for the management of adverse events during the course of the study) was not allowed. Patients were also ineligible if they had evidence of brain metastasis (as confirmed on imaging), primary ocular or mucosal melanoma, or autoimmune disease.
Study Oversight
The protocol was approved by the appropriate institutional review boards or independent ethics committees. The study was conducted in accordance with the ethical principles originating from the Declaration of Helsinki and with Good Clinical Practice as defined by the International Conference on Harmonization. All participating patients gave written informed consent.
The trial was designed jointly by the senior academic authors and the sponsor, Bristol-Myers Squibb. Data were collected by the sponsor and analyzed in collaboration with the senior academic authors, who vouch for the completeness and accuracy of the data and analyses. An initial draft of the manuscript was prepared jointly by a writing committee that included five academic authors, the sponsor, and a professional medical writer employed by the sponsor. All the authors contributed to subsequent drafts and made the decision to submit the manuscript for publication. All the authors signed a confidentiality disclosure agreement with the sponsor. The protocol, including the statistical analysis plan, is available with the full text of this article at NEJM.org.
Study Design and Treatment
In this multinational, randomized, double-blind, phase 3 study, patients (stratified according to metastasis stage, study site, and ECOG performance status) were randomly assigned, in a 1:1 ratio, to receive either ipilimumab (at a dose of 10 mg per kilogram) plus dacarbazine (850 mg per square meter) or dacarbazine (850 mg per square meter) plus placebo at weeks 1, 4, 7, and 10, followed by dacarbazine alone every 3 weeks through week 22 (induction phase). Treatment was discontinued if toxic effects associated with the drug or progressive disease was noted during weeks 12 to 24. At week 24, patients with stable disease or an objective response during the induction phase who did not have a dose-limiting adverse event were eligible to enter a maintenance phase in which they received placebo or ipilimumab every 12 weeks until progression of the disease, development of toxic effects, or the end of the study.
In the initial design of the study, 500 patients were to undergo randomization, and progression-free survival was to be the primary end point. Emerging data from other ipilimumab trials suggested that conventional definitions of disease progression and response incompletely reflect overall survival among patients who appear to have a long-term benefit,18,19 and in an amendment approved by the Food and Drug Administration on October 9, 2008, the primary end point was changed from progression-free survival to overall survival before the treatment assignments were revealed. No change in the size of the study was required, since it was already fully powered to assess overall survival. No interim analysis was conducted. Secondary end points included progression-free survival, the rate of best overall response (defined as the proportion of all randomly assigned patients who had a complete or partial response), the rate of disease control (defined as a complete response, a partial response, or stable disease), the time to a response, the duration of the response, and safety. Responses were defined according to the modified World Health Organization criteria as the sum of the products of bidimensional measurements of target lesions; a complete response is defined by the disappearance of all known lesions, a partial response by a decrease of at least 50% from baseline in the sum of the products of the diameters of index lesions, stable disease by failure to meet the criteria for either partial response or progressive disease, and progressive disease by a 25% increase in an existing lesion or the development of a new lesion. Tumor assessments were performed by the local investigator and by a central independent review committee.
Assessments
Radiologic and photographic tumor assessments were performed in all patients at baseline and at week 12, and in patients in whom the disease had not progressed, at weeks 16, 20, and 24 and every 6 weeks through week 48. For patients in whom the disease had not progressed and who remained in the study beyond week 48, tumor assessments were performed every 12 weeks. Patients with progressive disease who entered the follow-up phase were recommended to receive two additional tumor assessments as part of the standard of care. All efficacy end points (except survival) were based on assessments performed by the independent review committee, whose members were not aware of the treatment assignments.
Adverse events were graded with the use of the National Cancer Institute Common Terminology Criteria for Adverse Events, version 3.0 (http://ctep.cancer.gov/protocoldevelopment/electronic_applications/docs/ctcaev3.pdf). Adverse events were reported from the date of the first dose up to and including 70 days after the final dose. The study included two additional safety analyses. One was an analysis of immune-related adverse events (described previously12), which were defined as adverse events that were, according to the judgment of the investigator, associated with inflammation. The list of potential inflammation-associated adverse events was defined prospectively, in the protocol, before the database was locked. The other additional safety analysis was an exploratory analysis performed to determine whether specific adverse events were likely to be immune-mediated and associated with ipilimumab treatment. Immune-mediated adverse reactions, identified through retrospective review of the data, were adjudicated by a physician employed by the sponsor, in order to exclude noninflammatory causes of the event, such as infection or tumor progression. The immune-mediated adverse reactions included specific events of clinical interest, such as enterocolitis, hepatitis, dermatitis, neuropathies, or endocrinopathies, including hypophysitis.
Statistical Analysis
All analyses of efficacy were performed as prespecified in the protocol except for the 3-year survival rate, which was analyzed post hoc. The target number of events for the primary analysis was 416 deaths, which we estimated would give the study approximately 90% power to detect a 37% increase in median overall survival to 11 months with ipilimumab plus dacarbazine, with a corresponding hazard ratio for death of 0.727, assuming a total sample of 500 patients (250 randomly assigned to each group) and a median survival of 8 months for the patients receiving dacarbazine plus placebo. For the analysis of overall survival, a log-rank test was performed, at a two-sided alpha level of 0.05, stratified according to metastasis stage (M0, M1a, M1b, or M1c) and ECOG performance status (0 or 1), as classified at the time of randomization. The final analysis of progression-free survival was conducted on a database that was locked after 416 events had been documented, as originally planned. The hazard ratios for overall survival and progression-free survival with ipilimumab plus dacarbazine as compared with dacarbazine plus placebo, and the associated two-sided 95% confidence intervals, were estimated with the use of a stratified Cox proportional-hazards model. Survival functions were estimated with the use of the Kaplan–Meier method. A hierarchical testing procedure was implemented for a comparison of the treatment groups in the order of the following end points: overall survival, progression-free survival, rate of disease control, and rate of best overall response. Additional details of the methods are provided in the Supplementary Appendix, available at NEJM.org.
Results
Patients and Treatment
Between August 8, 2006, and January 22, 2008, a total of 250 patients were randomly assigned to receive ipilimumab plus dacarbazine (ipilimumab–dacarbazine group) and 252 were randomly assigned to receive dacarbazine plus placebo (dacarbazine group). The baseline characteristics of the patients were balanced between the two groups (Table 1Table 1
Demographic and Baseline Clinical Characteristics of the Patients.). A total of 92 patients in the ipilimumab–dacarbazine group (36.8%) and 165 patients in the dacarbazine group (65.5%) received all four doses of ipilimumab or placebo. At least one maintenance dose was administered in 43 patients in the ipilimumab–dacarbazine group (17.2%) and 53 in the dacarbazine group (21.0%). The follow-up time between the start of the study (the first visit of the first enrolled patient) and the end of the study (the last visit of the last enrolled patient) was 54 months, and the follow-up time between the time the last patient underwent randomization (the first visit of the last patient) and the end of the study was 36.6 months.
The most frequent reason for discontinuation of the study drug across the entire study was disease progression (in 46.2% of patients in the ipilimumab–dacarbazine group and 77.3% in the dacarbazine group). Discontinuation due to a drug-related adverse event was reported in 89 of the 247 patients in the ipilimumab–dacarbazine group who received at least one dose of the study drug (36.0%) and 10 of the 251 patients in the dacarbazine group who received at least one dose of the study drug (4.0%): 85 of the 247 patients (34.4%) and 10 of the 251 patients (4.0%) in the two groups, respectively, discontinued the study drug because of a drug-related adverse event after receiving treatment in the induction phase; 4 of the 43 patients in the ipilimumab–dacarbazine group who received at least one maintenance dose (9.3%) and none of the 53 patients in the dacarbazine group who received at least one maintenance dose discontinued the therapy after receiving treatment in the maintenance phase.
Therapy after disease progression was balanced between the two groups; 54.7% of the patients in the ipilimumab–dacarbazine group and 59.0% in the dacarbazine group received subsequent therapy. In the ipilimumab–dacarbazine group, 37.7% of the patients received chemotherapy, and 2% immunotherapy; in the dacarbazine group, 34.7% received chemotherapy, and 2% immunotherapy. One patient in the dacarbazine group received the BRAF inhibitor, vemurafenib, at the time of disease progression, but tumors were not routinely assessed for the presence of the BRAF V600E mutation.
Efficacy
Efficacy analyses were performed on the intention-to-treat population. A survival analysis was performed after 414 deaths occurred, 37 months after the last patient was enrolled. The median overall survival in the ipilimumab–dacarbazine group was 11.2 months (95% confidence interval [CI], 9.4 to 13.6), as compared with 9.1 months (95% CI, 7.8 to 10.5) in the dacarbazine group, with estimated survival rates in the two groups, respectively, of 47.3% and 36.3% at 1 year, 28.5% and 17.9% at 2 years, and 20.8% and 12.2% at 3 years (hazard ratio for death with ipilimumab–dacarbazine, 0.72; P<0.001) (Figure 1AFigure 1
There was a 24% reduction in the risk of progression in the ipilimumab–dacarbazine group as compared with the dacarbazine group (hazard ratio for progression, 0.76; P=0.006). The median values for progression-free survival were similar in the two groups because the first assessment of progression occurred at week 12 after the true median. After the first tumor assessment, the Kaplan–Meier curves separated (Figure 1B).
The rate of disease control (i.e., a complete or partial response or stable disease) did not differ significantly between the two groups: 33.2% in the ipilimumab–dacarbazine group and 30.2% in the dacarbazine group (P=0.41). The rate of best overall response (i.e., a complete or partial response) was 15.2% in the ipilimumab–dacarbazine group and 10.3% in the dacarbazine group (P=0.09) (Table 2Table 2
Efficacy Results.). The median duration of response among all randomly assigned patients with a complete or partial response was 19.3 months (95% CI, 12.1 to 26.1) in the ipilimumab–dacarbazine group and 8.1 months (95% CI, 5.19 to 19.8) in the dacarbazine group (P=0.03) (Figure 1C). Some patients in the study who were receiving ipilimumab had an improvement from partial response to complete response after 6 months (data not shown). Responses in the presence of new lesions were also observed, although these were not captured as part of the best overall response.
Safety
The safety analysis included all patients who underwent randomization and received at least one dose of the assigned study drug (498 patients). The adverse events reported in the safety population are listed in Table 3Table 3
Adverse Events and Immune-Related Adverse Events.. Adverse events (all grades) for which there was a higher incidence in the ipilimumab–dacarbazine group than in the dacarbazine group included elevation of alanine aminotransferase levels (in 33.2% of patients vs. 5.6%), elevation of aspartate aminotransferase levels (29.1% vs. 5.6%), diarrhea (36.4% vs. 24.7%), pruritus (29.6% vs. 8.8%), and rash (24.7% vs. 6.8%). Grade 3 or 4 adverse events occurred in 56.3% of patients receiving ipilimumab plus dacarbazine and in 27.5% of patients receiving placebo plus dacarbazine (P<0.001).
No gastrointestinal perforations were reported. No cases of hypophysitis were noted in the ipilimumab–dacarbazine group except for a single case in a patient receiving maintenance therapy that was reported on day 364 (which was outside the protocol-specified reporting window of <70 days after the last dose — a period representing 5 times the half-life of ipilimumab — and was therefore not categorized as an “on-study” event). No drug-related deaths were reported in the ipilimumab–dacarbazine group; one fatal gastrointestinal hemorrhage was reported in the dacarbazine group. Nausea and vomiting (see the table in the Supplementary Appendix) as well as myelosuppression (data not shown), which are common side effects of dacarbazine, were not increased in the ipilimumab–dacarbazine group as compared with the dacarbazine group.
The most common study-drug–related adverse events were those classified as immune-related adverse events, which were seen in 77.7% of the patients treated with ipilimumab plus dacarbazine and 38.2% of the patients treated with dacarbazine and placebo (Table 3). The most common immune-related adverse events in the ipilimumab–dacarbazine group were elevated liver-function values, with grade 3 or 4 elevations in liver-function values noted in 17.4 to 20.7% of the patients.
An alternative characterization of inflammatory events was performed in which noninflammatory causes of the event (e.g., tumor progression or infection) were ruled out (immune-mediated adverse reactions). Severe (grade 3 or higher) immune-mediated adverse reactions were seen in 38.1% of the patients in the ipilimumab–dacarbazine group and 4.4% of the patients in the dacarbazine group. The most common grade 3 or 4 immune-mediated adverse reaction was immune-mediated hepatitis, which was seen in 78 patients in the ipilimumab–dacarbazine group (31.6%) and in 6 patients in the dacarbazine group (2.4%). Grade 3 or 4 immune-mediated enterocolitis was seen in 12 patients in the ipilimumab–dacarbazine group (4.9%) and no patients in the dacarbazine group. Hepatic immune-mediated adverse reactions were generally reversible with treatment according to established guidelines specified in the research protocol. The proportion of patients who received glucocorticoids or other immunosuppressant agents after the emergence of high-grade immune-mediated hepatitis was 80.8% (63 of 78 patients, including 5 patients who received mycophenolate mofetil) in the ipilimumab–dacarbazine group and 33.3% (2 of 6 patients) in the dacarbazine group. High-grade elevations in liver-function values were normalized in 67.9% of patients in the ipilimumab–dacarbazine group, with a median time to normalization of 9.9 weeks (range, 1.0 to 56.1; interquartile range, 7.0 to 15.0). No patient died as a result of complications of immune-mediated hepatitis or enterocolitis during the course of the study.
Among the 43 patients who received ipilimumab and the 53 patients who received placebo during the maintenance phase, the most common adverse events (all grades, occurring in >5% of patients in the ipilimumab group) were rash (25.6% vs. 5.7%), pruritus (16.3% vs. 3.8%), diarrhea (14.0% vs. 5.7%), nausea (7.0% vs. 5.7%), and fatigue (9.3% vs. 3.8%). Low-grade increases in liver-function values were noted in 2 patients receiving ipilimumab during the maintenance phase. No high-grade elevations in liver-function values were noted among the patients receiving ipilimumab during the maintenance phase. High-grade adverse events during the maintenance phase were infrequent; among the grade 3 or 4 adverse events noted were colitis and diarrhea (in 1 patient) and rash or pruritus (in 3 patients). No grade 3 or 4 adverse events occurred in patients receiving placebo during the maintenance phase.
Discussion
In this phase 3 study, ipilimumab (at a dose of 10 mg per kilogram), in combination with dacarbazine (at a dose of 850 mg per square meter), as compared with dacarbazine plus placebo, was associated with a significant improvement in overall survival among patients with previously untreated metastatic melanoma. More than 50% of the patients had M1c disease (indicating the presence of visceral metastases, elevated lactate dehydrogenase levels, or both), and more than 35% had baseline elevations in lactate dehydrogenase levels — both of which are associated with poor survival.20,21 Durable objective responses were observed (median duration of best overall response, 19.3 months in the ipilimumab–dacarbazine group, vs. 8.1 months in the dacarbazine group). Prolonged survival was noted among some patients who were followed for up to 4 years. In the ipilimumab–dacarbazine group, an estimated 28.5% of the patients were alive at 2 years, and an estimated 20.8% at 3 years, as compared with an estimated 17.9% and 12.2%, respectively, in the dacarbazine group.
The rates of some high-grade adverse events in the current study differ from those in previous phase 2 studies of ipilimumab monotherapy (at a dose of 10 mg per kilogram).13,22-24 The absence of gastrointestinal perforations and the low rates of other grade 3 or 4 gastrointestinal events are in contrast to the results of phase 2 studies involving 325 patients (rate of diarrhea, 4% in this study vs. 11% in the previous studies; rate of colitis, 2% vs. 5%). No cases of hypophysitis were observed during the course of this study, whereas 2% of the patients in the previous studies had high-grade endocrinopathy. The rate of grade 3 or 4 rash was similar (1% in the current study and 2% in the previous studies). However, the rates of high-grade hepatic adverse events in the current study were higher than those in the previous studies (elevated alanine aminotransferase level, 21% vs. 8%; elevated aspartate aminotransferase level, 17% vs. 7%). The apparent shift in the rates of adverse events associated with ipilimumab may be due to its combination with dacarbazine, which is known to cause hepatotoxic effects when it is used as monotherapy.25-27 The role of systemic glucocorticoids (which were administered to manage hepatic events) in the apparent reduction in gastrointestinal and endocrine events is undefined.
In summary, this trial showed that there was a significant improvement in overall survival among patients with previously untreated metastatic melanoma who received ipilimumab plus dacarbazine as compared with dacarbazine plus placebo. Adverse events other than those typically seen with dacarbazine or ipilimumab therapy were not identified. An increase in liver-function values is an important side effect that was observed more frequently than expected with the combination therapy. Other ipilimumab-associated adverse events (enterocolitis and endocrinopathy) were observed, albeit at a rate that was lower than expected. The key side effects of ipilimumab were managed through adherence to treatment according to well-established guidelines, including the administration of systemic glucocorticoids or other immunosuppressant agents.
Supported by Bristol-Myers Squibb.
Disclosure forms provided by the authors are available with the full text of this article at NEJM.org.
This article (10.1056/NEJMoa1104621) was published on June 5, 2011, and updated on June 6, 2011, at NEJM.org.
We thank the patients and all the investigators who participated in the study and the representatives of the sponsor, Haolan Lu, Ph.D., Mamatha Kodidela, and Veerle de Pril, for their support in statistical analysis. Professional medical writing and editorial assistance were provided by Sudha Vemuri, Ph.D., and Ananya Bhattacharya, Ph.D., of Bristol-Myers Squibb.
Source Information
From the Institute Gustave, Roussy, Villejuif (C.R.); Centre Hospitalier, Lyon Sud, Pierre Bénite (L.T.); Hôpital Saint Louis University, Paris (C.L.); and Hôpital de la Timone, Marseille (J.-J.G.) — all in France; Dnepropetrovsk State Medical Center, Dnepropetrovsk, Ukraine (I.B.); The Angeles Clinic and Research Institute, Santa Monica, CA (S.O.); H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL (J.W.); University Medical Center, Tuebingen, Germany (C.G.); Cliniques Universitaires Saint-Luc, Brussels (J.-F.B.) and Bristol-Myers Squibb, Braine-l'Alleud (S.F.) — both in Belgium; Istituto Europeo di Oncologia, Milan (A.T.) and University Hospital of Siena, Siena (M.M.) — both in Italy; Mid Essex Hospitals National Health Service Trust, Essex, United Kingdom (N.D.); Oncology Specialists, Park Ridge, IL (J.R.); University of Kiel, Kiel, Germany (A.H.); Lady Davis Institute and Segal Cancer Center, Jewish General Hospital, McGill University, Montreal (W.M.); Hospital Clinic, Barcelona, Spain (P.G.); Hadassah Hebrew University Hospital, Sharett Institute of Oncology, Jerusalem, Israel (M.L.); Medical University of Vienna, Vienna (K.H.); Medimmune, Gaithersburg, MD (R.I.); Bristol-Myers Squibb, Wallingford, CT (T.-T.C., A.H.); Bristol-Myers Squibb, Lawrenceville, NJ (R.H.); and Memorial Sloan-Kettering Cancer Center, New York (J.D.W.).
Address reprint requests to Dr. Wolchok at Memorial Sloan-Kettering Cancer Center, 1275 York Ave., New York, NY 10021, or at wolchokj@mskcc.org.
- References
References
1
Middleton MR Grob JJ Aaronson N
Web of Science | Medline2
Falkson CI Ibrahim J Kirkwood JM Coates AS Atkins MB Blum RH
Web of Science | Medline3
Rusthoven JJ Quirt IC Iscoe NA
Web of Science | Medline4
Julia F Thomas L Dumontet C Dalle S
CrossRef | Web of Science | Medline5
Agarwala SS
CrossRef | Web of Science | Medline6
Atkins MB Lotze MT Dutcher JP
Web of Science | Medline7
Atkins MB, Kunkel L, Sznol M, Rosenberg SA. High-dose recombinant interleukin-2 therapy in patients with metastatic melanoma: long-term survival update Cancer J Sci Am 2000;6:Suppl 1:S11-S14.
8
Melero I Hervas-Stubbs S Glennie M Pardoll DM Chen L
CrossRef | Web of Science | Medline9
O'Day SJ Hamid O Urba WJ
CrossRef | Web of Science | Medline10
Fong L Small EJ
CrossRef | Web of Science | Medline11
Robert C Ghiringhelli F
Web of Science | Medline12
Hodi FS O'Day SJ McDermott DF
Free Full Text | Web of Science | Medline13
Wolchok JD Neyns B Linette G
CrossRef | Web of Science | Medline14
Hersh EM O'Day SJ Powderly J
CrossRef | Web of Science | Medline15
Mokyr MB Kalinichenko T Gorelik L Bluestone JA
Web of Science | Medline16
Zitvogel L Apetoh L Ghiringhelli F Kroemer G
CrossRef | Web of Science | Medline17
Oken MM Creech RH Tormey DC
CrossRef | Web of Science | Medline18
Wolchok JD Hoos A O'Day S
CrossRef | Web of Science | Medline19
Hoos A, Eggermont AM, Janetzki S, et al. Improved endpoints for cancer immunotherapy trials. J Natl Cancer Inst. 2010;102:1388-97.
20
Balch CM Gershenwald JE Soong SJ
CrossRef | Web of Science | Medline21
Bedikian AY Johnson MM Warneke CL
CrossRef | Web of Science | Medline22
Weber J Thompson JA Hamid O
CrossRef | Web of Science | Medline23
O'Day SJ Maio M Chiarion-Sileni V
CrossRef | Web of Science | Medline24
Schmidt H Hamid O Nissan A
CrossRef25
Dancygier H Runne U Leuschner U Milbradt R Classen M
Web of Science | Medline26
Greenstone MA Dowd PM Mikhailidis DP Scheuer PJ
CrossRef | Web of Science | Medline27
Frosch PJ Czarnetzki BM Macher E Grundmann E Gottschalk I
CrossRef | Web of Science | Medline
- Citing Articles (1619)
Citing Articles
1
Patrick A. Ott, F. Stephen Hodi, Howard L. Kaufman, Jon M. Wigginton, Jedd D. Wolchok. . (2017) Combination immunotherapy: a road map. Journal for ImmunoTherapy of Cancer 5:1.
CrossRef2
Jun Wang, Ruirong Yuan, Wenru Song, Jingwei Sun, Delong Liu, Zihai Li. . (2017) PD-1, PD-L1 (B7-H1) and Tumor-Site Immune Modulation Therapy: The Historical Perspective. Journal of Hematology & Oncology 10:1.
CrossRef3
Gerardo Botti, Federica Fratangelo, Margherita Cerrone, Giuseppina Liguori, Monica Cantile, Anna Maria Anniciello, Stefania Scala, Crescenzo D’Alterio, Chiara Trimarco, Angela Ianaro, Giuseppe Cirino, Corrado Caracò, Maria Colombino, Giuseppe Palmieri, Stefano Pepe, Paolo Antonio Ascierto, Francesco Sabbatino, Giosuè Scognamiglio. . (2017) COX-2 expression positively correlates with PD-L1 expression in human melanoma cells. Journal of Translational Medicine 15:1.
CrossRef4
Tala Achkar, Ahmad A. Tarhini. . (2017) The use of immunotherapy in the treatment of melanoma. Journal of Hematology & Oncology 10:1.
CrossRef5
Luc Cabel, Elika Loir, Gwenaelle Gravis, Pernelle Lavaud, Christophe Massard, Laurence Albiges, Giulia Baciarello, Yohann Loriot, Karim Fizazi. . (2017) Long-term complete remission with ipilimumab in metastatic castrate-resistant prostate cancer: case report of two patients. Journal for ImmunoTherapy of Cancer 5:1.
CrossRef6
Sacha Gnjatic, Vincenzo Bronte, Laura Rosa Brunet, Marcus O. Butler, Mary L. Disis, Jérôme Galon, Leif G. Hakansson, Brent A. Hanks, Vaios Karanikas, Samir N. Khleif, John M. Kirkwood, Lance D. Miller, Dolores J. Schendel, Isabelle Tanneau, Jon M. Wigginton, Lisa H. Butterfield. . (2017) Identifying baseline immune-related biomarkers to predict clinical outcome of immunotherapy. Journal for ImmunoTherapy of Cancer 5:1.
CrossRef7
Raphael B. Moreira, Lana Hamieh, Evisa Gjini, Ana Lako, Katherine M. Krajewski, Charles H. Yoon, Patrick A. Ott. . (2017) Regression of multifocoal in transit melanoma metastases after palliative resection of dominant masses and 2 years after treatment with ipilimumab. Journal for ImmunoTherapy of Cancer 5:1.
CrossRef8
Wenjun Wang, Puyi Lie, Minzhang Guo, Jianxing He. . (2017) Risk of hepatotoxicity in cancer patients treated with immune checkpoint inhibitors: A systematic review and meta-analysis of published data. International Journal of Cancer 141:5, 1018-1028.
CrossRef9
Dirk Schadendorf, James Larkin, Jedd Wolchok, F. Stephen Hodi, Vanna Chiarion-Sileni, Rene Gonzalez, Piotr Rutkowski, Jean-Jacques Grob, C. Lance Cowey, Christopher Lao, John Wagstaff, Margaret K. Callahan, Michael A. Postow, Michael Smylie, Pier Francesco Ferrucci, Reinhard Dummer, Andrew Hill, Fiona Taylor, Javier Sabater, Dana Walker, Srividya Kotapati, Amy Abernethy, Georgina V. Long. . (2017) Health-related quality of life results from the phase III CheckMate 067 study. European Journal of Cancer 82, 80-91.
CrossRef10
Amaury Daste, Charlotte Domblides, Marine Gross-goupil, Camille Chakiba, Amandine Quivy, Valérie Cochin, Erwan de Mones, Nicolas Larmonier, Pierre Soubeyran, Alain Ravaud. . (2017) Immune checkpoint inhibitors and elderly people: A review. European Journal of Cancer 82, 155-166.
CrossRef11
Bhargavi Pulluri, Abhijeet Kumar, Montaser Shaheen, Joanne Jeter, Srinath Sundararajan. . (2017) Tumor microenvironment changes leading to resistance of immune checkpoint inhibitors in metastatic melanoma and strategies to overcome resistance. Pharmacological Research 123, 95-102.
CrossRef12
Sheng Zhang, Fei Liang, Wenfeng Li, Qing Wang. . (2017) Risk of treatment-related mortality in cancer patients treated with ipilimumab: A systematic review and meta-analysis. European Journal of Cancer 83, 71-79.
CrossRef13
Andrea Forschner, Susann-Cathrin Olthof, Brigitte G?ckel, Peter Martus, Werner Vach, Christian la Foug?re, Konstantin Nikolaou, Ulrike Keim, Thomas Kurt Eigentler, Claus Garbe, Christina Pfannenberg. . (2017) Impact of 18F-FDG-PET/CT on surgical management in patients with advanced melanoma: an outcome based analysis. European Journal of Nuclear Medicine and Molecular Imaging 44:8, 1312-1318.
CrossRef14
Lingeng Lu, Yalai Bai, Zuoheng Wang. . (2017) Elevated T cell activation score is associated with improved survival of breast cancer. Breast Cancer Research and Treatment 164:3, 689-696.
CrossRef15
Leisha A. Emens, Paolo A. Ascierto, Phillip K. Darcy, Sandra Demaria, Alexander M.M. Eggermont, William L. Redmond, Barbara Seliger, Francesco M. Marincola. . (2017) Cancer immunotherapy: Opportunities and challenges in the rapidly evolving clinical landscape. European Journal of Cancer 81, 116-129.
CrossRef16
Audrey Monneur, Jilliana Monnier, Caroline Gaudy-Marqueste, Raynier Devillier, Renaud Sabatier. . (2017) Immune checkpoints inhibitors for solid tumours after allogeneic haematopoietic stem-cell transplantation: About four clinical cases. European Journal of Cancer 81, 138-141.
CrossRef17
Kate Poropatich, Joel Fontanarosa, Sandeep Samant, Jeffrey A. Sosman, Bin Zhang. . (2017) Cancer Immunotherapies: Are They as Effective in the Elderly?. Drugs & Aging 11.
CrossRef18
Bernardo Leon Rapoport, Ronwyn van Eeden, Vincent Sibaud, Joel B. Epstein, Jean Klastersky, Matti Aapro, Devan Moodley. . (2017) Supportive care for patients undergoing immunotherapy. Supportive Care in Cancer 121.
CrossRef19
T. Read, S. Webber, J. Tan, M. Wagels, H. Schaider, H.P. Soyer, B.M. Smithers. . (2017) Diphenylcyclopropenone for the treatment of cutaneous in-transit melanoma metastases - results of a prospective, non-randomized, single-centre study. Journal of the European Academy of Dermatology and Venereology 27.
CrossRef20
Natasha Lakin, Robert Rulach, Stefan Nowicki, Kathreena M. Kurian. . (2017) Current Advances in Checkpoint Inhibitors: Lessons from Non-Central Nervous System Cancers and Potential for Glioblastoma. Frontiers in Oncology 7.
CrossRef21
Prajwal Boddu, Hagop Kantarjian, Guillermo Garcia-Manero, James Allison, Padmanee Sharma, Naval Daver. . (2017) The emerging role of immune checkpoint based approaches in AML and MDS. Leukemia & Lymphoma 617, 1-13.
CrossRef22
Enrico Franceschi, Santino Minichillo, Alba A. Brandes. . (2017) Pharmacotherapy of Glioblastoma: Established Treatments and Emerging Concepts. CNS Drugs 18.
CrossRef23
James Larkin, David Minor, Sandra D'Angelo, Bart Neyns, Michael Smylie, Wilson H. Miller, Ralf Gutzmer, Gerald Linette, Bartosz Chmielowski, Christopher D. Lao, Paul Lorigan, Kenneth Grossmann, Jessica C. Hassel, Mario Sznol, Adil Daud, Jeffrey Sosman, Nikhil Khushalani, Dirk Schadendorf, Christoph Hoeller, Dana Walker, George Kong, Christine Horak, Jeffrey Weber. . (2017) Overall Survival in Patients With Advanced Melanoma Who Received Nivolumab Versus Investigator?s Choice Chemotherapy in CheckMate 037: A Randomized, Controlled, Open-Label Phase III Trial. Journal of Clinical Oncology, JCO.2016.71.802.
CrossRef24
Cong Luo, Jiayu Shen. . (2017) Research progress in advanced melanoma. Cancer Letters 397, 120-126.
CrossRef25
Elyse Shuk, Alexander N. Shoushtari, Jason Luke, Michael A. Postow, Maggie Callahan, James J. Harding, Katherine G. Roth, Marisa Flavin, Adrian Granobles, Jana Christian, Geoffrey Gold, Maria Schoenhammer, Mallorie Gordon, Nicholas Cimaglia, Robert Dyson, Noah Goodman-Davis, Marta N. Colgan, Itisha S. Jefferson, Rodrigo Munhoz, Sandra D’Angelo, Jedd Wolchok, Paul Chapman, Ping Chi, Richard D. Carvajal, Jennifer L. Hay. . (2017) Patient perspectives on ipilimumab across the melanoma treatment trajectory. Supportive Care in Cancer 25:7, 2155-2167.
CrossRef26
Kamran A. Ahmed, Sungjune Kim, Louis B. Harrison. . (2017) Novel Opportunities to Use Radiation Therapy with Immune Checkpoint Inhibitors for Melanoma Management. Surgical Oncology Clinics of North America 26:3, 515-529.
CrossRef27
Roy A. Raad, Rajni Kannan, Kathleen Madden, Anna Pavlick. . (2017) Ipilimumab-Induced Organizing Pneumonia on 18F-FDG PET/CT in a Patient With Malignant Melanoma. Clinical Nuclear Medicine 42:7, e345-e346.
CrossRef28
Vickie R. Shannon. . (2017) Pneumotoxicity associated with immune checkpoint inhibitor therapies. Current Opinion in Pulmonary Medicine 23:4, 305-316.
CrossRef29
M. B. Atkins, J. I. Clark, D. I. Quinn. . (2017) Immune checkpoint inhibitors in advanced renal cell carcinoma: experience to date and future directions. Annals of Oncology 28:7, 1484-1494.
CrossRef30
Sebastian Scheich, Martin Sebastian. . (2017) Immuncheckpointinhibitoren. Der Onkologe 23:7, 575-584.
CrossRef31
Claire Jacquin-Porretaz, Charl?e Nardin, Eve Puzenat, Blandine Roche-Kubler, Fran?ois Aubin, Franck Schillo, Lucie Meillet, Sophie Borot, Lucine Vuitton, St?phane Koch, Virginie Westeel, Pascale Jacoulet, Jean Paul Cervoni, Vincent Di Martino, Adrien Chauchet, Daniel Wendling, Marc Badoz, Didier Ducloux, Laurent Tatu, Bernard Delbosc. . (2017) Effets secondaires des inhibiteurs de checkpoint utilis?s dans le traitement des m?lanomes et d?autres cancers. La Presse M?dicale.
CrossRef32
Stefano Guadagni, Giammaria Fiorentini, Marco Clementi, Giancarlo Palumbo, Alessandro Chiominto, Sonia Cappelli, Francesco Masedu, Marco Valenti. . (2017) Melphalan hypoxic perfusion with hemofiltration for melanoma locoregional metastases in the pelvis. Journal of Surgical Research 215, 114-124.
CrossRef33
Claire F. Friedman, Jedd D. Wolchok. . (2017) Checkpoint inhibition and melanoma: Considerations in treating the older adult. Journal of Geriatric Oncology 8:4, 237-241.
CrossRef34
Kimberly M. Komatsubara, Richard D. Carvajal. . (2017) Immunotherapy for the Treatment of Uveal Melanoma: Current Status and Emerging Therapies. Current Oncology Reports 19:7.
CrossRef35
Amélie Boespflug, Julie Caramel, Stephane Dalle, Luc Thomas. . (2017) Treatment of NRAS -mutated advanced or metastatic melanoma: rationale, current trials and evidence to date. Therapeutic Advances in Medical Oncology 9:7, 481-492.
CrossRef36
Reinhart Speeckaert, Nanja van Geel. . (2017) Targeting CTLA-4, PD-L1 and IDO to modulate immune responses in vitiligo. Experimental Dermatology 26:7, 630-634.
CrossRef37
Mario Sznol, Michael A. Postow, Marianne J. Davies, Anna C. Pavlick, Elizabeth R. Plimack, Montaser Shaheen, Colleen Veloski, Caroline Robert. . (2017) Endocrine-related adverse events associated with immune checkpoint blockade and expert insights on their management. Cancer Treatment Reviews 58, 70-76.
CrossRef38
Jeong A. Park, Nai-Kong V. Cheung. . (2017) Limitations and opportunities for immune checkpoint inhibitors in pediatric malignancies. Cancer Treatment Reviews 58, 22-33.
CrossRef39
Yasuhiro Fujisawa, Koji Yoshino, Atsushi Otsuka, Takeru Funakoshi, Taku Fujimura, Yuki Yamamoto, Hiroo Hata, Masahiko Gosho, Ryota Tanaka, Kei Yamaguchi, Yumi Nonomura, Ikuko Hirai, Sadanori Furudate, Hisako Okuhira, Keisuke Imafuku, Megumi Aoki, Shigeto Matsushita. . (2017) Fluctuations in routine blood count might signal severe immune-related adverse events in melanoma patients treated with nivolumab.. Journal of Dermatological Science.
CrossRef40
Georgina V Long, Victoria Atkinson, Jonathan S Cebon, Michael B Jameson, Bernie M Fitzharris, Catriona M McNeil, Andrew G Hill, Antoni Ribas, Michael B Atkins, John A Thompson, Wen-Jen Hwu, F Stephen Hodi, Alexander M Menzies, Alexander D Guminski, Richard Kefford, Benjamin Y Kong, Babak Tamjid, Archana Srivastava, Anna J Lomax, Mohammed Islam, Xinxin Shu, Scot Ebbinghaus, Nageatte Ibrahim, Matteo S Carlino. . (2017) Standard-dose pembrolizumab in combination with reduced-dose ipilimumab for patients with advanced melanoma (KEYNOTE-029): an open-label, phase 1b trial. The Lancet Oncology.
CrossRef41
C. Br?ggemann, M. C. Kirchberger, S. M. Goldinger, B. Weide, A. Konrad, M. Erdmann, D. Schadendorf, R. S. Croner, L. Kr?henb?hl, K. C. K?hler, C. Hafner, W. Leisgang, F. Kiesewetter, R. Dummer, G. Schuler, M. St?rzl, L. Heinzerling. . (2017) Predictive value of PD-L1 based on mRNA level in the treatment of stage IV melanoma with ipilimumab. Journal of Cancer Research and Clinical Oncology 55.
CrossRef42
Sapna P. Patel, Dae Won Kim, Roland L. Bassett, Suzanne Cain, Edwina Washington, Wen-Jen Hwu, Kevin B. Kim, Nicholas E. Papadopoulos, Jade Homsi, Patrick Hwu, Agop Y. Bedikian. . (2017) A phase II study of ipilimumab plus temozolomide in patients with metastatic melanoma. Cancer Immunology, Immunotherapy 33.
CrossRef43
Clélia Coutzac, Julien Adam, Emilie Soularue, Michael Collins, Antoine Racine, Charlotte Mussini, Lisa Boselli, Nyam Kamsukom, Christine Mateus, Mélinda Charrier, Lydie Cassard, David Planchard, Vincent Ribrag, Karim Fizazi, Yohann Loriot, Patricia Lepage, Jean-Yves Scoazec, Caroline Robert, Franck Carbonnel, Nathalie Chaput. . (2017) Colon Immune-Related Adverse Events: Anti-CTLA-4 and Anti-PD-1 Blockade Induce Distinct Immunopathological Entities. Journal of Crohn's and Colitis.
CrossRef44
Debora Basile, Silvio Ken Garattini, Marta Bonotto, Elena Ongaro, Mariaelena Casagrande, Monica Cattaneo, Valentina Fanotto, Elisa De Carlo, Fotios Loupakis, Federica Urbano, Francesca V. Negri, Nicoletta Pella, Marco Russano, Oronzo Brunetti, Mario Scartozzi, Daniele Santini, Nicola Silvestris, Andrea Casadei Gardini, Marco Puzzoni, Lorenzo Calvetti, Nadia Cardarelli, Giuseppe Aprile. . (2017) Immunotherapy for colorectal cancer: where are we heading?. Expert Opinion on Biological Therapy 17:6, 709-721.
CrossRef45
Randy F. Sweis, Jason J. Luke. . (2017) Mechanistic and pharmacologic insights on immune checkpoint inhibitors. Pharmacological Research 120, 1-9.
CrossRef46
Jennifer D. Possick. . (2017) Pulmonary Toxicities from Checkpoint Immunotherapy for Malignancy. Clinics in Chest Medicine 38:2, 223-232.
CrossRef47
Klaus G. Griewank, Bastian Schilling. . (2017) Next-Generation Sequencing to Guide Treatment of Advanced Melanoma. American Journal of Clinical Dermatology 18:3, 303-310.
CrossRef48
Christopher D. Zahm, Viswa Teja Colluru, Douglas G. McNeel. . (2017) DNA vaccines for prostate cancer. Pharmacology & Therapeutics 174, 27-42.
CrossRef49
Kasper Guldbrandsen, Helle Hendel, Seppo Langer, Barbara Fischer. . (2017) Nuclear Molecular Imaging Strategies in Immune Checkpoint Inhibitor Therapy. Diagnostics 7:2, 23.
CrossRef50
Jessica C. Hassel, Lucie Heinzerling, Jens Aberle, Oliver Bähr, Thomas K. Eigentler, Marc-Oliver Grimm, Victor Grünwald, Jan Leipe, Niels Reinmuth, Julia K. Tietze, Jörg Trojan, Lisa Zimmer, Ralf Gutzmer. . (2017) Combined immune checkpoint blockade (anti-PD-1/anti-CTLA-4): Evaluation and management of adverse drug reactions. Cancer Treatment Reviews 57, 36-49.
CrossRef51
N. Chaput, P. Lepage, C. Coutzac, E. Soularue, K. Le Roux, C. Monot, L. Boselli, E. Routier, L. Cassard, M. Collins, T. Vaysse, L. Marthey, A. Eggermont, V. Asvatourian, E. Lanoy, C. Mateus, C. Robert, F. Carbonnel. . (2017) Baseline gut microbiota predicts clinical response and colitis in metastatic melanoma patients treated with ipilimumab. Annals of Oncology 28:6, 1368-1379.
CrossRef52
Thomas K. Eigentler, Corinna Mühlenbein, Markus Follmann, Dirk Schadendorf, Claus Garbe. . (2017) S3-Leitlinie Diagnostik, Therapie und Nachsorge des Melanoms - Update 2015/2016, Kurzversion 2.0. JDDG: Journal der Deutschen Dermatologischen Gesellschaft 15:6, e1-e41.
CrossRef53
Joao Paulo da Silveira Nogueira Lima, Mina Georgieva, Benjamin Haaland, Gilberto de Lima Lopes. . (2017) A systematic review and network meta-analysis of immunotherapy and targeted therapy for advanced melanoma. Cancer Medicine 6:6, 1143-1153.
CrossRef54
Matthew Foote, Tavis Read, Janine Thomas, Michael Wagels, Bryan Burmeister, B. Mark Smithers. . (2017) Results of a phase II, open-label, non-comparative study of intralesional PV-10 followed by radiotherapy for the treatment of in-transit or metastatic melanoma. Journal of Surgical Oncology 115:7, 891-897.
CrossRef55
Maria Giovanna Dal Bello, Angela Alama, Simona Coco, Irene Vanni, Francesco Grossi. . (2017) Understanding the checkpoint blockade in lung cancer immunotherapy. Drug Discovery Today.
CrossRef56
Veronica De Rosa, Francesca Di Rella, Antonio Di Giacomo, Giuseppe Matarese. . (2017) Regulatory T cells as suppressors of anti-tumor immunity: Role of metabolism. Cytokine & Growth Factor Reviews 35, 15-25.
CrossRef57
Antje Hoering, Brian Durie, Hongwei Wang, John Crowley. . (2017) End points and statistical considerations in immuno-oncology trials: impact on multiple myeloma. Future Oncology 13:13, 1181-1193.
CrossRef58
Chunyan Hao, Jinhui Tian, Huiling Liu, Fei Li, Hongxia Niu, Bingdong Zhu. . (2017) Efficacy and safety of anti-PD-1 and anti-PD-1 combined with anti-CTLA-4 immunotherapy to advanced melanoma. Medicine 96:26, e7325.
CrossRef59
Ganesh M. Shankar, Bryan D. Choi, Benjamin L. Grannan, Kevin Oh, John H. Shin. . (2017) Effect of Immunotherapy Status on Outcomes in Patients With Metastatic Melanoma to the Spine. SPINE 42:12, E721-E725.
CrossRef60
Carmen Stecher, Claire Battin, Judith Leitner, Markus Zettl, Katharina Grabmeier-Pfistershammer, Christoph Höller, Gerhard J. Zlabinger, Peter Steinberger. . (2017) PD-1 Blockade Promotes Emerging Checkpoint Inhibitors in Enhancing T Cell Responses to Allogeneic Dendritic Cells. Frontiers in Immunology 8.
CrossRef61
Upendra P. Hegde, Bijay Mukherji. . (2017) Current status of chimeric antigen receptor engineered T cell-based and immune checkpoint blockade-based cancer immunotherapies. Cancer Immunology, Immunotherapy 12.
CrossRef62
Aya Agha, Ahmad A. Tarhini. . (2017) Adjuvant Therapy for Melanoma. Current Oncology Reports 19:5.
CrossRef63
Alexander M Menzies, Georgina V Long. . (2017) Optimum dosing of ipilimumab in melanoma: too little, too late?. The Lancet Oncology 18:5, 558-559.
CrossRef64
Paolo A Ascierto, Michele Del Vecchio, Caroline Robert, Andrzej Mackiewicz, Vanna Chiarion-Sileni, Ana Arance, Céleste Lebbé, Lars Bastholt, Omid Hamid, Piotr Rutkowski, Catriona McNeil, Claus Garbe, Carmen Loquai, Brigitte Dreno, Luc Thomas, Jean-Jacques Grob, Gabriella Liszkay, Marta Nyakas, Ralf Gutzmer, Joanna Pikiel, Florent Grange, Christoph Hoeller, Virginia Ferraresi, Michael Smylie, Dirk Schadendorf, Laurent Mortier, Inge Marie Svane, Delphine Hennicken, Anila Qureshi, Michele Maio. . (2017) Ipilimumab 10 mg/kg versus ipilimumab 3 mg/kg in patients with unresectable or metastatic melanoma: a randomised, double-blind, multicentre, phase 3 trial. The Lancet Oncology 18:5, 611-622.
CrossRef65
Benjamin P. Davis, Zuhair K. Ballas. . (2017) Biologic response modifiers: Indications, implications, and insights. Journal of Allergy and Clinical Immunology 139:5, 1445-1456.
CrossRef66
Jung-Soo Pyo, Guhyun Kang. . (2017) Immunotherapy in advanced melanoma: a network meta-analysis. Immunotherapy 9:6, 471-479.
CrossRef67
Tresa McGranahan, Gordon Li, Seema Nagpal. . (2017) History and current state of immunotherapy in glioma and brain metastasis. Therapeutic Advances in Medical Oncology 9:5, 347-368.
CrossRef68
V. H. Koelzer, K. Glatz, L. Bubendorf, A. Weber, A. Gaspert, G. Cathomas, A. Lugli, A. Zippelius, W. Kempf, K. D. Mertz. . (2017) Pathologie der Nebenwirkungen von Immune-Checkpoint-Inhibitoren. Der Pathologe 38:3, 197-208.
CrossRef69
Jingyu Zhang, Dai Liu, Guangfu Li, Kevin F. Staveley-O’Carroll, Julie N. Graff, Zihai Li, Jennifer D. Wu. . (2017) Antibody-mediated neutralization of soluble MIC significantly enhances CTLA4 blockade therapy. Science Advances 3:5, e1602133.
CrossRef70
I. Escandell, J.M. Martín, E. Jordá. . (2017) Novedades en inmunología del melanoma. Actas Dermo-Sifiliográficas.
CrossRef71
Lydia Dyck, Kingston H.G. Mills. . (2017) Immune checkpoints and their inhibition in cancer and infectious diseases. European Journal of Immunology 47:5, 765-779.
CrossRef72
Rakesh R. Ramjiawan, Arjan W. Griffioen, Dan G. Duda. . (2017) Anti-angiogenesis for cancer revisited: Is there a role for combinations with immunotherapy?. Angiogenesis 20:2, 185-204.
CrossRef73
Emilie Bernichon, Chloé Rancoule, Alexis Vallard, Julien Langrand-Escure, Benoîte Mery, Jean-Baptiste Guy, Nicolas Magné. . (2017) Immunothérapie : après le focus sur les voies de signalisation, l’activation d’un système. Bulletin du Cancer 104:5, 462-475.
CrossRef74
Avinash Gupta, Fabio Gomes, Paul Lorigan. . (2017) The role for chemotherapy in the modern management of melanoma. Melanoma Management 4:2, 125-136.
CrossRef75
Daniel Y Wang, Douglas B Johnson. . (2017) When to consider alternatives to front-line immune therapies in metastatic melanoma. Melanoma Management 4:2, 71-74.
CrossRef76
S. Bockel, D. Antoni, É. Deutsch, F. Mornex. . (2017) Immunothérapie et radiothérapie. Cancer/Radiothérapie 21:3, 244-255.
CrossRef77
Manohan Sinnadurai, Kerrie L. McDonald. . (2017) Immune checkpoint inhibition and its relationship with hypermutation phenoytype as a potential treatment for Glioblastoma. Journal of Neuro-Oncology 132:3, 359-372.
CrossRef78
B. Martínez-Amores Martínez, F.J. Vicente Martín, M. Durán Poveda, R. Molina Villaverde. . (2017) Melanoma. Medicine - Programa de Formación Médica Continuada Acreditado 12:33, 1980-1989.
CrossRef79
Laila Ritsma, Ipsita Dey-Guha, Nilesh Talele, Xavier Sole, Salony, Joeeta Chowdhury, Kenneth N. Ross, Sridhar Ramaswamy, Salvatore V Pizzo. . (2017) Integrin β1 activation induces an anti-melanoma host response. PLOS ONE 12:4, e0175300.
CrossRef80
Danielle M. Lussier, Nicole T. Appel, John L. Johnson, Joseph N. Blattman. . 2017. Immune Checkpoint Blockade: Subjugation of the Masses. Osteosarcoma - Biology, Behavior and Mechanisms.
CrossRef81
Mario Martínez Soldevilla, Helena Villanueva, Fernando Pastor. . 2017. Aptamers as a Promising Therapeutic Tool for Cancer Immunotherapy. Immunotherapy - Myths, Reality, Ideas, Future.
CrossRef82
Adi Nosrati, Katy K Tsai, Simone M Goldinger, Paul Tumeh, Barbara Grimes, Kimberly Loo, Alain P Algazi, Thi Dan Linh Nguyen-Kim, Mitchell Levesque, Reinhard Dummer, Omid Hamid, Adil Daud. . (2017) Evaluation of clinicopathological factors in PD-1 response: derivation and validation of a prediction scale for response to PD-1 monotherapy. British Journal of Cancer 116:9, 1141-1147.
CrossRef83
June Y. Hou, Caitlin Baptiste, Radhika Bangalore Hombalegowda, Ana I. Tergas, Rebecca Feldman, Nathaniel L. Jones, Sudeshna Chatterjee-Paer, Ama Bus-Kwolfski, Jason D. Wright, William M. Burke. . (2017) Vulvar and vaginal melanoma: A unique subclass of mucosal melanoma based on a comprehensive molecular analysis of 51 cases compared with 2253 cases of nongynecologic melanoma. Cancer 123:8, 1333-1344.
CrossRef84
Paola Queirolo, Beatrice Dozin, Anna Morabito, Barbara Banelli, Patrizia Piccioli, Cristiana Fava, Claudio Leo, Roberta Carosio, Stefania Laurent, Vincenzo Fontana, Pier Francesco Ferrucci, Chiara Martinoli, Emilia Cocorocchio, Angelo Battaglia, Paolo A. Ascierto, Mariaelena Capone, Ester Simeone, Federica De Galitiis, Elena Pagani, Gian Carlo Antonini Cappellini, Paolo Marchetti, Michele Guida, Stefania Tommasi, Mario Mandalà, Barbara Merelli, Pietro Quaglino, Paolo Fava, Massimo Guidoboni, Massimo Romani, Francesco Spagnolo, Maria Pia Pistillo. . (2017) Association of CTLA-4 Gene Variants with Response to Therapy and Long-term Survival in Metastatic Melanoma Patients Treated with Ipilimumab: An Italian Melanoma Intergroup Study. Frontiers in Immunology 8.
CrossRef85
Junbao Yang, Maris S. Jones, Romela Irene Ramos, Alfred A. Chan, Agnes F. Lee, Leland J. Foshag, Peter A. Sieling, Mark B. Faries, Delphine J. Lee. . (2017) Insights into Local Tumor Microenvironment Immune Factors Associated with Regression of Cutaneous Melanoma Metastases by Mycobacterium bovis Bacille Calmette–Guérin. Frontiers in Oncology 7.
CrossRef86
A. D. Ricart. . (2017) Drug-induced liver injury in Oncology. Annals of Oncology.
CrossRef87
Jason J. Luke, Keith T. Flaherty, Antoni Ribas, Georgina V. Long. . (2017) Targeted agents and immunotherapies: optimizing outcomes in melanoma. Nature Reviews Clinical Oncology 34.
CrossRef88
Elisabetta Trino, Cristina Mantovani, Serena Badellino, Umberto Ricardi, Andrea Riccardo Filippi. . (2017) Radiosurgery/stereotactic radiotherapy in combination with immunotherapy and targeted agents for melanoma brain metastases. Expert Review of Anticancer Therapy 17:4, 347-356.
CrossRef89
Omar Abdel-Rahman, Hani Oweira, Ulf Petrausch, Daniel Helbling, Jan Schmidt, Meinrad Mannhart, Arianeb Mehrabi, Othmar Schöb, Anwar Giryes. . (2017) Immune-related ocular toxicities in solid tumor patients treated with immune checkpoint inhibitors: a systematic review. Expert Review of Anticancer Therapy 17:4, 387-394.
CrossRef90
Jianhong Zhu, Junyan Wu, Guocheng Li, Jianfang Li, Yin Lin, Zhichao He, Chen Su, Wenxia Zhao, Qianqian Wu, Zepeng Chen, Kaifeng Qiu. . (2017) Meta-analysis of randomized controlled trials for the incidence and risk of fatal adverse events in cancer patients treated with ipilimumab. Expert Opinion on Drug Safety 16:4, 423-428.
CrossRef91
O. Abdel-Rahman, D. Helbling, J. Schmidt, U. Petrausch, A. Giryes, A. Mehrabi, O. Schöb, M. Mannhart, H. Oweira. . (2017) Treatment-related Death in Cancer Patients Treated with Immune Checkpoint Inhibitors: A Systematic Review and Meta-analysis. Clinical Oncology 29:4, 218-230.
CrossRef92
Geoffrey Y. Ku. . (2017) The Current Status of Immunotherapies in Esophagogastric Cancer. Surgical Oncology Clinics of North America 26:2, 277-292.
CrossRef93
D.L. Morganstein, Z. Lai, L. Spain, S. Diem, D. Levine, C. Mace, M. Gore, J. Larkin. . (2017) Thyroid abnormalities following the use of cytotoxic T-lymphocyte antigen-4 and programmed death receptor protein-1 inhibitors in the treatment of melanoma. Clinical Endocrinology 86:4, 614-620.
CrossRef94
Lisa Zimmer, Susmitha Apuri, Zeynep Eroglu, Lisa A. Kottschade, Andrea Forschner, Ralf Gutzmer, Max Schlaak, Lucie Heinzerling, Angela M. Krackhardt, Carmen Loquai, Svetomir N. Markovic, Richard W. Joseph, Kelly Markey, Jochen S. Utikal, Carsten Weishaupt, Simone M. Goldinger, Vernon K. Sondak, Jonathan S. Zager, Dirk Schadendorf, Nikhil I. Khushalani. . (2017) Ipilimumab alone or in combination with nivolumab after progression on anti-PD-1 therapy in advanced melanoma. European Journal of Cancer 75, 47-55.
CrossRef95
Julia K. Tietze, Daniela Angelova, Markus V. Heppt, Markus Reinholz, William J. Murphy, Michael Spannagl, Thomas Ruzicka, Carola Berking. . (2017) The proportion of circulating CD45RO + CD8 + memory T cells is correlated with clinical response in melanoma patients treated with ipilimumab. European Journal of Cancer 75, 268-279.
CrossRef96
Paolo Antonio Ascierto, Remo Accorona, Gerardo Botti, Davide Farina, Piero Fossati, Gemma Gatta, Helen Gogas, Davide Lombardi, Roberto Maroldi, Piero Nicolai, Marco Ravanelli, Vito Vanella. . (2017) Mucosal melanoma of the head and neck. Critical Reviews in Oncology/Hematology 112, 136-152.
CrossRef97
Mauro Loi, Isacco Desideri, Daniela Greto, Monica Mangoni, Mariangela Sottili, Icro Meattini, Carlotta Becherini, Francesca Terziani, Camilla Delli Paoli, Emanuela Olmetto, Pierluigi Bonomo, Lorenzo Livi. . (2017) Radiotherapy in the age of cancer immunology: Current concepts and future developments. Critical Reviews in Oncology/Hematology 112, 1-10.
CrossRef98
A. Neubauer. . (2017) Immuntherapie von Tumorerkrankungen mit Checkpoint-Inhibitoren. Der Internist 58:4, 409-423.
CrossRef99
Franck Carbonnel, Emilie Soularue, Clélia Coutzac, Nathalie Chaput, Christine Mateus, Patricia Lepage, Caroline Robert. . (2017) Inflammatory bowel disease and cancer response due to anti-CTLA-4: is it in the flora?. Seminars in Immunopathology 39:3, 327-331.
CrossRef100
Juan Martin-Liberal, Cinta Hierro, Maria Ochoa de Olza, Jordi Rodon. . (2017) Immuno-Oncology: The Third Paradigm in Early Drug Development. Targeted Oncology 12:2, 125-138.
CrossRef101
Zohreh Amoozgar, Michael S Goldberg. . (2017) Surface modulation of polymeric nanocarriers enhances the stability and delivery of proteins and small molecules. Nanomedicine 12:7, 729-743.
CrossRef102
Anna S. Berghoff, Matthias Preusser. . (2017) Targeted Therapies for Melanoma Brain Metastases. Current Treatment Options in Neurology 19:4.
CrossRef103
M.C. Pérez Gago, O. Saavedra Santa Gadea, L. de la Cruz-Merino. . (2017) Nuevos avances de tratamiento inmunobiológico en el melanoma avanzado. Actas Dermo-Sifiliográficas.
CrossRef104
Reinhard Dummer, Dirk Schadendorf, Paolo A Ascierto, Ana Arance, Caroline Dutriaux, Anna Maria Di Giacomo, Piotr Rutkowski, Michele Del Vecchio, Ralf Gutzmer, Mario Mandala, Luc Thomas, Lev Demidov, Claus Garbe, David Hogg, Gabriella Liszkay, Paola Queirolo, Ernesto Wasserman, James Ford, Marine Weill, L Andres Sirulnik, Valentine Jehl, Viviana Bozón, Georgina V Long, Keith Flaherty. . (2017) Binimetinib versus dacarbazine in patients with advanced NRAS -mutant melanoma (NEMO): a multicentre, open-label, randomised, phase 3 trial. The Lancet Oncology 18:4, 435-445.
CrossRef105
Georg Richtig, Barbara Ehall, Erika Richtig, Ariane Aigelsreiter, Tony Gutschner, Martin Pichler. . (2017) Function and Clinical Implications of Long Non-Coding RNAs in Melanoma. International Journal of Molecular Sciences 18:4, 715.
CrossRef106
James L. Gulley, Ravi A. Madan, Russell Pachynski, Peter Mulders, Nadeem A. Sheikh, James Trager, Charles G. Drake. . (2017) Role of Antigen Spread and Distinctive Characteristics of Immunotherapy in Cancer Treatment. JNCI: Journal of the National Cancer Institute 109:4.
CrossRef107
C. Melis, A. Rogiers, O. Bechter, Joost J. van den Oord. . (2017) Molecular genetic and immunotherapeutic targets in metastatic melanoma. Virchows Archiv 17.
CrossRef108
Nigel Fleeman, Adrian Bagust, Angela Boland, Sophie Beale, Marty Richardson, Ashma Krishan, Angela Stainthorpe, Ahmed Abdulla, Eleanor Kotas, Lindsay Banks, Miranda Payne. . (2017) Talimogene Laherparepvec for Treating Metastatic Melanoma: An Evidence Review Group Perspective of a NICE Single Technology Appraisal. PharmacoEconomics 11.
CrossRef109
Louise A. Jackett, Richard A. Scolyer, James F. Bishop, John F. Thompson. . 2017. Primary Melanoma of the Lung. Textbook of Uncommon Cancer, 285-292.
CrossRef110
Ryuhjin Ahn, Valérie Sabourin, Alicia M. Bolt, Steven Hébert, Stephanie Totten, Nicolas De Jay, Maria Carolina Festa, Yoon Kow Young, Young Kyuen Im, Tony Pawson, Antonis E. Koromilas, William J. Muller, Koren K. Mann, Claudia L. Kleinman, Josie Ursini-Siegel. . (2017) The Shc1 adaptor simultaneously balances Stat1 and Stat3 activity to promote breast cancer immune suppression. Nature Communications 8, 14638.
CrossRef111
Nicolas Jacquelot, Jonathan M. Pitt, David P. Enot, Maria Paula Roberti, Connie P M. Duong, Sylvie Rusakiewicz, Alexander M. Eggermont, Laurence Zitvogel. . (2017) Immune biomarkers for prognosis and prediction of responses to immune checkpoint blockade in cutaneous melanoma. OncoImmunology 182, 00-00.
CrossRef112
Yukiya Narita, Kei Muro. . (2017) Challenges in molecular targeted therapy for gastric cancer: considerations for efficacy and safety. Expert Opinion on Drug Safety 16:3, 319-327.
CrossRef113
Andrew S. Luksik, Russell Maxwell, Tomas Garzon-Muvdi, Michael Lim. . (2017) The Role of Immune Checkpoint Inhibition in the Treatment of Brain Tumors. Neurotherapeutics 14.
CrossRef114
2017. Bibliography. Iterative Learning Control for Multi-agent Systems Coordination, 233-243.
CrossRef115
Paul Letendre, Varun Monga, Mohammed Milhem, Yousef Zakharia. . (2017) Ipilimumab: from preclinical development to future clinical perspectives in melanoma. Future Oncology 13:7, 625-636.
CrossRef116
C. Franklin, E. Livingstone, A. Roesch, B. Schilling, D. Schadendorf. . (2017) Immunotherapy in melanoma: Recent advances and future directions. European Journal of Surgical Oncology (EJSO) 43:3, 604-611.
CrossRef117
M.C.T. van Zeijl, A.J. van den Eertwegh, J.B. Haanen, M.W.J.M. Wouters. . (2017) (Neo)adjuvant systemic therapy for melanoma. European Journal of Surgical Oncology (EJSO) 43:3, 534-543.
CrossRef118
D. Kee, G. McArthur. . (2017) Immunotherapy of melanoma. European Journal of Surgical Oncology (EJSO) 43:3, 594-603.
CrossRef119
Andrea Forschner, Felizitas Eichner, Teresa Amaral, Ulrike Keim, Claus Garbe, Thomas Kurt Eigentler. . (2017) Improvement of overall survival in stage IV melanoma patients during 2011–2014: analysis of real-world data in 441 patients of the German Central Malignant Melanoma Registry (CMMR). Journal of Cancer Research and Clinical Oncology 143:3, 533-540.
CrossRef120
Kilian Wistuba-Hamprecht, Alexander Martens, Florian Heubach, Emanuela Romano, Marnix Geukes Foppen, Jianda Yuan, Michael Postow, Phillip Wong, Domenico Mallardo, Bastian Schilling, Anna Maria Di Giacomo, Amir Khammari, Brigitte Dreno, Michele Maio, Dirk Schadendorf, Paolo A. Ascierto, Jedd D. Wolchok, Christian U. Blank, Claus Garbe, Graham Pawelec, Benjamin Weide. . (2017) Peripheral CD8 effector-memory type 1 T-cells correlate with outcome in ipilimumab-treated stage IV melanoma patients. European Journal of Cancer 73, 61-70.
CrossRef121
Kazuto Harada, Dilsa Mizrak Kaya, Yusuke Shimodaira, Jaffer A. Ajani. . (2017) Global chemotherapy development for gastric cancer. Gastric Cancer 20:S1, 92-101.
CrossRef122
Abdul W. Ansari, Mohammad A. Khan, Reinhold E. Schmidt, Dieter C. Broering. . (2017) Harnessing the immunotherapeutic potential of T-lymphocyte co-signaling molecules in transplantation. Immunology Letters 183, 8-16.
CrossRef123
Marco Donia, Marie Louise Kimper-Karl, Katrine Lundby Høyer, Lars Bastholt, Henrik Schmidt, Inge Marie Svane. . (2017) The majority of patients with metastatic melanoma are not represented in pivotal phase III immunotherapy trials. European Journal of Cancer 74, 89-95.
CrossRef124
Tsuyoshi Hamada, NaNa Keum, Reiko Nishihara, Shuji Ogino. . (2017) Molecular pathological epidemiology: new developing frontiers of big data science to study etiologies and pathogenesis. Journal of Gastroenterology 52:3, 265-275.
CrossRef125
Dan Ishihara, Laurentiu Pop, Tsuguhide Takeshima, Puneeth Iyengar, Raquibul Hannan. . (2017) Rationale and evidence to combine radiation therapy and immunotherapy for cancer treatment. Cancer Immunology, Immunotherapy 66:3, 281-298.
CrossRef126
J. McLachlan, S. Boussios, A. Okines, D. Glaessgen, S. Bodlar, R. Kalaitzaki, A. Taylor, S. Lalondrelle, M. Gore, S. Kaye, S. Banerjee. . (2017) The Impact of Systemic Therapy Beyond First-line Treatment for Advanced Cervical Cancer. Clinical Oncology 29:3, 153-160.
CrossRef127
Corneel Coens, Stefan Suciu, Vanna Chiarion-Sileni, Jean-Jacques Grob, Reinhard Dummer, Jedd D Wolchok, Henrik Schmidt, Omid Hamid, Caroline Robert, Paolo A Ascierto, Jon M Richards, Celeste Lebbé, Virginia Ferraresi, Michael Smylie, Jeffrey S Weber, Michele Maio, Andrew Bottomley, Srividya Kotapati, Veerle de Pril, Alessandro Testori, Alexander M M Eggermont. . (2017) Health-related quality of life with adjuvant ipilimumab versus placebo after complete resection of high-risk stage III melanoma (EORTC 18071): secondary outcomes of a multinational, randomised, double-blind, phase 3 trial. The Lancet Oncology 18:3, 393-403.
CrossRef128
Sandro Pasquali, Vanna Chiarion-Sileni, Carlo Riccardo Rossi, Simone Mocellin. . (2017) Immune checkpoint inhibitors and targeted therapies for metastatic melanoma: A network meta-analysis. Cancer Treatment Reviews 54, 34-42.
CrossRef129
Juan Martin-Liberal, María Ochoa de Olza, Cinta Hierro, Alena Gros, Jordi Rodon, Josep Tabernero. . (2017) The expanding role of immunotherapy. Cancer Treatment Reviews 54, 74-86.
CrossRef130
Gareth Rivalland, Andrew M. Scott, Thomas John. . (2017) Standard of care in immunotherapy trials: Challenges and considerations. Human Vaccines & Immunotherapeutics 19, 1-15.
CrossRef131
Chung-Shien Lee, Christan M. Thomas, Kimberly E. Ng. . (2017) An Overview of the Changing Landscape of Treatment for Advanced Melanoma. Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy 37:3, 319-333.
CrossRef132
Hugo Arasanz, Alejandra Lacalle, Maria José Lecumberri, Ángela Fernández de Lascoiti, Idoia Blanco-Luquin, María GatoCañas, Leyre Pérez-Ricarte, Miren Zuazo, Grazyna Kochan, David Escors. . (2017) Immunotherapy in malignant melanoma: recent approaches and new perspectives. Melanoma Management 4:1, 39-48.
CrossRef133
Cory A Brennick, Mariam M George, William L Corwin, Pramod K Srivastava, Hakimeh Ebrahimi-Nik. . (2017) Neoepitopes as cancer immunotherapy targets: key challenges and opportunities. Immunotherapy 9:4, 361-371.
CrossRef134
Maiko Wada, Takamichi Ito, Gaku Tsuji, Takeshi Nakahara, Akihito Hagihara, Masutaka Furue, Hiroshi Uchi. . (2017) Acral lentiginous melanoma versus other melanoma: A single-center analysis in Japan. The Journal of Dermatology 61.
CrossRef135
David J. Hermel, Patrick A. Ott. . (2017) Combining forces: the promise and peril of synergistic immune checkpoint blockade and targeted therapy in metastatic melanoma. Cancer and Metastasis Reviews 36:1, 43-50.
CrossRef136
Fabian V. Filipp. . (2017) Precision medicine driven by cancer systems biology. Cancer and Metastasis Reviews 36:1, 91-108.
CrossRef137
D D George, V A Armenio, S C Katz. . (2017) Combinatorial immunotherapy for melanoma. Cancer Gene Therapy 24:3, 141-147.
CrossRef138
N B Jamieson, A V Maker. . (2017) Gene-expression profiling to predict responsiveness to immunotherapy. Cancer Gene Therapy 24:3, 134-140.
CrossRef139
Wenwen Du, Min Yang, Abbey Turner, Chunling Xu, Robert Ferris, Jianan Huang, Lawrence Kane, Binfeng Lu. . (2017) TIM-3 as a Target for Cancer Immunotherapy and Mechanisms of Action. International Journal of Molecular Sciences 18:3, 645.
CrossRef140
Naoka Murakami, Shveta Motwani, Leonardo V. Riella. . (2017) Renal complications of immune checkpoint blockade. Current Problems in Cancer 41:2, 100-110.
CrossRef141
Arutselvan Natarajan, Aaron T. Mayer, Robert E. Reeves, Claude M. Nagamine, Sanjiv Sam Gambhir. . (2017) Development of Novel ImmunoPET Tracers to Image Human PD-1 Checkpoint Expression on Tumor-Infiltrating Lymphocytes in a Humanized Mouse Model. Molecular Imaging and Biology.
CrossRef142
Padmanee Sharma, Sumit K. Subudhi, Karl Peggs, Sangeeta Goswami, Jianjun Gao, Sergio Quezada, James P. Allison. . 2017. Cancer Immunotherapy. Holland-Frei Cancer Medicine, 1-23.
CrossRef143
Mark Yarchoan, Burles A. Johnson, Eric R. Lutz, Daniel A. Laheru, Elizabeth M. Jaffee. . (2017) Targeting neoantigens to augment antitumour immunity. Nature Reviews Cancer 17:4, 209-222.
CrossRef144
Bernardo L. Rapoport, Daniel A. Vorobiof, Lydia M. Dreosti, Adam Nosworthy, Georgina McAdam, Johan P. Jordaan, Helen Miller-Jansön, Margreet de Necker, Janetta C. de Beer, Hennie Duvenhage. . (2017) Ipilimumab in Pretreated Patients With Advanced Malignant Melanoma: Results of the South African Expanded-Access Program. Journal of Global Oncology, JGO006544.
CrossRef145
Vivek Kumar, Neha Chaudhary, Mohit Garg, Charalampos S. Floudas, Parita Soni, Abhinav B. Chandra. . (2017) Current Diagnosis and Management of Immune Related Adverse Events (irAEs) Induced by Immune Checkpoint Inhibitor Therapy. Frontiers in Pharmacology 8.
CrossRef146
Andrea K. Miyahira, Sameek Roychowdhury, Sangeeta Goswami, Joseph E. Ippolito, Saul J. Priceman, Colin C. Pritchard, Karen S. Sfanos, Sumit K. Subudhi, Jonathan W. Simons, Kenneth J. Pienta, Howard R. Soule. . (2017) Beyond Seed and Soil: Understanding and Targeting Metastatic Prostate Cancer; Report From the 2016 Coffey-Holden Prostate Cancer Academy Meeting. The Prostate 77:2, 123-144.
CrossRef147
Chalermrat Bunchorntavakul, K. Rajender Reddy. . (2017) Drug Hepatotoxicity. Clinics in Liver Disease 21:1, 115-134.
CrossRef148
Minzhi Xing, Hasmukh J. Prajapati, Renumathy Dhanasekaran, David H. Lawson, Nima Kokabi, Bree R. Eaton, Hyun S. Kim. . (2017) Selective Internal Yttrium-90 Radioembolization Therapy (90Y-SIRT) Versus Best Supportive Care in Patients With Unresectable Metastatic Melanoma to the Liver Refractory to Systemic Therapy. American Journal of Clinical Oncology 40:1, 27-34.
CrossRef149
Anouk Jochems, Maartje G. Schouwenburg, Brenda Leeneman, Margreet G. Franken, Alfons J.M. van den Eertwegh, John B.A.G. Haanen, Hans Gelderblom, Carin A. Uyl-de Groot, Maureen J.B. Aarts, Franchette W.P.J. van den Berkmortel, Willeke A.M. Blokx, Mathilde C. Cardous-Ubbink, Gerard Groenewegen, Jan Willem B. de Groot, Geke A.P. Hospers, Ellen Kapiteijn, Rutger H. Koornstra, Wim H. Kruit, Marieke W. Louwman, Djura Piersma, Rozemarijn S. van Rijn, Albert J. ten Tije, Gerard Vreugdenhil, Michel W.J.M. Wouters, Jacobus J.M. van der Hoeven. . (2017) Dutch Melanoma Treatment Registry: Quality assurance in the care of patients with metastatic melanoma in the Netherlands. European Journal of Cancer 72, 156-165.
CrossRef150
Ibiayi Dagogo-Jack, Corey M. Gill, Daniel P. Cahill, Sandro Santagata, Priscilla K. Brastianos. . (2017) Treatment of brain metastases in the modern genomic era. Pharmacology & Therapeutics 170, 64-72.
CrossRef151
P. Arenberger, A. Fialova, S. Gkalpakiotis, A. Pavlikova, I. Puzanov, M. Arenbergerova. . (2017) Melanoma antigens are biomarkers for ipilimumab response. Journal of the European Academy of Dermatology and Venereology 31:2, 252-259.
CrossRef152
M. Alhusseini, J. Samantray. . (2017) Autoimmune diabetes superimposed on type 2 diabetes in a patient initiated on immunotherapy for lung cancer. Diabetes & Metabolism 43:1, 86-88.
CrossRef153
John Wen-Cheng Chang, Jun Guo, Chia-Yen Hung, Si Lu, Sang Joon Shin, Richard Quek, Anthony Ying, Gwo Fuang Ho, Huu Sau Nguyen, Boman Dhabhar, Virote Sriuranpong, Maria Luisa Tiambeng, Nugroho Prayogo, Naoya Yamazaki. . (2017) Sunrise in melanoma management: Time to focus on melanoma burden in Asia. Asia-Pacific Journal of Clinical Oncology.
CrossRef154
M. Kostine, L. Chiche, E. Lazaro, P. Halfon, C. Charpin, D. Arniaud, F. Retornaz, P. Blanco, N. Jourde-Chiche, C. Richez, C. Stavris. . (2017) Opportunistic autoimmunity secondary to cancer immunotherapy (OASI): An emerging challenge. La Revue de Médecine Interne.
CrossRef155
Casey Quinn, Qiufei Ma, Amber Kudlac, Stephen Palmer, Beth Barber, Zhongyun Zhao. . (2017) Relative Efficacy of Granulocyte-Macrophage Colony-Stimulating Factor, Dacarbazine, and Glycoprotein 100 in Metastatic Melanoma: An Indirect Treatment Comparison. Advances in Therapy 34:2, 495-512.
CrossRef156
Padmanee Sharma, Siwen Hu-Lieskovan, Jennifer A. Wargo, Antoni Ribas. . (2017) Primary, Adaptive, and Acquired Resistance to Cancer Immunotherapy. Cell 168:4, 707-723.
CrossRef157
Eszter Lázár-Molnár, Lisa Scandiuzzi, Indranil Basu, Thomas Quinn, Eliezer Sylvestre, Edith Palmieri, Udupi A. Ramagopal, Stanley G. Nathenson, Chandan Guha, Steven C. Almo. . (2017) Structure-guided development of a high-affinity human Programmed Cell Death-1: Implications for tumor immunotherapy. EBioMedicine.
CrossRef158
Panagiotis J. Vlachostergios, Giuseppe Galletti, Jessica Palmer, Linda Lam, Beerinder S. Karir, Scott T. Tagawa. . (2017) Antibody therapeutics for treating prostate cancer: where are we now and what comes next?. Expert Opinion on Biological Therapy 17:2, 135-149.
CrossRef159
Ahmad A. Tarhini, Yan Lin, Hui-Min Lin, Priyanka Vallabhaneni, Cindy Sander, William LaFramboise, Lana Hamieh. . (2017) Expression profiles of immune-related genes are associated with neoadjuvant ipilimumab clinical benefit. OncoImmunology 6:2, e1231291.
CrossRef160
Sylvain Ladoire, Valentin Derangère, Laurent Arnould, Marion Thibaudin, Bruno Coudert, Veronique Lorgis, Isabelle Desmoulins, Marie Chaix, Pierre Fumoleau, François Ghiringhelli. . (2017) La réponse immunitaire anti-tumorale dans le cancer du sein : état des lieux et perspectives thérapeutiques. Annales de Pathologie 37:1, 133-141.
CrossRef161
Jonathan J. Lee, Daniela Kroshinsky, Mai P. Hoang. . (2017) Cutaneous Reactions to Targeted Therapy. The American Journal of Dermatopathology 39:2, 67-82.
CrossRef162
David J. Byun, Jedd D. Wolchok, Lynne M. Rosenberg, Monica Girotra. . (2017) Cancer immunotherapy — immune checkpoint blockade and associated endocrinopathies. Nature Reviews Endocrinology 13:4, 195-207.
CrossRef163
Ralph R. Weichselbaum, Hua Liang, Liufu Deng, Yang-Xin Fu. . (2017) Radiotherapy and immunotherapy: a beneficial liaison?. Nature Reviews Clinical Oncology 14:6, 365-379.
CrossRef164
Lucia Spath, Alessandra Ulivieri, Luca Lavra, Laura Fidanza, Marta Carlesimo, Maria Giubettini, Alessandra Narcisi, Emidio Luciani, Barbara Bucci, Daniela Pisani, Salvatore Sciacchitano, Armando Bartolazzi. . (2017) Antiproliferative Effects of 1α-OH-vitD3 in Malignant Melanoma: Potential Therapeutic implications. Scientific Reports 7, 40370.
CrossRef165
Or Cohen-Inbar, Han-Hsun Shih, Zhiyuan Xu, David Schlesinger, Jason P. Sheehan. . (2017) The effect of timing of stereotactic radiosurgery treatment of melanoma brain metastases treated with ipilimumab. Journal of Neurosurgery, 1-8.
CrossRef166
W. Joost Lesterhuis, Anthony Bosco, Michael J. Millward, Michael Small, Anna K. Nowak, Richard A. Lake. . (2017) Dynamic versus static biomarkers in cancer immune checkpoint blockade: unravelling complexity. Nature Reviews Drug Discovery 16:4, 264-272.
CrossRef167
Kristian M. Koller, Heath B. Mackley, Jason Liu, Henry Wagner, Giampaolo Talamo, Todd D. Schell, Colette Pameijer, Rogerio I. Neves, Bryan Anderson, Kathleen M. Kokolus, Carol A. Mallon, Joseph J. Drabick. . (2017) Improved survival and complete response rates in patients with advanced melanoma treated with concurrent ipilimumab and radiotherapy versus ipilimumab alone. Cancer Biology & Therapy 18:1, 36-42.
CrossRef168
Laura C Cappelli, Jarushka Naidoo, Clifton O Bingham, Ami A Shah. . (2017) Inflammatory arthritis due to immune checkpoint inhibitors: challenges in diagnosis and treatment. Immunotherapy 9:1, 5-8.
CrossRef169
Samantha Burugu, Karama Asleh-Aburaya, Torsten O. Nielsen. . (2017) Immune infiltrates in the breast cancer microenvironment: detection, characterization and clinical implication. Breast Cancer 24:1, 3-15.
CrossRef170
Atsushi Tanaka, Shimon Sakaguchi. . (2017) Regulatory T cells in cancer immunotherapy. Cell Research 27:1, 109-118.
CrossRef171
Mark P. Breazzano, Ronald W. Milam, Sean A. Batson, Douglas B. Johnson, Anthony B. Daniels. . (2017) Immunotherapy for Uveal Melanoma. International Ophthalmology Clinics 57:1, 29-39.
CrossRef172
F. Aya, A. Fernandez-Martinez, L. Gaba, I. Victoria, M. Tosca, E. Pineda, P. Gascon, A. Prat, A. Arance. . (2017) Sequential treatment with immunotherapy and BRAF inhibitors in BRAF-mutant advanced melanoma. Clinical and Translational Oncology 19:1, 119-124.
CrossRef173
Nicholas D. Klemen, Paul L. Feingold, Stephanie L. Goff, Marybeth S. Hughes, Udai S. Kammula, James C. Yang, David S. Schrump, Steven A. Rosenberg, Richard M. Sherry. . (2017) Metastasectomy Following Immunotherapy with Adoptive Cell Transfer for Patients with Advanced Melanoma. Annals of Surgical Oncology 24:1, 135-141.
CrossRef174
Joseph Chao, Marwan Fakih. . 2017. Surgical Considerations and Emergencies in the Cancer Patient Receiving Immunotherapy. Surgical Emergencies in the Cancer Patient, 31-44.
CrossRef175
Ling Yi, Zhuohong Yan, Hongyan Jia, Xiaojue Wang, Yanlin Zhao, Hongtao Zhang. . (2017) CD137-CRDI is not necessary in the role of contacting its natural ligand. Immunology and Cell Biology 95:1, 24-32.
CrossRef176
N. Sekhon, R.A. Kumbla, M. Mita. . 2017. Current Trends in Cancer Therapy. Cardio-Oncology, 1-24.
CrossRef177
Joshua E. Allen, Wafik S. El-Deiry. . 2017. Targeting Oncoproteins for Molecular Cancer Therapy. The Molecular Basis of Human Cancer, 727-756.
CrossRef178
Ke-Hua Li, Thomas Griffin, Neda Nikbakht, Le Qu, Hong-Duo Chen, Chundi He, Li-Xin Xia. . 2017. Neoplasms. Practical Immunodermatology, 279-296.
CrossRef179
Laura A Johnson, Carl H June. . (2017) Driving gene-engineered T cell immunotherapy of cancer. Cell Research 27:1, 38-58.
CrossRef180
Antoine Millet, Anthony R. Martin, Cyril Ronco, Stéphane Rocchi, Rachid Benhida. . (2017) Metastatic Melanoma: Insights Into the Evolution of the Treatments and Future Challenges. Medicinal Research Reviews 37:1, 98-148.
CrossRef181
Kenar D. Jhaveri, Rimda Wanchoo, Vipulbhai Sakhiya, Daniel W. Ross, Steven Fishbane. . (2017) Adverse Renal Effects of Novel Molecular Oncologic Targeted Therapies: A Narrative Review. Kidney International Reports 2:1, 108-123.
CrossRef182
Hina J. Shah, Abhishek R. Keraliya, Jyothi P. Jagannathan, Sree Harsha Tirumani, Vikram R. Lele, Pamela J. DiPiro. . (2017) Diffuse Large B-Cell Lymphoma in the Era of Precision Oncology: How Imaging Is Helpful. Korean Journal of Radiology 18:1, 54.
CrossRef183
Masaru Ide, Shinichi Koba, Naoko Sueoka-Aragane, Akemi Sato, Yuri Nagano, Takuya Inoue, Noriyuki Misago, Yutaka Narisawa, Shinya Kimura, Eisaburo Sueoka. . (2017) Mutation Profile of B-Raf Gene Analyzed by fully Automated System and Clinical Features in Japanese Melanoma Patients. Pathology & Oncology Research 23:1, 181-188.
CrossRef184
Kimberly Loo, Adil I. Daud. . (2017) Inhibitors of Cytotoxic T Lymphocyte Antigen 4 and Programmed Death 1/Programmed Death 1 Ligand for Metastatic Melanoma, Dual Versus Monotherapy—Summary of Advances and Future Directions for Studying These Drugs. The Cancer Journal 23:1, 3-9.
CrossRef185
Siwen Hu-Lieskovan, Antoni Ribas. . (2017) New Combination Strategies Using Programmed Cell Death 1/Programmed Cell Death Ligand 1 Checkpoint Inhibitors as a Backbone. The Cancer Journal 23:1, 10-22.
CrossRef186
Freddy E. Escorcia, Michael A. Postow, Christopher A. Barker. . (2017) Radiotherapy and Immune Checkpoint Blockade for Melanoma. The Cancer Journal 23:1, 32-39.
CrossRef187
Benjamin Izar, Meredith M. Regan, David F. McDermott. . (2017) Clinical Trial Design and Endpoints for Stage IV Melanoma in the Modern Era. The Cancer Journal 23:1, 63-67.
CrossRef188
Latifa Rbah-Vidal, Aurélien Vidal, Emilie M.F. Billaud, Sophie Besse, Isabelle Ranchon-Cole, Florence Mishellany, Yann Perrot, Lydia Maigne, Nicole Moins, Jean-Luc Guerquin-Kern, Françoise Degoul, Jean-Michel Chezal, Philippe Auzeloux, Elisabeth Miot-Noirault. . (2017) Theranostic Approach for Metastatic Pigmented Melanoma Using ICF15002, a Multimodal Radiotracer for Both PET Imaging and Targeted Radionuclide Therapy. Neoplasia 19:1, 17-27.
CrossRef189
Alexander M. M. Eggermont, Dirk Schadendorf, Caroline Robert. . 2017. Immune Checkpoint Inhibitors in Melanoma Define a New Era in Immunotherapy Aiming for Cure. Melanoma Development, 427-436.
CrossRef190
Takahiro Ebata. . 2017. Immunotherapy. Molecular Targeted Therapy of Lung Cancer, 227-237.
CrossRef191
Shigehisa Kitano, Ayumu Ito, Youngji Kim. . 2017. Immunotherapy for Renal Cell Cancer (RCC). Renal Cell Carcinoma, 295-317.
CrossRef192
J Elassaiss-Schaap, S Rossenu, A Lindauer, SP Kang, R de Greef, JR Sachs, DP de Alwis. . (2017) Using Model-Based “Learn and Confirm” to Reveal the Pharmacokinetics-Pharmacodynamics Relationship of Pembrolizumab in the KEYNOTE-001 Trial. CPT: Pharmacometrics & Systems Pharmacology 6:1, 21-28.
CrossRef193
M Ahamadi, T Freshwater, M Prohn, CH Li, DP de Alwis, R de Greef, J Elassaiss-Schaap, A Kondic, JA Stone. . (2017) Model-Based Characterization of the Pharmacokinetics of Pembrolizumab: A Humanized Anti-PD-1 Monoclonal Antibody in Advanced Solid Tumors. CPT: Pharmacometrics & Systems Pharmacology 6:1, 49-57.
CrossRef194
Wojciech Szopa, Thomas A. Burley, Gabriela Kramer-Marek, Wojciech Kaspera. . (2017) Diagnostic and Therapeutic Biomarkers in Glioblastoma: Current Status and Future Perspectives. BioMed Research International 2017, 1-13.
CrossRef195
Mark K. Singh, Daryl R. Godden. . 2017. Skin Cancer of the Head and Neck. Maxillofacial Surgery, 714-727.
CrossRef196
Kevin J. Harrington. . 2017. Chemotherapy and Targeted Agents. Maxillofacial Surgery, 339-354.
CrossRef197
Lawrence Kashat, Christopher H. Le, Alexander G. Chiu. . (2017) The Role of Targeted Therapy in the Management of Sinonasal Malignancies. Otolaryngologic Clinics of North America 50:2, 443.
CrossRef198
Yael Diesendruck, Itai Benhar. . (2017) Novel immune check point inhibiting antibodies in cancer therapy—Opportunities and challenges. Drug Resistance Updates 30, 39-47.
CrossRef199
Won Kim, Lawrence Fong. . (2017) Can Prostate Cancer Really Respond to Immunotherapy?. Journal of Clinical Oncology 35:1, 4-5.
CrossRef200
Tomasz M. Beer, Eugene D. Kwon, Charles G. Drake, Karim Fizazi, Christopher Logothetis, Gwenaelle Gravis, Vinod Ganju, Jonathan Polikoff, Fred Saad, Piotr Humanski, Josep M. Piulats, Pablo Gonzalez Mella, Siobhan S. Ng, Dirk Jaeger, Francis X. Parnis, Fabio A. Franke, Javier Puente, Roman Carvajal, Lisa Sengeløv, M. Brent McHenry, Arvind Varma, Alfonsus J. van den Eertwegh, Winald Gerritsen. . (2017) Randomized, Double-Blind, Phase III Trial of Ipilimumab Versus Placebo in Asymptomatic or Minimally Symptomatic Patients With Metastatic Chemotherapy-Naive Castration-Resistant Prostate Cancer. Journal of Clinical Oncology 35:1, 40-47.
CrossRef201
Lucia Masarova, Hagop Kantarjian, Guillermo Garcia-Mannero, Farhad Ravandi, Padmanee Sharma, Naval Daver. . 2017. Harnessing the Immune System Against Leukemia: Monoclonal Antibodies and Checkpoint Strategies for AML. Immunotherapy, 73-95.
CrossRef202
Anisha B. Patel, Omar Pacha. . 2017. Skin Reactions to Immune Checkpoint Inhibitors. Immunotherapy, 175-184.
CrossRef203
Tasha Hughes, Howard L. Kaufman. . 2017. CTLA-4. Cancer Therapeutic Targets, 157-170.
CrossRef204
Danijela Jelovac, Leisha A. Emens. . 2017. Whole-Cell Vaccines. Cancer Therapeutic Targets, 561-574.
CrossRef205
David L. Chen, Cheryl Armstrong, Mariah R. Brown. . 2017. Immunobiology and Immune Based Therapies of Melanoma. Clinical and Basic Immunodermatology, 871-890.
CrossRef206
Diwakar Davar, Armita Bahrami, Alberto S. Pappo, John M. Kirkwood. . 2017. Malignant Melanoma in the Adolescent and Young Adult (AYA) Population. Cancer in Adolescents and Young Adults, 231-267.
CrossRef207
Clizia Zichi, Marcello Tucci, Gianmarco Leone, Consuelo Buttigliero, Francesca Vignani, Daniele Pignataro, Giorgio V. Scagliotti, Massimo Di Maio. . (2017) Immunotherapy for Patients with Advanced Urothelial Cancer: Current Evidence and Future Perspectives. BioMed Research International 2017, 1-13.
CrossRef208
Matthew D Hellmann, Naiyer A Rizvi, Jonathan W Goldman, Scott N Gettinger, Hossein Borghaei, Julie R Brahmer, Neal E Ready, David E Gerber, Laura Q Chow, Rosalyn A Juergens, Frances A Shepherd, Scott A Laurie, William J Geese, Shruti Agrawal, Tina C Young, Xuemei Li, Scott J Antonia. . (2017) Nivolumab plus ipilimumab as first-line treatment for advanced non-small-cell lung cancer (CheckMate 012): results of an open-label, phase 1, multicohort study. The Lancet Oncology 18:1, 31-41.
CrossRef209
Lei Zheng, Elizabeth M. Jaffee. . 2017. Vaccine Therapy and Immunotherapy for Pancreatic Cancer. Pancreatic Cancer, 1-45.
CrossRef210
Kazuto Harada, Dilsa Mizrak Kaya, Shumei Song, Hideo Baba, Jaffer A Ajani. . (2017) Genomic profiling of colorectal cancers and the future of personalized treatment. Colorectal Cancer.
CrossRef211
Letizia Procaccio, Marta Schirripa, Matteo Fassan, Loredana Vecchione, Francesca Bergamo, Alessandra Anna Prete, Rossana Intini, Chiara Manai, Vincenzo Dadduzio, Alice Boscolo, Vittorina Zagonel, Sara Lonardi. . (2017) Immunotherapy in Gastrointestinal Cancers. BioMed Research International 2017, 1-17.
CrossRef212
Marie Vétizou, Romain Daillère, Laurence Zitvogel. . (2017) Rôle du microbiote intestinal dans la réponse aux thérapies anti-tumorales. Biologie Aujourd'hui 211:1, 51-67.
CrossRef213
Earn?H. Gan, Anna?L. Mitchell, Ruth Plummer, Simon Pearce, Petros Perros. . (2017) Tremelimumab-Induced Graves Hyperthyroidism?. European Thyroid Journal 6:3, 167-170.
CrossRef214
Taeryool Koo, In Ah Kim. . (2016) Radiotherapy and immune checkpoint blockades: a snapshot in 2016. Radiation Oncology Journal 34:4, 250-259.
CrossRef215
Hassan Izzedine, Christine Mateus, Céline Boutros, Caroline Robert, Philippe Rouvier, Zahir Amoura, Alexis Mathian. . (2016) Renal effects of immune checkpoint inhibitors. Nephrology Dialysis Transplantation, gfw382.
CrossRef216
Todd A. Aguilera, Marjan Rafat, Laura Castellini, Hussein Shehade, Mihalis S. Kariolis, Angela Bik-Yu Hui, Henning Stehr, Rie von Eyben, Dadi Jiang, Lesley G. Ellies, Albert C. Koong, Maximilian Diehn, Erinn B. Rankin, Edward E. Graves, Amato J. Giaccia. . (2016) Reprogramming the immunological microenvironment through radiation and targeting Axl. Nature Communications 7, 13898.
CrossRef217
Anne-Sophie Hamy, Hélène Bonsang-Kitzis, Marick Lae, Matahi Moarii, Benjamin Sadacca, Alice Pinheiro, Marion Galliot, Judith Abecassis, Cecile Laurent, Fabien Reyal, William B. Coleman. . (2016) A Stromal Immune Module Correlated with the Response to Neoadjuvant Chemotherapy, Prognosis and Lymphocyte Infiltration in HER2-Positive Breast Carcinoma Is Inversely Correlated with Hormonal Pathways. PLOS ONE 11:12, e0167397.
CrossRef218
Benjamin Weide, Alexander Martens, Kilian Wistuba-Hamprecht, Henning Zelba, Ludwig Maier, Hans-Peter Lipp, Bernhard D. Klumpp, Daniel Soffel, Thomas K. Eigentler, Claus Garbe. . (2016) Combined treatment with ipilimumab and intratumoral interleukin-2 in pretreated patients with stage IV melanoma—safety and efficacy in a phase II study. Cancer Immunology, Immunotherapy 17.
CrossRef219
Noboru Yamamoto, Hiroshi Nokihara, Yasuhide Yamada, Takashi Shibata, Yosuke Tamura, Yoshitaka Seki, Kazunori Honda, Yuko Tanabe, Hiroshi Wakui, Tomohide Tamura. . (2016) Phase I study of Nivolumab, an anti-PD-1 antibody, in patients with malignant solid tumors. Investigational New Drugs 68.
CrossRef220
Mehmet Asim Bilen, Sumit K. Subudhi, Jianjun Gao, Nizar M. Tannir, Shi-Ming Tu, Padmanee Sharma. . (2016) Acute rhabdomyolysis with severe polymyositis following ipilimumab-nivolumab treatment in a cancer patient with elevated anti-striated muscle antibody. Journal for ImmunoTherapy of Cancer 4:1.
CrossRef221
Giuseppe V. Masucci, Alessandra Cesano, Rachael Hawtin, Sylvia Janetzki, Jenny Zhang, Ilan Kirsch, Kevin K. Dobbin, John Alvarez, Paul B. Robbins, Senthamil R. Selvan, Howard Z. Streicher, Lisa H. Butterfield, Magdalena Thurin. . (2016) Validation of biomarkers to predict response to immunotherapy in cancer: Volume I — pre-analytical and analytical validation. Journal for ImmunoTherapy of Cancer 4:1.
CrossRef222
Asim Amin, David H. Lawson, April K.S. Salama, Henry B. Koon, Troy Guthrie, Sajeve S. Thomas, Steven J. O’Day, Montaser F. Shaheen, Bin Zhang, Stephen Francis, F. Stephen Hodi. . (2016) Phase II study of vemurafenib followed by ipilimumab in patients with previously untreated BRAF-mutated metastatic melanoma. Journal for ImmunoTherapy of Cancer 4:1.
CrossRef223
Melissa A. Wilson, Kelly Guld, Steven Galetta, Ryan D. Walsh, Julia Kharlip, Madhura Tamhankar, Suzanne McGettigan, Lynn M. Schuchter, Leslie A. Fecher. . (2016) Acute visual loss after ipilimumab treatment for metastatic melanoma. Journal for ImmunoTherapy of Cancer 4:1.
CrossRef224
Smitha Menon, Sarah Shin, Grace Dy. . (2016) Advances in Cancer Immunotherapy in Solid Tumors. Cancers 8:12, 106.
CrossRef225
Sebastian Lundgren, Jonna Berntsson, Björn Nodin, Patrick Micke, Karin Jirström. . (2016) Prognostic impact of tumour-associated B cells and plasma cells in epithelial ovarian cancer. Journal of Ovarian Research 9:1.
CrossRef226
Jason M. Redman, Geoffrey T. Gibney, Michael B. Atkins. . (2016) Advances in immunotherapy for melanoma. BMC Medicine 14:1.
CrossRef227
Jordan Amdahl, Lei Chen, Thomas E. Delea. . (2016) Network Meta-analysis of Progression-Free Survival and Overall Survival in First-Line Treatment of BRAF Mutation-Positive Metastatic Melanoma. Oncology and Therapy 4:2, 239-256.
CrossRef228
Daphne Day, Aaron R. Hansen. . (2016) Immune-Related Adverse Events Associated with Immune Checkpoint Inhibitors. BioDrugs 30:6, 571-584.
CrossRef229
Melina E. Marmarelis, Meredith R. Davis, Nilay S. Sethi, Katherine M. Krajewksi, Rana R. McKay, Toni K. Choueiri, Patrick A. Ott. . (2016) Tumor control with PD-1 inhibition in a patient with concurrent metastatic melanoma and renal cell carcinoma. Journal for ImmunoTherapy of Cancer 4:1.
CrossRef230
Ruth J. Davis, Robert L. Ferris, Nicole C. Schmitt. . (2016) Costimulatory and coinhibitory immune checkpoint receptors in head and neck cancer: unleashing immune responses through therapeutic combinations. Cancers of the Head & Neck 1:1.
CrossRef231
Geoffrey T Gibney, Louis M Weiner, Michael B Atkins. . (2016) Predictive biomarkers for checkpoint inhibitor-based immunotherapy. The Lancet Oncology 17:12, e542-e551.
CrossRef232
Matteo Simonelli, Luca Di Tommaso, Marina Baretti, Armando Santoro. . (2016) Pathological characterization of nivolumab-related liver injury in a patient with glioblastoma. Immunotherapy 8:12, 1363-1369.
CrossRef233
Teofila Seremet, Alexander Koch, Yanina Jansen, Max Schreuer, Sofie Wilgenhof, Véronique Del Marmol, Danielle Liènard, Kris Thielemans, Kelly Schats, Mark Kockx, Wim Van Criekinge, Pierre G. Coulie, Tim De Meyer, Nicolas van Baren, Bart Neyns. . (2016) Molecular and epigenetic features of melanomas and tumor immune microenvironment linked to durable remission to ipilimumab-based immunotherapy in metastatic patients. Journal of Translational Medicine 14:1.
CrossRef234
Tai-Tsang Chen. . (2016) Predicting analysis times in randomized clinical trials with cancer immunotherapy. BMC Medical Research Methodology 16:1.
CrossRef235
Ajjai Alva, Gregory A. Daniels, Michael K. K. Wong, Howard L. Kaufman, Michael A. Morse, David F. McDermott, Joseph I. Clark, Sanjiv S. Agarwala, Gerald Miletello, Theodore F. Logan, Ralph J. Hauke, Brendan Curti, John M. Kirkwood, Rene Gonzalez, Asim Amin, Mayer Fishman, Neeraj Agarwal, James N. Lowder, Hong Hua, Sandra Aung, Janice P. Dutcher. . (2016) Contemporary experience with high-dose interleukin-2 therapy and impact on survival in patients with metastatic melanoma and metastatic renal cell carcinoma. Cancer Immunology, Immunotherapy 65:12, 1533-1544.
CrossRef236
Andrew S. Brohl, Nikhil I. Khushalani, Zeynep Eroglu, Joseph Markowitz, Ram Thapa, Y. Ann Chen, Ragini Kudchadkar, Jeffrey S. Weber. . (2016) A phase IB study of ipilimumab with peginterferon alfa-2b in patients with unresectable melanoma. Journal for ImmunoTherapy of Cancer 4:1.
CrossRef237
Daphne Day, Lillian L. Siu. . (2016) Approaches to modernize the combination drug development paradigm. Genome Medicine 8:1.
CrossRef238
Carrie Luu, Nikhil I. Khushalani, Jonathan S. Zager. . (2016) Intralesional and systemic immunotherapy for metastatic melanoma. Expert Opinion on Biological Therapy 16:12, 1491-1499.
CrossRef239
Jurjen Tel, Rutger Koornstra, Nienke de Haas, Vincent van Deutekom, Harm Westdorp, Steve Boudewijns, Nielka van Erp, Stefania Di Blasio, Winald Gerritsen, Carl G. Figdor, I. Jolanda M. de Vries, Stanleyson V. Hato. . (2016) Preclinical exploration of combining plasmacytoid and myeloid dendritic cell vaccination with BRAF inhibition. Journal of Translational Medicine 14:1.
CrossRef240
Max Schreuer, Geert Meersseman, Sari Van Den Herrewegen, Yanina Jansen, Ines Chevolet, Ambre Bott, Sofie Wilgenhof, Teofila Seremet, Bart Jacobs, Ronald Buyl, Geert Maertens, Bart Neyns. . (2016) Quantitative assessment of BRAF V600 mutant circulating cell-free tumor DNA as a tool for therapeutic monitoring in metastatic melanoma patients treated with BRAF/MEK inhibitors. Journal of Translational Medicine 14:1.
CrossRef241
Stergios Boussios, Esmeralda Seraj, George Zarkavelis, Dimitrios Petrakis, Aristomenes Kollas, Aikaterini Kafantari, Abraam Assi, Konstantina Tatsi, Nicholas Pavlidis, George Pentheroudakis. . (2016) Management of patients with recurrent/advanced cervical cancer beyond first line platinum regimens: Where do we stand? A literature review. Critical Reviews in Oncology/Hematology 108, 164-174.
CrossRef242
Gautham Gampa, Shruthi Vaidhyanathan, Brynna Wilken-Resman, Karen E. Parrish, Svetomir N. Markovic, Jann N. Sarkaria, William F. Elmquist. . (2016) Challenges in the Delivery of Therapies to Melanoma Brain Metastases. Current Pharmacology Reports 2:6, 309-325.
CrossRef243
Jie Deng, Isabelle Le Mercier, Anna Kuta, Randolph J. Noelle. . (2016) A New VISTA on combination therapy for negative checkpoint regulator blockade. Journal for ImmunoTherapy of Cancer 4:1.
CrossRef244
Marta Polkowska, Edyta Czepielewska, Małgorzata Kozłowska-Wojciechowska. . (2016) Drug Combinations as the New Standard for Melanoma Treatment. Current Treatment Options in Oncology 17:12.
CrossRef245
Lucie Heinzerling, Patrick A. Ott, F. Stephen Hodi, Aliya N. Husain, Azadeh Tajmir-Riahi, Hussein Tawbi, Matthias Pauschinger, Thomas F. Gajewski, Evan J. Lipson, Jason J. Luke. . (2016) Cardiotoxicity associated with CTLA4 and PD1 blocking immunotherapy. Journal for ImmunoTherapy of Cancer 4:1.
CrossRef246
Jarrett J. Failing, Heidi D. Finnes, Lisa A. Kottschade, Jacob B. Allred, Svetomir N. Markovic. . (2016) Effects of commonly used chronic medications on the outcomes of ipilimumab therapy in patients with metastatic melanoma. Melanoma Research 26:6, 609-615.
CrossRef247
Jackie Evans, George Laking, Matthew Strother, Tony Wang, Scott Metcalfe, Gary Blick, Reinhard Pauls, Steffan Crausaz. . (2016) Mind the gap: An analysis of foregone health gains from unfunded cancer medicines in New Zealand. Seminars in Oncology 43:6, 625-637.
CrossRef248
Chiara Tommasino, Lucrezia Gambardella, Maria Buoncervello, Roger J. Griffin, Bernard T. Golding, Manuela Alberton, Daniele Macchia, Massimo Spada, Bruna Cerbelli, Giulia d’Amati, Walter Malorni, Lucia Gabriele, Anna Maria Giammarioli. . (2016) New derivatives of the antimalarial drug Pyrimethamine in the control of melanoma tumor growth: an in vitro and in vivo study. Journal of Experimental & Clinical Cancer Research 35:1.
CrossRef249
C. Bisschop, M.S. Bruijn, M.W. Stenekes, G.F.H. Diercks, G.A.P. Hospers. . (2016) Foreign body reaction triggered by cytotoxic T lymphocyte-associated protein 4 blockade 25 years after dermal filler injection. British Journal of Dermatology 175:6, 1351-1353.
CrossRef250
Anthony J. Hatswell, Joshua Porter, Dawn Lee, Nadine Hertel, Nicholas R. Latimer. . (2016) The Cost of Costing Treatments Incorrectly: Errors in the Application of Drug Prices in Economic Evaluation Due to Failing to Account for the Distribution of Patient Weight. Value in Health 19:8, 1055-1058.
CrossRef251
Marc Uemura, Faa’k Faisal, Cara Haymaker, Natalie McQuail, Elizabeth Sirmans, Courtney W. Hudgens, Lydia Barbara, Chantale Bernatchez, Jonathan L. Curry, Patrick Hwu, Michael T. Tetzlaff, Adi Diab. . (2016) A case report of Grover’s disease from immunotherapy-a skin toxicity induced by inhibition of CTLA-4 but not PD-1. Journal for ImmunoTherapy of Cancer 4:1.
CrossRef252
T. J. Vreeland, G. T. Clifton, G. S. Herbert, D. F. Hale, D. O. Jackson, J. S. Berry, G. E. Peoples. . (2016) Gaining ground on a cure through synergy: combining checkpoint inhibitors with cancer vaccines. Expert Review of Clinical Immunology 12:12, 1347-1357.
CrossRef253
Alexander M.M. Eggermont. . (2016) Adjuvant ipilimumab in stage III melanoma: New landscape, new questions. European Journal of Cancer 69, 39-42.
CrossRef254
Sofia Farkona, Eleftherios P. Diamandis, Ivan M. Blasutig. . (2016) Cancer immunotherapy: the beginning of the end of cancer?. BMC Medicine 14:1.
CrossRef255
Chan Kim, Eun Kyung Kim, Hun Jung, Hong Jae Chon, Jung Woo Han, Kyoo-Ho Shin, Hyuk Hu, Kyung Sik Kim, Young Deuk Choi, Sunghoon Kim, Young Han Lee, Jin-Suck Suh, Joong Bae Ahn, Hyun Cheol Chung, Sung Hoon Noh, Sun Young Rha, Soo Hee Kim, Hyo Song Kim. . (2016) Prognostic implications of PD-L1 expression in patients with soft tissue sarcoma. BMC Cancer 16:1.
CrossRef256
Archana Anantharaman, Terence Friedlander, David Lu, Rachel Krupa, Gayatri Premasekharan, Jeffrey Hough, Matthew Edwards, Rosa Paz, Karla Lindquist, Ryon Graf, Adam Jendrisak, Jessica Louw, Lyndsey Dugan, Sarah Baird, Yipeng Wang, Ryan Dittamore, Pamela L. Paris. . (2016) Programmed death-ligand 1 (PD-L1) characterization of circulating tumor cells (CTCs) in muscle invasive and metastatic bladder cancer patients. BMC Cancer 16:1.
CrossRef257
Adil I. Daud, Jedd D. Wolchok, Caroline Robert, Wen-Jen Hwu, Jeffrey S. Weber, Antoni Ribas, F. Stephen Hodi, Anthony M. Joshua, Richard Kefford, Peter Hersey, Richard Joseph, Tara C. Gangadhar, Roxana Dronca, Amita Patnaik, Hassane Zarour, Charlotte Roach, Grant Toland, Jared K. Lunceford, Xiaoyun Nicole Li, Kenneth Emancipator, Marisa Dolled-Filhart, S. Peter Kang, Scot Ebbinghaus, Omid Hamid. . (2016) Programmed Death-Ligand 1 Expression and Response to the Anti–Programmed Death 1 Antibody Pembrolizumab in Melanoma. Journal of Clinical Oncology 34:34, 4102-4109.
CrossRef258
V. Damuzzo, S. Solito, L. Pinton, E. Carrozzo, S. Valpione, J. Pigozzo, R. Arboretti Giancristofaro, V. Chiarion-Sileni, S. Mandruzzato. . (2016) Clinical implication of tumor-associated and immunological parameters in melanoma patients treated with ipilimumab. OncoImmunology 5:12, e1249559.
CrossRef259
Jose A. Figueroa, Camilo Pena, Leonardo Mirandola, Adair Reidy, J. Drew Payne, Nattamol Hosiriluck, Natallia Suvorava, Rakhshanda Layeequr Rahman, Adrienne R. Whitlow, Rashmi Verma, Everardo Cobos, Maurizio Chiriva-Internati. . 2016. Therapeutic Monoclonal Antibodies and Their Targets. Biosimilars of Monoclonal Antibodies, 113-153.
CrossRef260
Mary K. Tripp, Meg Watson, Sophie J. Balk, Susan M. Swetter, Jeffrey E. Gershenwald. . (2016) State of the science on prevention and screening to reduce melanoma incidence and mortality: The time is now. CA: A Cancer Journal for Clinicians 66:6, 460-480.
CrossRef261
Universe Leung, William R. Jarnagin. . 2016. Resection of noncolorectal liver metastases. Laparoscopic Liver, Pancreas, and Biliary Surgery, 214-230.
CrossRef262
Eggermont, Alexander M.M., Chiarion-Sileni, Vanna, Grob, Jean-Jacques, Dummer, Reinhard, Wolchok, Jedd D., Schmidt, Henrik, Hamid, Omid, Robert, Caroline, Ascierto, Paolo A., Richards, Jon M., Lebbé, Céleste, Ferraresi, Virginia, Smylie, Michael, Weber, Jeffrey S., Maio, Michele, Bastholt, Lars, Mortier, Laurent, Thomas, Luc, Tahir, Saad, Hauschild, Axel, Hassel, Jessica C., Hodi, F. Stephen, Taitt, Corina, de Pril, Veerle, de Schaetzen, Gaetan, Suciu, Stefan, Testori, Alessandro, . . (2016) Prolonged Survival in Stage III Melanoma with Ipilimumab Adjuvant Therapy. New England Journal of Medicine 375:19, 1845-1855.
Free Full Text263
Leila Khoja, Minnie Kibiro, Ur Metser, Craig Gedye, David Hogg, Marcus O Butler, Eshetu G Atenafu, Anthony M Joshua. . (2016) Patterns of response to anti-PD-1 treatment: an exploratory comparison of four radiological response criteria and associations with overall survival in metastatic melanoma patients. British Journal of Cancer 115:10, 1186-1192.
CrossRef264
Blanca de Unamuno Bustos, Rafael Botella Estrada. . (2016) Inmunoterapia del melanoma. Piel 31:9, 649-656.
CrossRef265
Max M. Wattenberg, Lawrence Fong, Ravi A. Madan, James L. Gulley. . (2016) Immunotherapy in genitourinary malignancies. Current Opinion in Urology 26:6, 501-507.
CrossRef266
Lidia M. Yshii, Christina M. Gebauer, Béatrice Pignolet, Emilie Mauré, Clémence Quériault, Mandy Pierau, Hiromitsu Saito, Noboru Suzuki, Monika Brunner-Weinzierl, Jan Bauer, Roland Liblau. . (2016) CTLA4 blockade elicits paraneoplastic neurological disease in a mouse model. Brain 139:11, 2923-2934.
CrossRef267
Ana Collazo-Lorduy, Matthew D. Galsky. . (2016) Combining chemotherapy and immune checkpoint blockade. Current Opinion in Urology 26:6, 508-513.
CrossRef268
Benjamin Herzberg, David E. Fisher. . (2016) Metastatic melanoma and immunotherapy. Clinical Immunology 172, 105-110.
CrossRef269
Marie Vétizou, Romain Daillère, Laurence Zitvogel. . (2016) Microbiote intestinal et réponses aux thérapies anti-tumorales. médecine/sciences 32:11, 974-982.
CrossRef270
Junsik Park, Minsuk Kwon, Eui-Cheol Shin. . (2016) Immune checkpoint inhibitors for cancer treatment. Archives of Pharmacal Research 39:11, 1577-1587.
CrossRef271
Or Cohen-Inbar, Menashe Zaaroor. . (2016) Glioblastoma multiforme targeted therapy: The Chlorotoxin story. Journal of Clinical Neuroscience 33, 52-58.
CrossRef272
Maarten Swart, Inge Verbrugge, Joost B. Beltman. . (2016) Combination Approaches with Immune-Checkpoint Blockade in Cancer Therapy. Frontiers in Oncology 6.
CrossRef273
Bibhusal Thapa, D. Neil Watkins, Tom John. . (2016) Immunotherapy for malignant mesothelioma: reality check. Expert Review of Anticancer Therapy 16:11, 1167-1176.
CrossRef274
A. Jose, P. Yiannoullou, S. Bhutani, H. Denley, M. Morton, M. Picton, A. Summers, D. van Dellen, T. Augustine. . (2016) Renal Allograft Failure After Ipilimumab Therapy for Metastatic Melanoma: A Case Report and Review of the Literature. Transplantation Proceedings 48:9, 3137-3141.
CrossRef275
Justine V. Cohen, Hussain Tawbi, Kim A. Margolin, Ravi Amravadi, Marcus Bosenberg, Priscilla K. Brastianos, Veronica L. Chiang, John de Groot, Isabella C. Glitza, Meenhard Herlyn, Sheri L. Holmen, Lucia B. Jilaveanu, Andrew Lassman, Stergios Moschos, Michael A. Postow, Reena Thomas, John A. Tsiouris, Patrick Wen, Richard M. White, Timothy Turnham, Michael A. Davies, Harriet M. Kluger. . (2016) Melanoma central nervous system metastases: current approaches, challenges, and opportunities. Pigment Cell & Melanoma Research 29:6, 627-642.
CrossRef276
Joana Felix, Bruno Cassinat, Raphael Porcher, Marie-Hélène Schlageter, Eve Maubec, Cécile Pages, Barouyr Baroudjian, Laurence Homyrda, Wahid Boukouaci, Ryad Tamouza, Martine Bagot, Anne Caignard, Antoine Toubert, Céleste Lebbé, Hélène Moins-Teisserenc. . (2016) Relevance of serum biomarkers associated with melanoma during follow-up of anti-CTLA-4 immunotherapy. International Immunopharmacology 40, 466-473.
CrossRef277
Martin Reck, Alexander Luft, Aleksandra Szczesna, Libor Havel, Sang-We Kim, Wallace Akerley, Maria Catherine Pietanza, Yi-long Wu, Christoph Zielinski, Michael Thomas, Enriqueta Felip, Kathryn Gold, Leora Horn, Joachim Aerts, Kazuhiko Nakagawa, Paul Lorigan, Anne Pieters, Teresa Kong Sanchez, Justin Fairchild, David Spigel. . (2016) Phase III Randomized Trial of Ipilimumab Plus Etoposide and Platinum Versus Placebo Plus Etoposide and Platinum in Extensive-Stage Small-Cell Lung Cancer. Journal of Clinical Oncology 34:31, 3740-3748.
CrossRef278
Aude G. Chapuis, Ilana M. Roberts, John A. Thompson, Kim A. Margolin, Shailender Bhatia, Sylvia M. Lee, Heather L. Sloan, Ivy P. Lai, Erik A. Farrar, Felecia Wagener, Kendall C. Shibuya, Jianhong Cao, Jedd D. Wolchok, Philip D. Greenberg, Cassian Yee. . (2016) T-Cell Therapy Using Interleukin-21–Primed Cytotoxic T-Cell Lymphocytes Combined With Cytotoxic T-Cell Lymphocyte Antigen-4 Blockade Results in Long-Term Cell Persistence and Durable Tumor Regression. Journal of Clinical Oncology 34:31, 3787-3795.
CrossRef279
Bo Wang, Xuanyi Wang, Yumei Wen, Jing Fu, Hongyang Wang, Zhangmei Ma, Yan Shi, Bin Wang. . (2016) Suppression of established hepatocarcinoma in adjuvant only immunotherapy: alum triggers anti-tumor CD8+ T cell response. Scientific Reports 5:1.
CrossRef280
Austin G. Duffy, Oxana V. Makarova-Rusher, Tim F. Greten. . (2016) The case for immune-based approaches in biliary tract carcinoma. Hepatology 64:5, 1785-1791.
CrossRef281
Stéphane Oudard, Constance Thibault, Antoine Angelergues, Eric Tartour, Marc Olivier Timsit, Arnaud Mejean, Constance Michel, Yann Vano. . (2016) Immunothérapie dans les cancers de la prostate. Bulletin du Cancer 103, S144-S150.
CrossRef282
Cécile Pagès, Barouyr Baroudjian, Celeste Lebbé. . (2016) Immunothérapie et mélanome : l’exemple des anticorps immunomodulateurs. Bulletin du Cancer 103, S132-S137.
CrossRef283
Monica Marzagalli, Marina Montagnani Marelli, Lavinia Casati, Fabrizio Fontana, Roberta Manuela Moretti, Patrizia Limonta. . (2016) Estrogen Receptor β in Melanoma: From Molecular Insights to Potential Clinical Utility. Frontiers in Endocrinology 7.
CrossRef284
Sumit K. Subudhi, Ana Aparicio, Jianjun Gao, Amado J. Zurita, John C. Araujo, Christopher J. Logothetis, Salahaldin A. Tahir, Brinda R. Korivi, Rebecca S. Slack, Luis Vence, Ryan O. Emerson, Erik Yusko, Marissa Vignali, Harlan S. Robins, Jingjing Sun, James P. Allison, Padmanee Sharma. . (2016) Clonal expansion of CD8 T cells in the systemic circulation precedes development of ipilimumab-induced toxicities. Proceedings of the National Academy of Sciences 113:42, 11919-11924.
CrossRef285
Mohammed Dany, Rose Nganga, Alissar Chidiac, Edith Hanna, Sara Matar, Dirk Elston. . (2016) Advances in immunotherapy for melanoma management. Human Vaccines & Immunotherapeutics 12:10, 2501-2511.
CrossRef286
Dong Lin, Xinya Wang, Stephen Yiu Chuen Choi, Xinpei Ci, Xin Dong, Yuzhuo Wang. . (2016) Immune phenotypes of prostate cancer cells: Evidence of epithelial immune cell-like transition?. Asian Journal of Urology 3:4, 195-202.
CrossRef287
Lisa Kottschade, Adam Brys, Tobias Peikert, Mabel Ryder, Laura Raffals, Jerry Brewer, Paul Mosca, Svetomir Markovic. . (2016) A multidisciplinary approach to toxicity management of modern immune checkpoint inhibitors in cancer therapy. Melanoma Research 26:5, 469-480.
CrossRef288
S Latteyer, V Tiedje, B Schilling, D Führer. . (2016) Perspectives for immunotherapy in endocrine cancer. Endocrine-Related Cancer 23:10, R469-R484.
CrossRef289
Roni Engelstein, Sharon Merims, Galit Eisenberg, Jonathan Cohen, Stephen Frank, Tamar Hamburger, Shoshana Frankenburg, Ilan Ron, Ruth Isacson, Tal Grenader, Hanna Steinberg, Cyrille J. Cohen, Tamar Peretz, Michal Lotem. . (2016) Immune Monitoring of Patients Treated With a Whole-Cell Melanoma Vaccine Engineered to Express 4-1BBL. Journal of Immunotherapy 39:8, 321-328.
CrossRef290
S. Martín-Algarra, L. de la Cruz-Merino, V. Soriano, J. L. Manzano, E. Espinosa. . (2016) Clinical use of ipilimumab for metastatic melanoma in Spain: towards a more consistent approach. Clinical and Translational Oncology 18:10, 1044-1050.
CrossRef291
O. Abdel-Rahman, D. Helbling, J. Schmidt, U. Petrausch, A. Giryes, A. Mehrabi, O. Schöb, M. Mannhart, A. Zidan, H. Oweira. . (2016) Treatment-associated Fatigue in Cancer Patients Treated with Immune Checkpoint Inhibitors; a Systematic Review and Meta-analysis. Clinical Oncology 28:10, e127-e138.
CrossRef292
Christian Bauer, Benjamin Kühnemuth, Peter Duewell, Steffen Ormanns, Thomas Gress, Max Schnurr. . (2016) Prevailing over T cell exhaustion: New developments in the immunotherapy of pancreatic cancer. Cancer Letters 381:1, 259-268.
CrossRef293
C. Granier, S. Karaki, H. Roussel, C. Badoual, T. Tran, M. Anson, E. Fabre, S. Oudard, E. Tartour. . (2016) Immunothérapie des cancers : rationnel et avancées récentes. La Revue de Médecine Interne 37:10, 694-700.
CrossRef294
Leila Khoja, Eshetu G. Atenafu, Arnoud Templeton, Ye Qye, Mary Anne Chappell, Sam Saibil, David Hogg, Marcus O. Butler, Anthony M. Joshua. . (2016) The full blood count as a biomarker of outcome and toxicity in ipilimumab-treated cutaneous metastatic melanoma. Cancer Medicine 5:10, 2792-2799.
CrossRef295
Kristian M. Koller, Wenge Wang, Todd D. Schell, Eugene M. Cozza, Kathleen M. Kokolus, Rogerio I. Neves, Heath B. Mackley, Colette Pameijer, Anna Leung, Bryan Anderson, Carol A. Mallon, Gavin Robertson, Joseph J. Drabick. . (2016) Malignant melanoma—The cradle of anti-neoplastic immunotherapy. Critical Reviews in Oncology/Hematology 106, 25-54.
CrossRef296
Nitin Chakravarti, Doina Ivan, Van A. Trinh, Isabella C. Glitza, Jonathan L. Curry, Carlos Torres-Cabala, Michael T. Tetzlaff, Roland L. Bassett, Victor G. Prieto, Wen-Jen Hwu. . (2016) High cytotoxic T-lymphocyte-associated antigen 4 and phospho-Akt expression in tumor samples predicts poor clinical outcomes in ipilimumab-treated melanoma patients. Melanoma Research, 1.
CrossRef297
Elisabeth T. Tracy, Jennifer H. Aldrink. . (2016) Pediatric melanoma. Seminars in Pediatric Surgery 25:5, 290-298.
CrossRef298
Jianjun Gao, Lewis Zhichang Shi, Hao Zhao, Jianfeng Chen, Liangwen Xiong, Qiuming He, Tenghui Chen, Jason Roszik, Chantale Bernatchez, Scott E. Woodman, Pei-Ling Chen, Patrick Hwu, James P. Allison, Andrew Futreal, Jennifer A. Wargo, Padmanee Sharma. . (2016) Loss of IFN-γ Pathway Genes in Tumor Cells as a Mechanism of Resistance to Anti-CTLA-4 Therapy. Cell 167:2, 397-404.e9.
CrossRef299
C. Rory Goodwin, Nancy Abu-Bonsrah, Mark H. Bilsky, Jeremy J. Reynolds, Laurence D. Rhines, Ilya Laufer, Alexander C. Disch, Arpad Bozsodi, Shreyaskumar R. Patel, Ziya L. Gokaslan, Daniel M. Sciubba, Chetan Bettegowda. . (2016) Clinical Decision Making. SPINE 41, S171-S177.
CrossRef300
Nadeem Riaz, Jonathan J Havel, Sviatoslav M Kendall, Vladimir Makarov, Logan A Walsh, Alexis Desrichard, Nils Weinhold, Timothy A Chan. . (2016) Recurrent SERPINB3 and SERPINB4 mutations in patients who respond to anti-CTLA4 immunotherapy. Nature Genetics 48:11, 1327-1329.
CrossRef301
Stefan Hartmann, Jennifer R. Grandis. . (2016) Treatment of head and neck cancer in the elderly. Expert Opinion on Pharmacotherapy 17:14, 1903-1921.
CrossRef302
Andrew C. Titman. . (2016) Estimation of time-shift models with application to survival calibration in health technology assessment. Statistics in Medicine 35:20, 3645-3656.
CrossRef303
Sheng-Dong Wang, Heng-Yuan Li, Bing-Hao Li, Tao Xie, Ting Zhu, Ling-Ling Sun, Hai-Yong Ren, Zhao-Ming Ye. . (2016) The role of CTLA-4 and PD-1 in anti-tumor immune response and their potential efficacy against osteosarcoma. International Immunopharmacology 38, 81-89.
CrossRef304
J Dick, N Lang, A Slynko, A Kopp-Schneider, C Schulz, A Dimitrakopoulou-Strauss, AH Enk, JC Hassel. . (2016) Use of LDH and autoimmune side effects to predict response to ipilimumab treatment. Immunotherapy 8:9, 1033-1044.
CrossRef305
Arun Rajan, Chul Kim, Christopher R. Heery, Udayan Guha, James L. Gulley. . (2016) Nivolumab, anti-programmed death-1 (PD-1) monoclonal antibody immunotherapy: Role in advanced cancers. Human Vaccines & Immunotherapeutics 12:9, 2219-2231.
CrossRef306
A. Vozy, C. Coutzac. . (2016) Colite induite par les inhibiteurs de checkpoint immunitaire : anticorps anti-CTLA-4 et anticorps anti-PD-1/PDL-1. Oncologie 18:9-10, 501-508.
CrossRef307
T. Lambert, L. Doucet. . (2016) Immunothérapie et dysfonctions thyroïdiennes : mise au point sur les connaissances actuelles. Oncologie 18:9-10, 509-515.
CrossRef308
Mark C. Mochel, Michael E. Ming, Sotonye Imadojemu, Tara C. Gangadhar, Lynn M. Schuchter, Rosalie Elenitsas, Aimee S. Payne, Emily Y. Chu. . (2016) Cutaneous autoimmune effects in the setting of therapeutic immune checkpoint inhibition for metastatic melanoma. Journal of Cutaneous Pathology 43:9, 787-791.
CrossRef309
C. Gervais. . (2016) Enjeux et perspectives des immunothérapies : un dossier entièrement réalisé par de jeunes oncologues. Oncologie 18:9-10, 499-500.
CrossRef310
E. Colle, T. Andre, C. Lebbe, C. Borg. . (2016) Facteurs prédictifs et biomarqueurs précoces de réponse aux inhibiteurs de checkpoint immunologiques (anti-PD-1, anti-PD-L1). Oncologie 18:9-10, 533-542.
CrossRef311
Katja Vouk, Ursula Benter, Mayur M. Amonkar, Alessia Marocco, Ceilidh Stapelkamp, Sylvie Pfersch, Laure Benjamin. . (2016) Cost and economic burden of adverse events associated with metastatic melanoma treatments in five countries. Journal of Medical Economics 19:9, 900-912.
CrossRef312
Saskia Santegoets, Marij Welters, Sjoerd van der Burg. . (2016) Monitoring of the Immune Dysfunction in Cancer Patients. Vaccines 4:3, 29.
CrossRef313
Jonna Berntsson, Björn Nodin, Jakob Eberhard, Patrick Micke, Karin Jirström. . (2016) Prognostic impact of tumour-infiltrating B cells and plasma cells in colorectal cancer. International Journal of Cancer 139:5, 1129-1139.
CrossRef314
Adam K. Brys, Raghavendra Gowda, Daniel B. Loriaux, Gavin P. Robertson, Paul J. Mosca. . (2016) Nanotechnology-based strategies for combating toxicity and resistance in melanoma therapy. Biotechnology Advances 34:5, 565-577.
CrossRef315
Omar Abdel-Rahman. . (2016) Combination or single-agent ipilimumab as immunotherapy of advanced melanoma: a critical review. Melanoma Management 3:3, 231-243.
CrossRef316
Antonia Digklia, Olivier Michielin. . (2016) The cutting edge of metastatic melanoma therapy. Melanoma Management 3:3, 217-229.
CrossRef317
Kilian Wistuba-Hamprecht, Alexander Martens, Karin Haehnel, Marnix Geukes Foppen, Jianda Yuan, Michael A. Postow, Phillip Wong, Emanuela Romano, Amir Khammari, Brigitte Dreno, Mariaelena Capone, Paolo A. Ascierto, Ilja Demuth, Elisabeth Steinhagen-Thiessen, Anis Larbi, Bastian Schilling, Dirk Schadendorf, Jedd D. Wolchok, Christian U. Blank, Graham Pawelec, Claus Garbe, Benjamin Weide. . (2016) Proportions of blood-borne Vδ1+ and Vδ2+ T-cells are associated with overall survival of melanoma patients treated with ipilimumab. European Journal of Cancer 64, 116-126.
CrossRef318
C. Caux. . (2016) Immunoth?rapie : les checkpoints. Revue des Maladies Respiratoires Actualit?s 8:5, 387-398.
CrossRef319
B. Lo, J. M. Fritz, H. C. Su, G. Uzel, M. B. Jordan, M. J. Lenardo. . (2016) CHAI and LATAIE: new genetic diseases of CTLA-4 checkpoint insufficiency. Blood 128:8, 1037-1042.
CrossRef320
R K Spartacus, Rajan Paliwal, Rohitashwa Dana, Shwetha Mutha, Prashant Bhatt, Anees Malavat. . (2016) Metastatic Anorectal Melanoma: A Case Report. Iranian Journal of Cancer Prevention In Press:In Press.
CrossRef321
Sung W. Han, Hua Zhong. . 2016. Recent Development in Methodology for Gene Network Problems and Inferences. Healthcare Analytics: From Data to Knowledge to Healthcare Improvement, 1-29.
CrossRef322
Lewis Zhichang Shi, Tihui Fu, Baoxiang Guan, Jianfeng Chen, Jorge M. Blando, James P. Allison, Liangwen Xiong, Sumit K. Subudhi, Jianjun Gao, Padmanee Sharma. . (2016) Interdependent IL-7 and IFN-γ signalling in T-cell controls tumour eradication by combined α-CTLA-4+α-PD-1 therapy. Nature Communications 7, 12335.
CrossRef323
Andrea Guennoun, Heba Sidahmed, Cristina Maccalli, Barbara Seliger, Francesco M. Marincola, Davide Bedognetti. . (2016) Harnessing the immune system for the treatment of melanoma: current status and future prospects. Expert Review of Clinical Immunology 12:8, 879-893.
CrossRef324
Pol Specenier. . (2016) Ipilimumab in melanoma. Expert Review of Anticancer Therapy 16:8, 811-826.
CrossRef325
Michael C. Burns, Aidan O’donnell, Igor Puzanov. . (2016) Pembrolizumab for the treatment of advanced melanoma. Expert Opinion on Orphan Drugs 4:8, 867-873.
CrossRef326
Gulden Menderes, Christopher Hicks, Jonathan D. Black, Carlton L. Schwab, Alessandro D. Santin. . (2016) Immune checkpoint inhibitors in gynecologic cancers with lessons learned from non-gynecologic cancers. Expert Opinion on Biological Therapy 16:8, 989-1004.
CrossRef327
Steve Boudewijns, Rutger H. T. Koornstra, Harm Westdorp, Gerty Schreibelt, Alfons J. M. van den Eertwegh, Marnix H. Geukes Foppen, John B. Haanen, I. Jolanda M. de Vries, Carl G. Figdor, Kalijn F. Bol, Winald R. Gerritsen. . (2016) Ipilimumab administered to metastatic melanoma patients who progressed after dendritic cell vaccination. OncoImmunology 5:8, e1201625.
CrossRef328
Zhenyu Xu, Jing Shen, Maggie Haitian Wang, Tao Yi, Yangyang Yu, Yinxin Zhu, Bo Chen, Jianping Chen, Longfei Li, Minxing Li, Jian Zuo, Hui Jiang, Dexi Zhou, Jiajie Luan, Zhangang Xiao. . (2016) Comprehensive molecular profiling of the B7 family of immune-regulatory ligands in breast cancer. OncoImmunology 5:8, e1207841.
CrossRef329
C. Velter, B. Cribier, F. Goldwasser, P. Vinant. . (2016) Directives anticipées en dermato-oncologie : situation actuelle et perspectives. Annales de Dermatologie et de Vénéréologie 143:8-9, 505-511.
CrossRef330
Elias Kotteas, Muhammad Wasif Saif, Konstantinos Syrigos. . (2016) Immunotherapy for pancreatic cancer. Journal of Cancer Research and Clinical Oncology 142:8, 1795-1805.
CrossRef331
Marios P Decatris, Kenneth J O'Byrne. . (2016) Immune checkpoint inhibitors as first-line and salvage therapy for advanced non-small-cell lung cancer. Future Oncology 12:15, 1805-1822.
CrossRef332
Dijendra Nath Roy, Ritobrata Goswami. . (2016) Drugs of abuse and addiction: A slippery slope toward liver injury. Chemico-Biological Interactions 255, 92-105.
CrossRef333
J. M. Pitt, A. Marabelle, A. Eggermont, J.-C. Soria, G. Kroemer, L. Zitvogel. . (2016) Targeting the tumor microenvironment: removing obstruction to anticancer immune responses and immunotherapy. Annals of Oncology 27:8, 1482-1492.
CrossRef334
I. Giannini, D. A. Cutrignelli, L. Resta, A. Gentile, L. Vincenti. . (2016) Metastatic melanoma of the gallbladder: report of two cases and a review of the literature. Clinical and Experimental Medicine 16:3, 295-300.
CrossRef335
Markus V. Heppt, Thomas K. Eigentler, Katharina C. Kähler, Rudolf A. Herbst, Daniela Göppner, Thilo Gambichler, Jens Ulrich, Edgar Dippel, Carmen Loquai, Beatrice Schell, Bastian Schilling, Susanne G. Schäd, Erwin S. Schultz, Fanny Matheis, Julia K. Tietze, Carola Berking. . (2016) Immune checkpoint blockade with concurrent electrochemotherapy in advanced melanoma: a retrospective multicenter analysis. Cancer Immunology, Immunotherapy 65:8, 951-959.
CrossRef336
Merete Krogh, Ib Christensen, Marna Bouwhuis, Julia S. Johansen, Peter Nørgaard, Henrik Schmidt, Johan Hansson, Stefan Suciu, Alexander M.M. Eggermont, Lars Bastholt. . (2016) Prognostic and predictive value of YKL-40 in stage IIB-III melanoma. Melanoma Research 26:4, 367-376.
CrossRef337
Rawad Elias, Joshua Morales, Yasser Rehman, Humera Khurshid. . (2016) Immune Checkpoint Inhibitors in Older Adults. Current Oncology Reports 18:8.
CrossRef338
D. Lee, J. Porter, N. Hertel, A. J. Hatswell, A. Briggs. . (2016) Modelling Comparative Efficacy of Drugs with Different Survival Profiles: Ipilimumab, Vemurafenib and Dacarbazine in Advanced Melanoma. BioDrugs 30:4, 307-319.
CrossRef339
Amanda YL Goh, Christopher J Layton. . (2016) Evolving systemic targeted therapy strategies in uveal melanoma and implications for ophthalmic management: a review. Clinical & Experimental Ophthalmology 44:6, 509-519.
CrossRef340
Maria Alsina, Markus Moehler, Cinta Hierro, Raquel Guardeño, Josep Tabernero. . (2016) Immunotherapy for Gastric Cancer: A Focus on Immune Checkpoints. Targeted Oncology 11:4, 469-477.
CrossRef341
Nicolas Jacquelot, David P. Enot, Caroline Flament, Stéphane Dalle, Laurence Zitvogel. . (2016) L’expression des récepteurs de chimiokines à la surface des lymphocytes T reflète la dissémination métastatique du mélanome. médecine/sciences 32:8-9, 690-692.
CrossRef342
Rainer Hügel, Axel Muendlein, Lennart Volbeding, Heinz Drexel, Erika Richtig, Ulrike Wehkamp, Clemes Painsi, Bernhard Lange-Asschenfeldt, Axel Hauschild, Friederike Egberts. . (2016) Serum levels of hepatocyte growth factor as a potential tumor marker in patients with malignant melanoma. Melanoma Research 26:4, 354-360.
CrossRef343
Claus Garbe, Ketty Peris, Axel Hauschild, Philippe Saiag, Mark Middleton, Lars Bastholt, Jean-Jacques Grob, Josep Malvehy, Julia Newton-Bishop, Alexander J. Stratigos, Hubert Pehamberger, Alexander M. Eggermont. . (2016) Diagnosis and treatment of melanoma. European consensus-based interdisciplinary guideline – Update 2016. European Journal of Cancer 63, 201-217.
CrossRef344
Igor Puzanov, Mohammed M. Milhem, David Minor, Omid Hamid, Ai Li, Lisa Chen, Michael Chastain, Kevin S. Gorski, Abraham Anderson, Jeffrey Chou, Howard L. Kaufman, Robert H.I. Andtbacka. . (2016) Talimogene Laherparepvec in Combination With Ipilimumab in Previously Untreated, Unresectable Stage IIIB-IV Melanoma. Journal of Clinical Oncology 34:22, 2619-2626.
CrossRef345
Klaus G. Griewank. . (2016) Biomarkers in melanoma. Scandinavian Journal of Clinical and Laboratory Investigation 76:sup245, S104-S112.
CrossRef346
Shivshankari Rajkumar, Ian R Watson. . (2016) Molecular characterisation of cutaneous melanoma: creating a framework for targeted and immune therapies. British Journal of Cancer 115:2, 145-155.
CrossRef347
Vishwajith Sridharan, Danielle N Margalit, Stephanie A Lynch, Mariano Severgnini, Jun Zhou, Nicole G Chau, Guilherme Rabinowits, Jochen H Lorch, Peter S Hammerman, F Stephen Hodi, Robert I Haddad, Roy B Tishler, Jonathan D Schoenfeld. . (2016) Definitive chemoradiation alters the immunologic landscape and immune checkpoints in head and neck cancer. British Journal of Cancer 115:2, 252-260.
CrossRef348
Nengliang Yao, Sekwon Jang. . (2016) Adoption of ipilimumab in the United States: a Medicare study. Expert Review of Pharmacoeconomics & Outcomes Research 16:4, 439-440.
CrossRef349
Megan H. Pollack, Jonathan Aston, Mona Benrashid, Douglas B. Johnson, Igor Puzanov. . (2016) Talimogene laherparepvec in advanced melanoma. Expert Opinion on Orphan Drugs 4:7, 781-788.
CrossRef350
Roch Houot, Philippe Gaulard, Robert Schreiber, Ira Mellman, Olivier Lambotte, Pierre G. Coulie, Thierry Fest, Alan Korman, Ronald Levy, Margaret Shipp, Karin Tarte, Holbrook Kohrt, Aurélien Marabelle, Stephen Ansell, Hervé Watier, Andrea van Elsas, Arun Balakumaran, Frederick Arce Vargas, Sergio A. Quezada, Gilles Salles, Daniel Olive. . (2016) Immunomodulatory antibodies for the treatment of lymphoma: Report on the CALYM Workshop. OncoImmunology 5:7, e1186323.
CrossRef351
Joana Felix, Jérome Lambert, Marie Roelens, Eve Maubec, Hélène Guermouche, Cécile Pages, Irina Sidina, Debora J. Cordeiro, Guitta Maki, François Chasset, Raphaël Porcher, Martine Bagot, Anne Caignard, Antoine Toubert, Céleste Lebbé, Hélène Moins-Teisserenc. . (2016) Ipilimumab reshapes T cell memory subsets in melanoma patients with clinical response. OncoImmunology 5:7, 1136045.
CrossRef352
Blanca Homet Moreno, Stephen Mok, Begonya Comin-Anduix, Siwen Hu-Lieskovan, Antoni Ribas. . (2016) Combined treatment with dabrafenib and trametinib with immune-stimulating antibodies for BRAF mutant melanoma. OncoImmunology 5:7, e1052212.
CrossRef353
Mariacarmela Santarpia, Elisa Giovannetti, Christian Rolfo, Niki Karachaliou, Maria González-Cao, Giuseppe Altavilla, Rafael Rosell. . (2016) Recent developments in the use of immunotherapy in non-small cell lung cancer. Expert Review of Respiratory Medicine 10:7, 781-798.
CrossRef354
Rikke B. Holmgaard, Alexandra Brachfeld, Billel Gasmi, David R. Jones, Marissa Mattar, Thompson Doman, Mary Murphy, David Schaer, Jedd D. Wolchok, Taha Merghoub. . (2016) Timing of CSF-1/CSF-1R signaling blockade is critical to improving responses to CTLA-4 based immunotherapy. OncoImmunology 5:7, e1151595.
CrossRef355
Jeffrey S Weber, Geoff Gibney, Ryan J Sullivan, Jeffrey A Sosman, Craig L Slingluff, Donald P Lawrence, Theodore F Logan, Lynn M Schuchter, Suresh Nair, Leslie Fecher, Elizabeth I Buchbinder, Elmer Berghorn, Mary Ruisi, George Kong, Joel Jiang, Christine Horak, F Stephen Hodi. . (2016) Sequential administration of nivolumab and ipilimumab with a planned switch in patients with advanced melanoma (CheckMate 064): an open-label, randomised, phase 2 trial. The Lancet Oncology 17:7, 943-955.
CrossRef356
Stephanie J. Hachey, Alexander D. Boiko. . (2016) Therapeutic implications of melanoma heterogeneity. Experimental Dermatology 25:7, 497-500.
CrossRef357
Jon Zugazagoitia, Cristiano Guedes, Santiago Ponce, Irene Ferrer, Sonia Molina-Pinelo, Luis Paz-Ares. . (2016) Current Challenges in Cancer Treatment. Clinical Therapeutics 38:7, 1551-1566.
CrossRef358
Christine Cambareri, Carmen F. Nobre, Laura A. Tuttle. . (2016) New Pharmaceutical Agents in Oncology. Physician Assistant Clinics 1:3, 435-463.
CrossRef359
Scott J Antonia, José A López-Martin, Johanna Bendell, Patrick A Ott, Matthew Taylor, Joseph Paul Eder, Dirk Jäger, M Catherine Pietanza, Dung T Le, Filippo de Braud, Michael A Morse, Paolo A Ascierto, Leora Horn, Asim Amin, Rathi N Pillai, Jeffry Evans, Ian Chau, Petri Bono, Akin Atmaca, Padmanee Sharma, Christopher T Harbison, Chen-Sheng Lin, Olaf Christensen, Emiliano Calvo. . (2016) Nivolumab alone and nivolumab plus ipilimumab in recurrent small-cell lung cancer (CheckMate 032): a multicentre, open-label, phase 1/2 trial. The Lancet Oncology 17:7, 883-895.
CrossRef360
Lesly A. Dossett, Ilan Ben-Shabat, Roger Olofsson Bagge, Jonathan S. Zager. . (2016) Clinical Response and Regional Toxicity Following Isolated Limb Infusion Compared with Isolated Limb Perfusion for In-Transit Melanoma. Annals of Surgical Oncology 23:7, 2330-2335.
CrossRef361
Mark R. Middleton, Stéphane Dalle, Joel Claveau, Pilar Mut, Sigrun Hallmeyer, Patrice Plantin, Martin Highley, Srividya Kotapati, Trong Kim Le, Jane Brokaw, Amy P. Abernethy. . (2016) Real-world treatment practice in patients with advanced melanoma in the era before ipilimumab: results from the IMAGE study. Cancer Medicine 5:7, 1436-1443.
CrossRef362
Sarah Freeston. . (2016) Combining immune checkpoint inhibitors for advanced melanoma: the key to optimizing treatment outcomes?. Journal of Comparative Effectiveness Research 5:4, 329-333.
CrossRef363
Akihiko Sano, Hitoshi Ojima, Daigo Ozawa, Atsushi Ogawa, Hiroyuki Ando, Makoto Sohda, Yasuyuki Fukai, Yasushi Mochida, Hiroyuki Kuwano. . (2016) Clinical significance of [18F]-fluoro-deoxy-glucose positron emission tomography/computed tomography in patients with primary malignant melanoma of the esophagus: report of three cases. Esophagus 13:3, 311-316.
CrossRef364
Stephanie A. Holler Howard, Katherine M. Krajewski, Jyothi P. Jagannathan, Marta Braschi-Amirfarzan, Sree H. Tirumani, Atul B. Shinagare, Nikhil H. Ramaiya. . (2016) A New Look at Toxicity in the Era of Precision Oncology: Imaging Findings, Their Relationship With Tumor Response, and Effect on Metastasectomy. American Journal of Roentgenology 207:1, 4-14.
CrossRef365
Hampig R. Kourie, Jean A. Klastersky. . (2016) Side-effects of checkpoint inhibitor-based combination therapy. Current Opinion in Oncology 28:4, 306-313.
CrossRef366
Andrea Riccardo Filippi, Paolo Fava, Serena Badellino, Chiara Astrua, Umberto Ricardi, Pietro Quaglino. . (2016) Radiotherapy and immune checkpoints inhibitors for advanced melanoma. Radiotherapy and Oncology 120:1, 1-12.
CrossRef367
Paul E. Hughes, Sean Caenepeel, Lawren C. Wu. . (2016) Targeted Therapy and Checkpoint Immunotherapy Combinations for the Treatment of Cancer. Trends in Immunology 37:7, 462-476.
CrossRef368
Samer Tabchi, Christine Messier, Normand Blais. . (2016) Immune-mediated respiratory adverse events of checkpoint inhibitors. Current Opinion in Oncology 28:4, 269-277.
CrossRef369
Jagpal S. Klair, Mohit Girotra, Laura F. Hutchins, Kari D. Caradine, Farshad Aduli, Mauricio Garcia-Saenz-de-Sicilia. . (2016) Ipilimumab-Induced Gastrointestinal Toxicities: A Management Algorithm. Digestive Diseases and Sciences 61:7, 2132-2139.
CrossRef370
Seongseok Yun, Nicole D. Vincelette, Myke R. Green, Andrea E. Wahner Hendrickson, Ivo Abraham. . (2016) Targeting immune checkpoints in unresectable metastatic cutaneous melanoma: a systematic review and meta-analysis of anti-CTLA-4 and anti-PD-1 agents trials. Cancer Medicine 5:7, 1481-1491.
CrossRef371
Antonin Levy, Cyrus Chargari, Aurelien Marabelle, Jean-Luc Perfettini, Nicolas Magné, Eric Deutsch. . (2016) Can immunostimulatory agents enhance the abscopal effect of radiotherapy?. European Journal of Cancer 62, 36-45.
CrossRef372
Anthony O’Connor, Maria Marples, Clive Mulatero, John Hamlin, Alexander C. Ford. . (2016) Ipilimumab-induced colitis: experience from a tertiary referral center. Therapeutic Advances in Gastroenterology 9:4, 457-462.
CrossRef373
Gulden Menderes, Carlton L. Schwab, Jonathan Black, Alessandro D. Santin. . (2016) The Role of the Immune System in Ovarian Cancer and Implications on Therapy. Expert Review of Clinical Immunology 12:6, 681-695.
CrossRef374
Moshe C. Ornstein, Brian I. Rini. . (2016) The safety and efficacy of nivolumab for the treatment of advanced renal cell carcinoma. Expert Review of Anticancer Therapy 16:6, 577-584.
CrossRef375
Katharina Lankes, Gheorghe Hundorfean, Thomas Harrer, Ansgar J. Pommer, Abbas Agaimy, Irena Angelovska, Azadeh Tajmir-Riahi, Jonas Göhl, Gerold Schuler, Markus F. Neurath, Werner Hohenberger, Lucie Heinzerling. . (2016) Anti-TNF-refractory colitis after checkpoint inhibitor therapy: Possible role of CMV-mediated immunopathogenesis. OncoImmunology 5:6, e1128611.
CrossRef376
Brian T. Rekoske, Brian M. Olson, Douglas G. McNeel. . (2016) Antitumor vaccination of prostate cancer patients elicits PD-1/PD-L1 regulated antigen-specific immune responses. OncoImmunology 5:6, e1165377.
CrossRef377
Eytan Ben-Ami, Jacob Schachter. . (2016) Adjuvant treatment for stage III melanoma in the era of targeted medicine and immunotherapy. Melanoma Management 3:2, 137-147.
CrossRef378
Andrew JS Furness, Sergio A Quezada, Karl S Peggs. . (2016) Neoantigen heterogeneity: a key driver of immune response and sensitivity to immune checkpoint blockade?. Immunotherapy 8:7, 763-766.
CrossRef379
Sarah E. Henrickson, Melanie A. Ruffner, Mildred Kwan. . (2016) Unintended Immunological Consequences of Biologic Therapy. Current Allergy and Asthma Reports 16:6.
CrossRef380
Francesco Spagnolo, Virginia Picasso, Laura Spano, Enrica Tanda, Clary Venzano, Paola Queirolo. . (2016) Update on Metastatic Uveal Melanoma: Progress and Challenges. BioDrugs 30:3, 161-172.
CrossRef381
Manuela Terranova-Barberio, Scott Thomas, Pamela N Munster. . (2016) Epigenetic modifiers in immunotherapy: a focus on checkpoint inhibitors. Immunotherapy 8:6, 705-719.
CrossRef382
Jenny Lee, Richard Kefford, Matteo Carlino. . (2016) PD-1 and PD-L1 inhibitors in melanoma treatment: past success, present application and future challenges. Immunotherapy 8:6, 733-746.
CrossRef383
Rebecca C. Hoesli, Jeffrey S. Moyer. . (2016) Immunotherapy for Head and Neck Squamous Cell Carcinoma. Current Oral Health Reports 3:2, 74-81.
CrossRef384
Kyle Stang, Scott Silva, Alec M. Block, James S. Welsh. . (2016) The integration of radiation therapy and immunotherapy in melanoma management. Journal of Radiation Oncology 5:2, 131-142.
CrossRef385
Yana G Najjar, John M Kirkwood. . (2016) Neoadjuvant treatment for melanoma: current challenges and future perspectives. Melanoma Management 3:2, 149-159.
CrossRef386
S. Muenst, H. Läubli, S. D. Soysal, A. Zippelius, A. Tzankov, S. Hoeller. . (2016) The immune system and cancer evasion strategies: therapeutic concepts. Journal of Internal Medicine 279:6, 541-562.
CrossRef387
Lavinia Spain, James Larkin. . (2016) Weighing up the pros and cons of immune checkpoint inhibitors in the treatment of melanoma. Immunotherapy 8:6, 677-679.
CrossRef388
Chrisann Kyi, Michael A Postow. . (2016) Immune checkpoint inhibitor combinations in solid tumors: opportunities and challenges. Immunotherapy 8:7, 821-837.
CrossRef389
George Jour, Doina Ivan, Phyu P Aung. . (2016) Angiogenesis in melanoma: an update with a focus on current targeted therapies. Journal of Clinical Pathology 69:6, 472-483.
CrossRef390
Kimberly Loo, Adil Daud. . (2016) Emerging biomarkers as predictors to anti-PD1/PD-L1 therapies in advanced melanoma. Immunotherapy 8:7, 775-784.
CrossRef391
B. Lee, A. Wong, D. Kee, P. Neeson, M. Shackleton, G. McArthur, S. Sandhu. . (2016) The use of ipilimumab in patients with rheumatoid arthritis and metastatic melanoma. Annals of Oncology 27:6, 1174-1177.
CrossRef392
Sandra Demaria, C. Norman Coleman, Silvia C. Formenti. . (2016) Radiotherapy: Changing the Game in Immunotherapy. Trends in Cancer 2:6, 286-294.
CrossRef393
Xizhi Wen, Yao Wang, Ya Ding, Dandan Li, Jingjing Li, Yiqun Guo, Ruiqing Peng, Jingjing Zhao, Xing Zhang, Xiao-Shi Zhang. . (2016) Safety of immune checkpoint inhibitors in Chinese patients with melanoma. Melanoma Research 26:3, 284-289.
CrossRef394
Fausto Petrelli, Andrea Coinu, Mary Cabiddu, Karen Borgonovo, Mara Ghilardi, Veronica Lonati, Sandro Barni. . (2016) Early analysis of surrogate endpoints for metastatic melanoma in immune checkpoint inhibitor trials. Medicine 95:26, e3997.
CrossRef395
Christine Mateus, Cristina Libenciuc, Caroline Robert. . (2016) Place des anti-PD1 dans la prise en charge des mélanomes cutanés. Bulletin du Cancer 103:6, S4-S11.
CrossRef396
Lars Hofmann, Andrea Forschner, Carmen Loquai, Simone M. Goldinger, Lisa Zimmer, Selma Ugurel, Maria I. Schmidgen, Ralf Gutzmer, Jochen S. Utikal, Daniela Göppner, Jessica C. Hassel, Friedegund Meier, Julia K. Tietze, Ioannis Thomas, Carsten Weishaupt, Martin Leverkus, Renate Wahl, Ursula Dietrich, Claus Garbe, Michael C. Kirchberger, Thomas Eigentler, Carola Berking, Anja Gesierich, Angela M. Krackhardt, Dirk Schadendorf, Gerold Schuler, Reinhard Dummer, Lucie M. Heinzerling. . (2016) Cutaneous, gastrointestinal, hepatic, endocrine, and renal side-effects of anti-PD-1 therapy. European Journal of Cancer 60, 190-209.
CrossRef397
Eduard Cornelis Verschuren, Alfonsus Johannes van den Eertwegh, Janneke Wonders, Rob Michel Slangen, Foke van Delft, Adriaan van Bodegraven, Andra Neefjes-Borst, Nanne Klaas de Boer. . (2016) Clinical, Endoscopic, and Histologic Characteristics of Ipilimumab-Associated Colitis. Clinical Gastroenterology and Hepatology 14:6, 836-842.
CrossRef398
Nataniel H. Lester-Coll, Charles E. Rutter, Trevor J. Bledsoe, Sarah B. Goldberg, Roy H. Decker, James B. Yu. . (2016) Cost-Effectiveness of Surgery, Stereotactic Body Radiation Therapy, and Systemic Therapy for Pulmonary Oligometastases. International Journal of Radiation Oncology*Biology*Physics 95:2, 663-672.
CrossRef399
Michael B. Atkins, James Larkin. . (2016) Immunotherapy Combined or Sequenced With Targeted Therapy in the Treatment of Solid Tumors: Current Perspectives. JNCI: Journal of the National Cancer Institute 108:6.
CrossRef400
Rafael Aliosha Kaliks. . (2016) An update on clinical oncology for the non-oncologist. Einstein (São Paulo) 14:2, 294-299.
CrossRef401
Jonathan M. Pitt, Marie Vétizou, Romain Daillère, María Paula Roberti, Takahiro Yamazaki, Bertrand Routy, Patricia Lepage, Ivo Gomperts Boneca, Mathias Chamaillard, Guido Kroemer, Laurence Zitvogel. . (2016) Resistance Mechanisms to Immune-Checkpoint Blockade in Cancer: Tumor-Intrinsic and -Extrinsic Factors. Immunity 44:6, 1255-1269.
CrossRef402
Omar Abdel-Rahman, Mona Fouad. . (2016) Risk of pneumonitis in cancer patients treated with immune checkpoint inhibitors: a meta-analysis. Therapeutic Advances in Respiratory Disease 10:3, 183-193.
CrossRef403
Rebecca B Delconte, Tatiana B Kolesnik, Laura F Dagley, Jai Rautela, Wei Shi, Eva M Putz, Kimberley Stannard, Jian-Guo Zhang, Charis Teh, Matt Firth, Takashi Ushiki, Christopher E Andoniou, Mariapia A Degli-Esposti, Phillip P Sharp, Caroline E Sanvitale, Giuseppe Infusini, Nicholas P D Liau, Edmond M Linossi, Christopher J Burns, Sebastian Carotta, Daniel H D Gray, Cyril Seillet, Dana S Hutchinson, Gabrielle T Belz, Andrew I Webb, Warren S Alexander, Shawn S Li, Alex N Bullock, Jeffery J Babon, Mark J Smyth, Sandra E Nicholson, Nicholas D Huntington. . (2016) CIS is a potent checkpoint in NK cell–mediated tumor immunity. Nature Immunology 17:7, 816-824.
CrossRef404
Susanne H. Baumeister, Gordon J. Freeman, Glenn Dranoff, Arlene H. Sharpe. . (2016) Coinhibitory Pathways in Immunotherapy for Cancer. Annual Review of Immunology 34:1, 539-573.
CrossRef405
S Bowyer, P Prithviraj, P Lorigan, J Larkin, G McArthur, V Atkinson, M Millward, M Khou, S Diem, S Ramanujam, B Kong, E Liniker, A Guminski, P Parente, M C Andrews, S Parakh, J Cebon, G V Long, M S Carlino, O Klein. . (2016) Efficacy and toxicity of treatment with the anti-CTLA-4 antibody ipilimumab in patients with metastatic melanoma after prior anti-PD-1 therapy. British Journal of Cancer 114:10, 1084-1089.
CrossRef406
Celine Boutros, Ahmad Tarhini, Emilie Routier, Olivier Lambotte, Francois Leroy Ladurie, Franck Carbonnel, Hassane Izzeddine, Aurelien Marabelle, Stephane Champiat, Armandine Berdelou, Emilie Lanoy, Matthieu Texier, Cristina Libenciuc, Alexander M. M. Eggermont, Jean-Charles Soria, Christine Mateus, Caroline Robert. . (2016) Safety profiles of anti-CTLA-4 and anti-PD-1 antibodies alone and in combination. Nature Reviews Clinical Oncology 13:8, 473-486.
CrossRef407
Paola Savoia, Chiara Astrua, Paolo Fava. . (2016) Ipilimumab (Anti-Ctla-4 Mab) in the treatment of metastatic melanoma: Effectiveness and toxicity management. Human Vaccines & Immunotherapeutics 12:5, 1092-1101.
CrossRef408
Joseph M. Ryan, Jeffrey S. Wasser, Adam J. Adler, Anthony T. Vella. . (2016) Enhancing the safety of antibody-based immunomodulatory cancer therapy without compromising therapeutic benefit: Can we have our cake and eat it too?. Expert Opinion on Biological Therapy 16:5, 655-674.
CrossRef409
Hans A. Schlößer, Uta Drebber, Michael Kloth, Martin Thelen, Sacha I. Rothschild, Simon Haase, Maria Garcia-Marquez, Kerstin Wennhold, Felix Berlth, Alexander Urbanski, Hakan Alakus, Astrid Schauss, Alexander Shimabukuro-Vornhagen, Sebastian Theurich, Ute Warnecke-Ebertz, Dirk L. Stippel, Alfred Zippelius, Reinhard Büttner, Michael Hallek, Arnulf H. Hölscher, Thomas Zander, Stefan P. Mönig, Michael von Bergwelt-Baildon. . (2016) Immune checkpoints programmed death 1 ligand 1 and cytotoxic T lymphocyte associated molecule 4 in gastric adenocarcinoma. OncoImmunology 5:5, e1100789.
CrossRef410
Omar Abdel-Rahman, Mona Fouad. . (2016) A network meta-analysis of the risk of immune-related renal toxicity in cancer patients treated with immune checkpoint inhibitors. Immunotherapy 8:5, 665-674.
CrossRef411
Silvia Carvalho, Francesca Levi-Schaffer, Michael Sela, Yosef Yarden. . (2016) Immunotherapy of cancer: from monoclonal to oligoclonal cocktails of anti-cancer antibodies: IUPHAR Review 18. British Journal of Pharmacology 173:9, 1407-1424.
CrossRef412
Xin Chen, Yong Du, XiuQing Lin, Yan Qian, Ting Zhou, ZhiMing Huang. . (2016) CD4+CD25+ regulatory T cells in tumor immunity. International Immunopharmacology 34, 244-249.
CrossRef413
U. Keilholz, D. Schadendorf. . (2016) Blockade von Immuncheckpoints. Forum 31:3, 226-229.
CrossRef414
Pascale Bardo-Brouard, Victoire Vieillard, Tala Shekarian, Aurélien Marabelle, Alain Astier, Muriel Paul. . (2016) Stability of ipilimumab in its original vial after opening allows its use for at least 4 weeks and facilitates pooling of residues. European Journal of Cancer 58, 8-16.
CrossRef415
Lara V. Maul, Michael Weichenthal, Katharina C. Kähler, Axel Hauschild. . (2016) Successful Anti-PD-1 Antibody Treatment in a Metastatic Melanoma Patient With Known Severe Autoimmune Disease. Journal of Immunotherapy 39:4, 188-190.
CrossRef416
Margaret K. Callahan, Michael A. Postow, Jedd D. Wolchok. . (2016) Targeting T Cell Co-receptors for Cancer Therapy. Immunity 44:5, 1069-1078.
CrossRef417
Frank A. Schildberg, Sarah R. Klein, Gordon J. Freeman, Arlene H. Sharpe. . (2016) Coinhibitory Pathways in the B7-CD28 Ligand-Receptor Family. Immunity 44:5, 955-972.
CrossRef418
Yuval Shaked. . (2016) Balancing efficacy of and host immune responses to cancer therapy: the yin and yang effects. Nature Reviews Clinical Oncology 13:10, 611-626.
CrossRef419
Sofie Wilgenhof, Jurgen Corthals, Carlo Heirman, Nicolas van Baren, Sophie Lucas, Pia Kvistborg, Kris Thielemans, Bart Neyns. . (2016) Phase II Study of Autologous Monocyte-Derived mRNA Electroporated Dendritic Cells (TriMixDC-MEL) Plus Ipilimumab in Patients With Pretreated Advanced Melanoma. Journal of Clinical Oncology 34:12, 1330-1338.
CrossRef420
Mark J. Smyth, Hideo Yagita, Grant A. McArthur. . (2016) Combination Anti-CTLA-4 and Anti-RANKL in Metastatic Melanoma. Journal of Clinical Oncology 34:12, e104-e106.
CrossRef421
Roberta Castiglione, Michaela A. Ihle, Carina Heydt, Anne M. Schultheis, Sabine Merkelbach-Bruse, Cornelia Mauch, Reinhard Büttner. . (2016) The impact of sequencing on diagnosis and treatment of malignant melanoma. Expert Review of Molecular Diagnostics 16:4, 423-433.
CrossRef422
Laurel M. Schunselaar, Josine M.M.F. Quispel-Janssen, Jacques J. C. Neefjes, Paul Baas. . (2016) A catalogue of treatment and technologies for malignant pleural mesothelioma. Expert Review of Anticancer Therapy 16:4, 455-463.
CrossRef423
Antonio Maria Grimaldi, Francesco M. Marincola, Paolo Antonio Ascierto. . (2016) Single versus combination immunotherapy drug treatment in melanoma. Expert Opinion on Biological Therapy 16:4, 433-441.
CrossRef424
Serena S. Kwek, James Kahn, Samantha K. Greaney, Jera Lewis, Edward Cha, Li Zhang, Robert W. Weber, Lonnie Leonard, Svetomir N. Markovic, Lawrence Fong, Lynn E. Spitler. . (2016) GM-CSF and ipilimumab therapy in metastatic melanoma: Clinical outcomes and immunologic responses. OncoImmunology 5:4, e1101204.
CrossRef425
Joyce M. van Dodewaard-de Jong, Saskia JAM Santegoets, Peter M. van de Ven, Jurjen Versluis, Henk M. W. Verheul, Tanja D. de Gruijl, Winald R. Gerritsen, Alfons J. M. van den Eertwegh. . (2016) Improved efficacy of mitoxantrone in patients with castration-resistant prostate cancer after vaccination with GM-CSF-transduced allogeneic prostate cancer cells. OncoImmunology 5:4, e1105431.
CrossRef426
Maria B. Schiavone, Vance Broach, Alexander N. Shoushtari, Richard D. Carvajal, Kaled Alektiar, Marisa A. Kollmeier, Nadeem R. Abu-Rustum, Mario M. Leitao. . (2016) Combined immunotherapy and radiation for treatment of mucosal melanomas of the lower genital tract. Gynecologic Oncology Reports 16, 42-46.
CrossRef427
Julia M. Greene, Erika J. Schneble, Doreen O. Jackson, Diane F. Hale, Timothy J. Vreeland, Madeline Flores, Jonathan Martin, Garth S. Herbert, Mark O. Hardin, Xianzhong Yu, Thomas E. Wagner, George E. Peoples. . (2016) A phase I/IIa clinical trial in stage IV melanoma of an autologous tumor–dendritic cell fusion (dendritoma) vaccine with low dose interleukin-2. Cancer Immunology, Immunotherapy 65:4, 383-392.
CrossRef428
Casey Quinn, Qiufei Ma, Amber Kudlac, Stephen Palmer, Beth Barber, Zhongyun Zhao. . (2016) Indirect Treatment Comparison of Talimogene Laherparepvec Compared with Ipilimumab and Vemurafenib for the Treatment of Patients with Metastatic Melanoma. Advances in Therapy 33:4, 643-657.
CrossRef429
Nalan Akgül Babacan. . (2016) Will we have a new ending for Irvin Yalom's novel? A medical oncologist view. Journal of Oncological Science 2:1, 5-6.
CrossRef430
Pedro Magalhães-Costa. . (2016) Severe acute colitis induced by ipilimumab. Gastroenterología y Hepatología 39:4, 277-279.
CrossRef431
Tomohiro F. Nishijima, Hyman B. Muss, Shlomit S. Shachar, Stergios J. Moschos. . (2016) Comparison of efficacy of immune checkpoint inhibitors (ICIs) between younger and older patients: A systematic review and meta-analysis. Cancer Treatment Reviews 45, 30-37.
CrossRef432
Theresa Canavan, Wendy Cantrell. . (2016) Recognizing melanoma. The Nurse Practitioner 41:4, 24-29.
CrossRef433
Pedro Magalhães-Costa. . (2016) Severe acute colitis induced by ipilimumab. Gastroenterología y Hepatología (English Edition) 39:4, 277-279.
CrossRef434
Shohei Eto, Kozo Yoshikawa, Masaaki Nishi, Jun Higashijima, Takuya Tokunaga, Toshihiro Nakao, Hideya Kashihara, Chie Takasu, Takashi Iwata, Mitsuo Shimada. . (2016) Programmed cell death protein 1 expression is an independent prognostic factor in gastric cancer after curative resection. Gastric Cancer 19:2, 466-471.
CrossRef435
KM Morrissey, TM Yuraszeck, C-C Li, Y Zhang, S Kasichayanula. . (2016) Immunotherapy and Novel Combinations in Oncology: Current Landscape, Challenges, and Opportunities. Clinical and Translational Science 9:2, 89-104.
CrossRef436
K. Dietrich, M. Theobald. . (2016) Immunonkologische Therapiestrategien. best practice onkologie 11:2, 22-29.
CrossRef437
Valerie L. Herrmann, Daniel E. Wieland, Daniel F. Legler, Valentin Wittmann, Marcus Groettrup. . (2016) The STEAP1 262-270 peptide encapsulated into PLGA microspheres elicits strong cytotoxic T cell immunity in HLA-A*0201 transgenic mice-A new approach to immunotherapy against prostate carcinoma. The Prostate 76:5, 456-468.
CrossRef438
Claire F. Friedman, Michael A. Postow. . (2016) Emerging Tissue and Blood-Based Biomarkers that may Predict Response to Immune Checkpoint Inhibition. Current Oncology Reports 18:4.
CrossRef439
Yukiharu Todo, Kazuhira Okamoto, Yoshihiro Suzuki, Shinichiro Minobe, Hidenori Kato. . (2016) Radicality of initial surgery for primary malignant melanoma of the vagina. Melanoma Research 26:2, 173-180.
CrossRef440
L. Marthey, C. Mateus, C. Mussini, M. Nachury, S. Nancey, F. Grange, C. Zallot, L. Peyrin-Biroulet, J. F. Rahier, M. Bourdier de Beauregard, L. Mortier, C. Coutzac, E. Soularue, E. Lanoy, N. Kapel, D. Planchard, N. Chaput, C. Robert, F. Carbonnel. . (2016) Cancer Immunotherapy with Anti-CTLA-4 Monoclonal Antibodies Induces an Inflammatory Bowel Disease. Journal of Crohn's and Colitis 10:4, 395-401.
CrossRef441
P. F. Ferrucci, P. A. Ascierto, J. Pigozzo, M. Del Vecchio, M. Maio, G. C. Antonini Cappellini, M. Guidoboni, P. Queirolo, P. Savoia, M. Mandalà, E. Simeone, S. Valpione, M. Altomonte, F. Spagnolo, E. Cocorocchio, S. Gandini, D. Giannarelli, C. Martinoli. . (2016) Baseline neutrophils and derived neutrophil-to-lymphocyte ratio: prognostic relevance in metastatic melanoma patients receiving ipilimumab. Annals of Oncology 27:4, 732-738.
CrossRef442
Rikke B. Holmgaard, Dmitriy Zamarin, Alexander Lesokhin, Taha Merghoub, Jedd D. Wolchok. . (2016) Targeting myeloid-derived suppressor cells with colony stimulating factor-1 receptor blockade can reverse immune resistance to immunotherapy in indoleamine 2,3-dioxygenase-expressing tumors. EBioMedicine 6, 50-58.
CrossRef443
Axel Hoos. . (2016) Development of immuno-oncology drugs — from CTLA4 to PD1 to the next generations. Nature Reviews Drug Discovery 15:4, 235-247.
CrossRef444
Lora Dagi Glass, Ryan Sullivan, Suzanne K. Freitag. . (2016) New Translational Research in the Medical Management of Orbital Melanoma. Seminars in Ophthalmology 31:1-2, 53-58.
CrossRef445
Vandana Gupta, Piyush Trivedi. . (2016) Dermal Drug Delivery for Cutaneous Malignancies: Literature at a Glance. Journal of Pharmaceutical Innovation 11:1, 1-33.
CrossRef446
Benjamin Y Kong, Matteo S Carlino, Alexander M Menzies. . (2016) Biology and treatment of BRAF mutant metastatic melanoma. Melanoma Management 3:1, 33-45.
CrossRef447
Katherine Sanchez, David Page, Heather L. McArthur. . (2016) Immunotherapy in breast cancer: An overview of modern checkpoint blockade strategies and vaccines. Current Problems in Cancer 40:2-4, 151-162.
CrossRef448
Ziqiang Zhu, Wei Liu, Vladimir Gotlieb. . (2016) The rapidly evolving therapies for advanced melanoma—Towards immunotherapy, molecular targeted therapy, and beyond. Critical Reviews in Oncology/Hematology 99, 91-99.
CrossRef449
Ethan Ferrel, Andrew Roehrig, Erin Kaya, Jonathan Carlson, Benjamin Ling, Aaron Wagner, Alexander MacKay, Jason Call, John Demakas, Wayne Lamoreaux, Robert Fairbanks, Barton Cooke, Ben Peressini, Christopher Lee. . (2016) Retrospective Study of Metastatic Melanoma and Renal Cell Carcinoma to the Brain with Multivariate Analysis of Prognostic Pre-Treatment Clinical Factors. International Journal of Molecular Sciences 17:3, 400.
CrossRef450
Asad Javed, Shingo Sato, Takami Sato. . (2016) Autologous melanoma cell vaccine using monocyte-derived dendritic cells (NBS20/eltrapuldencel-T). Future Oncology 12:6, 751-762.
CrossRef451
Xiuwen Guan, Haijuan Wang, Fei Ma, Haili Qian, Zongbi Yi, Binghe Xu. . (2016) The Efficacy and Safety of Programmed Cell Death 1 and Programmed Cell Death 1 Ligand Inhibitors for Advanced Melanoma. Medicine 95:11, e3134.
CrossRef452
Linda Hammerich, Nina Bhardwaj, Holbrook E Kohrt, Joshua D Brody. . (2016) In situ vaccination for the treatment of cancer. Immunotherapy 8:3, 315-330.
CrossRef453
Lavinia Spain, Stefan Diem, James Larkin. . (2016) Management of toxicities of immune checkpoint inhibitors. Cancer Treatment Reviews 44, 51-60.
CrossRef454
Barouyr Baroudjian, Cécile Pagès, Céleste Lebbé. . (2016) Mélanomes, du diagnostic à la prise en charge. La Revue de l'Infirmière 65:219, 16-18.
CrossRef455
Susumu Suzuki, Takashi Ishida, Kazuhiro Yoshikawa, Ryuzo Ueda. . (2016) Current status of immunotherapy. Japanese Journal of Clinical Oncology 46:3, 191-203.
CrossRef456
Véronique Minard-Colin. . (2016) Les anticorps monoclonaux dirigés contre les checkpoints immunologiques : de nouvelles approches d’immunothérapie en onco-hématologie. Revue d'Oncologie Hématologie Pédiatrique 4:1, 5-12.
CrossRef457
Bernhard Mlecnik, Gabriela Bindea, Helen K. Angell, Pauline Maby, Mihaela Angelova, David Tougeron, Sarah E. Church, Lucie Lafontaine, Maria Fischer, Tessa Fredriksen, Maristella Sasso, Amélie M. Bilocq, Amos Kirilovsky, Anna C. Obenauf, Mohamad Hamieh, Anne Berger, Patrick Bruneval, Jean-Jacques Tuech, Jean-Christophe Sabourin, Florence Le Pessot, Jacques Mauillon, Arash Rafii, Pierre Laurent-Puig, Michael R. Speicher, Zlatko Trajanoski, Pierre Michel, Richard Sesboüe, Thierry Frebourg, Franck Pagès, Viia Valge-Archer, Jean-Baptiste Latouche, Jérôme Galon. . (2016) Integrative Analyses of Colorectal Cancer Show Immunoscore Is a Stronger Predictor of Patient Survival Than Microsatellite Instability. Immunity 44:3, 698-711.
CrossRef458
Elisa Fontana, Elizabeth C. Smyth. . (2016) Novel targets in the treatment of advanced gastric cancer: a perspective review. Therapeutic Advances in Medical Oncology 8:2, 113-125.
CrossRef459
Nicolas Jacquelot, David P. Enot, Caroline Flament, Nadège Vimond, Carolin Blattner, Jonathan M. Pitt, Takahiro Yamazaki, María Paula Roberti, Romain Daillère, Marie Vétizou, Vichnou Poirier-Colame, Michaëla Semeraro, Anne Caignard, Craig L. Slingluff, Federica Sallusto, Sylvie Rusakiewicz, Benjamin Weide, Aurélien Marabelle, Holbrook Kohrt, Stéphane Dalle, Andréa Cavalcanti, Guido Kroemer, Anna Maria Di Giacomo, Michele Maio, Phillip Wong, Jianda Yuan, Jedd Wolchok, Viktor Umansky, Alexander Eggermont, Laurence Zitvogel. . (2016) Chemokine receptor patterns in lymphocytes mirror metastatic spreading in melanoma. Journal of Clinical Investigation 126:3, 921-937.
CrossRef460
Jean Langhorne, Patrick E. Duffy. . (2016) Expanding the antimalarial toolkit: Targeting host–parasite interactions. The Journal of Experimental Medicine 213:2, 143-153.
CrossRef461
S Diem, B Kasenda, L Spain, J Martin-Liberal, R Marconcini, M Gore, J Larkin. . (2016) Serum lactate dehydrogenase as an early marker for outcome in patients treated with anti-PD-1 therapy in metastatic melanoma. British Journal of Cancer 114:3, 256-261.
CrossRef462
Noura Choudhury, Yusuke Nakamura. . (2016) Importance of immunopharmacogenomics in cancer treatment: Patient selection and monitoring for immune checkpoint antibodies. Cancer Science 107:2, 107-115.
CrossRef463
Elizabeth I. Buchbinder, Anupam Desai. . (2016) CTLA-4 and PD-1 Pathways. American Journal of Clinical Oncology 39:1, 98-106.
CrossRef464
Gerald Saldanha, Linda Potter, Yee Shin Lee, Sophie Watson, Priya Shendge, James H. Pringle. . (2016) MicroRNA-21 expression and its pathogenetic significance in cutaneous melanoma. Melanoma Research 26:1, 21-28.
CrossRef465
Jens Schreiner, Daniela S. Thommen, Petra Herzig, Marina Bacac, Christian Klein, Andreas Roller, Anton Belousov, Victor Levitsky, Spasenija Savic, Wolfgang Moersig, Franziska Uhlenbrock, Viola A. Heinzelmann-Schwarz, Pablo Umana, Pavel Pisa, M. von Bergwelt-Baildon, Didier Lardinois, Philipp Müller, Vaios Karanikas, Alfred Zippelius. . (2016) Expression of inhibitory receptors on intratumoral T cells modulates the activity of a T cell-bispecific antibody targeting folate receptor. OncoImmunology 5:2, e1062969.
CrossRef466
Benjamin Kasenda, Andrea Kühnl, Ian Chau. . (2016) Beginning of a novel frontier: T-cell-directed immune manipulation in lymphomas. Expert Review of Hematology 9:2, 123-135.
CrossRef467
Y. Lalami, A. Awada. . (2016) Innovative perspectives of immunotherapy in head and neck cancer. From relevant scientific rationale to effective clinical practice. Cancer Treatment Reviews 43, 113-123.
CrossRef468
Alexander Faje. . (2016) Immunotherapy and hypophysitis: clinical presentation, treatment, and biologic insights. Pituitary 19:1, 82-92.
CrossRef469
Erika Vacchelli, Fernando Aranda, Norma Bloy, Aitziber Buqué, Isabelle Cremer, Alexander Eggermont, Wolf Hervé Fridman, Jitka Fucikova, Jérôme Galon, Radek Spisek, Laurence Zitvogel, Guido Kroemer, Lorenzo Galluzzi. . (2016) Trial Watch—Immunostimulation with cytokines in cancer therapy. OncoImmunology 5:2, e1115942.
CrossRef470
Hans-Peter Gerber, Puja Sapra, Frank Loganzo, Chad May. . (2016) Combining antibody–drug conjugates and immune-mediated cancer therapy: What to expect?. Biochemical Pharmacology 102, 1-6.
CrossRef471
Omar Abdel-Rahman, Hesham ElHalawani, Mona Fouad. . (2016) Risk of endocrine complications in cancer patients treated with immune check point inhibitors: a meta-analysis. Future Oncology 12:3, 413-425.
CrossRef472
Kimberly M. Komatsubara, Richard D. Carvajal. . (2016) Selumetinib for the treatment of melanoma. Expert Opinion on Orphan Drugs 4:2, 223-231.
CrossRef473
S. Postel-Vinay, S. Aspeslagh, E. Lanoy, C. Robert, J.-C. Soria, A. Marabelle. . (2016) Challenges of phase 1 clinical trials evaluating immune checkpoint-targeted antibodies. Annals of Oncology 27:2, 214-224.
CrossRef474
Lidia Robert, Antoni Ribas, Siwen Hu-Lieskovan. . (2016) Combining targeted therapy with immunotherapy. Can 1+1 equal more than 2?. Seminars in Immunology 28:1, 73-80.
CrossRef475
Lucy Lee, Manish Gupta, Srikumar Sahasranaman. . (2016) Immune Checkpoint inhibitors: An introduction to the next-generation cancer immunotherapy. The Journal of Clinical Pharmacology 56:2, 157-169.
CrossRef476
Nayoung Lee, Labib R. Zakka, Martin C. Mihm, Tobias Schatton. . (2016) Tumour-infiltrating lymphocytes in melanoma prognosis and cancer immunotherapy. Pathology 48:2, 177-187.
CrossRef477
Hojabr Kakavand, James S. Wilmott, Georgina V. Long, Richard A. Scolyer. . (2016) Targeted therapies and immune checkpoint inhibitors in the treatment of metastatic melanoma patients: a guide and update for pathologists. Pathology 48:2, 194-202.
CrossRef478
Mathieu Rouanne, Yohann Loriot, Thierry Lebret, Jean-Charles Soria. . (2016) Novel therapeutic targets in advanced urothelial carcinoma. Critical Reviews in Oncology/Hematology 98, 106-115.
CrossRef479
Ryan J. Davey, Andre van der Westhuizen, Nikola A. Bowden. . (2016) Metastatic melanoma treatment: Combining old and new therapies. Critical Reviews in Oncology/Hematology 98, 242-253.
CrossRef480
N. Wald, Y. Le Corre, L. Martin, V. Mathieu, E. Goormaghtigh. . (2016) Infrared spectra of primary melanomas can predict response to chemotherapy: The example of dacarbazine. Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease 1862:2, 174-181.
CrossRef481
Mona Foth, Jasper Wouters, Ciaran de Chaumont, Peter Dynoodt, William M. Gallagher. . (2016) Prognostic and predictive biomarkers in melanoma: an update. Expert Review of Molecular Diagnostics 16:2, 223-237.
CrossRef482
Rodrigo Kraft Rovere, Maria Eduarda Pires de Souza, Danielle Louise da Maia Cidral, Sara Fernanda Hilgert, Yasmine Rodrigues Chamse Ddine, Carlos Efrain Stein, Giuliano Santos Borges, Adma Silva de Lima, , , , . . (2016) Melanoma patterns of distant relapse: a study of 108 cases from a South Brazilian center. Anais Brasileiros de Dermatologia 91:1, 40-43.
CrossRef483
N. D. Brunn, S. Mauze, D. Gu, D. Wiswell, R. Ueda, D. Hodges, A. M. Beebe, S. Zhang, E. Escandon. . (2016) The Role of Anti-Drug Antibodies in the Pharmacokinetics, Disposition, Target Engagement, and Efficacy of a GITR Agonist Monoclonal Antibody in Mice. Journal of Pharmacology and Experimental Therapeutics 356:3, 574-586.
CrossRef484
Lise Hoejberg, Dorte Gad, Niels Gyldenkerne, Lars Bastholt, . . (2016) Trends in melanoma in the elderly in Denmark, 1980–2012. Acta Oncologica 55:sup1, 52-58.
CrossRef485
S. Bidnur, R. Savdie, P.C. Black. . (2016) Inhibiting Immune Checkpoints for the Treatment of Bladder Cancer. Bladder Cancer 2:1, 15-25.
CrossRef486
C Ciccarese, S Alfieri, M Santoni, D Santini, M Brunelli, C Bergamini, L Licitra, R Montironi, G Tortora, F Massari. . (2016) New toxicity profile for novel immunotherapy agents: focus on immune-checkpoint inhibitors. Expert Opinion on Drug Metabolism & Toxicology 12:1, 57-75.
CrossRef487
Kalijn F Bol, Erik H J G Aarntzen, Florentien E M in 't Hout, Gerty Schreibelt, Jeroen H A Creemers, W Joost Lesterhuis, Winald R Gerritsen, Dirk J Grunhagen, Cornelis Verhoef, Cornelis J A Punt, Johannes J Bonenkamp, Johannes H W de Wilt, Carl G Figdor, I Jolanda M de Vries. . (2016) Favorable overall survival in stage III melanoma patients after adjuvant dendritic cell vaccination. OncoImmunology 5:1, e1057673.
CrossRef488
Tomonori Terada, Yoshihiko Omori, Nobuhiro Uwa, Kosuke Sagawa, Takeshi Mohri, Nobuo Saeki, Kota Kida, Kenzo Tsuzuki, Masafumi Sakagami. . (2016) A Case of Melanoma Metastasis to the Parotid Lymph Node from an Unknown Primary Site. Practica oto-rhino-laryngologica. Suppl. 145:0, 68-69.
CrossRef489
Manzoor M. Khan. . 2016. Monoclonal Antibodies as Therapeutic Agents. Immunopharmacology, 157-196.
CrossRef490
Bhavana Singh, April Salama. . (2016) Updates in Therapy for Advanced Melanoma. Cancers 8:1, 17.
CrossRef491
Lasse Lindholm Johansen, Jørgen Lock-Andersen, Thomas Vauvert F. Hviid. . (2016) The Pathophysiological Impact of HLA Class Ia and HLA-G Expression and Regulatory T Cells in Malignant Melanoma: A Review. Journal of Immunology Research 2016, 1-11.
CrossRef492
Austen Slade, Michael Tetzlaff, Van Anh Trinh, Wen-Jen Hwu, Curtis A. Pettaway. . 2016. Primary Urethral Melanoma. Rare Genitourinary Tumors, 173-189.
CrossRef493
Benjamin Izar, David P. Ryan, Bruce A. Chabner. . 2016. Principles of Chemotherapy. Clinical Radiation Oncology, 171-185.e2.
CrossRef494
Romany A. N. Johnpulle, Douglas B. Johnson, Jeffrey A. Sosman. . (2016) Molecular Targeted Therapy Approaches for BRAF Wild-Type Melanoma. Current Oncology Reports 18:1.
CrossRef495
Hiren Mandaliya, Nandini Singh, Sanila George, Mathew George. . (2016) Choroid Melanoma Metastasis to Spine: A Rare Case Report. Case Reports in Ophthalmological Medicine 2016, 1-2.
CrossRef496
Jonathan L. Curry, Ana M. Ciurea, Priyadharsini Nagarajan, Carlos A. Torres-Cabala. . 2016. Dermatologic Toxicities to Melanoma Targeted Therapies. Genetics of Melanoma, 267-277.
CrossRef497
Guoli Chen, Zhaohai Yang, James R. Eshleman, George J. Netto, Ming-Tseh Lin. . (2016) Molecular Diagnostics for Precision Medicine in Colorectal Cancer: Current Status and Future Perspective. BioMed Research International 2016, 1-12.
CrossRef498
Yuan Fang, Hexige Saiyin, Xinping Zhao, Yanhua Wu, Xu Han, Wenhui Lou. . (2016) IL-8–Positive Tumor-Infiltrating Inflammatory Cells Are a Novel Prognostic Marker in Pancreatic Ductal Adenocarcinoma Patients. Pancreas 45:5, 671-678.
CrossRef499
Anis Toumeh, Ramen Sakhi, Sarthi Shah, Sri Krishna Chaitanya Arudra, Luis E. De Las Casas, Roland T. Skeel. . (2016) Ipilimumab-Induced Granulomatous Disease Occurring Simultaneously With Disease Progression in a Patient With Metastatic Melanoma. American Journal of Therapeutics 23:4, e1068-e1071.
CrossRef500
Vikram R. Juneja, Martin W. LaFleur, Robert T. Manguso, Arlene H. Sharpe. . 2016. Enhancing the Efficacy of Checkpoint Blockade Through Combination Therapies. Novel Immunotherapeutic Approaches to the Treatment of Cancer, 1-39.
CrossRef501
Brandon D. Liebelt, Gaetano Finocchiaro, Amy B. Heimberger. . 2016. Principles of immunotherapy. Gliomas, 163-181.
CrossRef502
Denise M.S. van Marion, Urszula M. Domanska, Hetty Timmer-Bosscha, Annemiek M.E. Walenkamp. . (2016) Studying cancer metastasis: Existing models, challenges and future perspectives. Critical Reviews in Oncology/Hematology 97, 107-117.
CrossRef503
Omar Abdel-Rahman. . (2016) Immune checkpoints aberrations and gastric cancer; assessment of prognostic value and evaluation of therapeutic potentials. Critical Reviews in Oncology/Hematology 97, 65-71.
CrossRef504
M. M. Soldevilla, H. Villanueva, F. Pastor. . (2016) Aptamers: A Feasible Technology in Cancer Immunotherapy. Journal of Immunology Research 2016, 1-12.
CrossRef505
Hisashi Uhara. . (2016) New Treatments for Advanced Melanoma. Nishi Nihon Hifuka 78:1, 5-12.
CrossRef506
Shengdian Wang, Mingming Jia. . 2016. Antibody Therapies in Cancer. Progress in Cancer Immunotherapy, 1-67.
CrossRef507
Stefan Diem, Fabienne Keller, Reinhard Rüesch, Samia A. Maillard, Daniel E. Speiser, Reinhard Dummer, Marco Siano, Ursula Urner-Bloch, Simone M. Goldinger, Lukas Flatz. . (2016) Pembrolizumab-triggered Uveitis. Journal of Immunotherapy 39:9, 379-382.
CrossRef508
Jin Won Kim, Kyung Han Nam, Sang-Hoon Ahn, Do Joong Park, Hyung-Ho Kim, Se Hyun Kim, Hyun Chang, Jeong-Ok Lee, Yu Jung Kim, Hye Seung Lee, Jee Hyun Kim, Soo-Mee Bang, Jong Seok Lee, Keun-Wook Lee. . (2016) Prognostic implications of immunosuppressive protein expression in tumors as well as immune cell infiltration within the tumor microenvironment in gastric cancer. Gastric Cancer 19:1, 42-52.
CrossRef509
Linda Hammerich, Joshua D. Brody. . 2016. Immunomodulation Within a Single Tumor Site to Induce Systemic Antitumor Immunity: In Situ Vaccination for Cancer. Novel Immunotherapeutic Approaches to the Treatment of Cancer, 129-162.
CrossRef510
Riccardo Danielli, Ornella Cutaia, Carolina Fazio, Erika Bertocci, Ester Fonsatti, Michele Maio, Luana Calabrò. . 2016. ICOS Expression as Immunologic Marker in Immune Activating Monoclonal Antibodies. Tumor Immunology, 133-139.
CrossRef511
Grégory Verdeil, Silvia A. Fuertes Marraco, Timothy Murray, Daniel E. Speiser. . (2016) From T cell “exhaustion” to anti-cancer immunity. Biochimica et Biophysica Acta (BBA) - Reviews on Cancer 1865:1, 49-57.
CrossRef512
Steve Boudewijns, Harm Westdorp, Rutger H.T. Koornstra, Erik H.J.G. Aarntzen, Gerty Schreibelt, Jeroen H.A. Creemers, Cornelis J.A. Punt, Carl G. Figdor, I. Jolanda M. de Vries, Winald R. Gerritsen, Kalijn F. Bol. . (2016) Immune-related Adverse Events of Dendritic Cell Vaccination Correlate With Immunologic and Clinical Outcome in Stage III and IV Melanoma Patients. Journal of Immunotherapy 39:6, 241-248.
CrossRef513
Satoshi FUKUSHIMA. . (2016) A review of adverse events caused by immune checkpoint inhibitors. Japanese Journal of Clinical Immunology 39:1, 30-36.
CrossRef514
Nathalie Krecké, Anna Zimmer, Bettina Friesenhahn-Ochs, Cornelia S. L. Müller, Thomas Vogt, Claudia Pföhler. . (2016) Sneaky side effects and ineffectiveness of an immunotherapy with ipilimumab in a case of metastatic melanoma. Dermato-Endocrinology 8:1, e1199307.
CrossRef515
Alan E. Siroy, Michael A. Davies, Alexander J. Lazar. . 2016. The PI3K-AKT Pathway in Melanoma. Genetics of Melanoma, 165-180.
CrossRef516
Sangeeta Goswami, Ana Aparicio, Sumit K. Subudhi. . (2016) Immune Checkpoint Therapies in Prostate Cancer. The Cancer Journal 22:2, 117-120.
CrossRef517
Yasuhiro Fujisawa. . (2016) Targeted Cancer Therapy. Nishi Nihon Hifuka 78:3, 221-228.
CrossRef518
Timothy V. Waxweiler, David Raben. . 2016. Biologics and Their Interactions with Radiation. Clinical Radiation Oncology, 80-92.e4.
CrossRef519
Anand Rotte, Madhuri Bhandaru. . 2016. Melanoma—Treatment. Immunotherapy of Melanoma, 79-109.
CrossRef520
J. Farmer, K. Csomos, R. Bacchetta, J.E. Walter. . 2016. Congenital Immunodeficiency Diseases. Translational Immunology, 45-81.
CrossRef521
Matthew D. Hellmann, Claire F. Friedman, Jedd D. Wolchok. . 2016. Combinatorial Cancer Immunotherapies. Tumor Immunology, 251-277.
CrossRef522
Michal Lotem, Sharon Merims, Stephen Frank, Tamar Hamburger, Aviram Nissan, Luna Kadouri, Jonathan Cohen, Ravid Straussman, Galit Eisenberg, Shoshana Frankenburg, Einat Carmon, Bilal Alaiyan, Shlomo Shneibaum, Zeynep Ozge Ayyildiz, Murat Isbilen, Kerem Mert Senses, Ilan Ron, Hanna Steinberg, Yoav Smith, Eitan Shiloni, Ali Osmay Gure, Tamar Peretz. . (2016) Adjuvant Autologous Melanoma Vaccine for Macroscopic Stage III Disease: Survival, Biomarkers, and Improved Response to CTLA-4 Blockade. Journal of Immunology Research 2016, 1-12.
CrossRef523
Selma Ugurel, Joachim Röhmel, Paolo A. Ascierto, Keith T. Flaherty, Jean Jacques Grob, Axel Hauschild, James Larkin, Georgina V. Long, Paul Lorigan, Grant A. McArthur, Antoni Ribas, Caroline Robert, Dirk Schadendorf, Claus Garbe. . (2016) Survival of patients with advanced metastatic melanoma: The impact of novel therapies. European Journal of Cancer 53, 125-134.
CrossRef524
Lauren M. Kropp, Jennifer F. De Los Santos, Svetlana B. McKee, Robert M. Conry. . (2016) Radiotherapy to Control Limited Melanoma Progression Following Ipilimumab. Journal of Immunotherapy 39:9, 373-378.
CrossRef525
Mina N. Le, Michael A. Postow, Snehal G. Patel. . 2016. Head and Neck Cutaneous Melanoma. Head and Neck Cancer, 657-663.
CrossRef526
C. Garbe. . 2016. Kutane Nebenwirkungen neuer Krebsmedikamente. Allergologie, 305-312.
CrossRef527
Saad Jamshed, Edward E. Walsh, Lynda J. Dimitroff, Jeanine Seguin Santelli, Ann R. Falsey. . (2016) Improved immunogenicity of high-dose influenza vaccine compared to standard-dose influenza vaccine in adult oncology patients younger than 65 years receiving chemotherapy: A pilot randomized clinical trial. Vaccine 34:5, 630-635.
CrossRef528
J. Zaragoza, A. Caille, N. Beneton, G. Bens, F. Christiann, H. Maillard, L. Machet. . (2016) High neutrophil to lymphocyte ratio measured before starting ipilimumab treatment is associated with reduced overall survival in patients with melanoma. British Journal of Dermatology 174:1, 146-151.
CrossRef529
Sebastian Zahnreich, Arnulf Mayer, Carmen Loquai, Stephan Grabbe, Heinz Schmidberger. . (2016) Radiotherapy with BRAF inhibitor therapy for melanoma: progress and possibilities. Future Oncology 12:1, 95-106.
CrossRef530
Van A. Trinh, Yeorim Ahn, Wen-Jen Hwu. . 2016. Immunotherapy in Melanoma. Genetics of Melanoma, 207-236.
CrossRef531
Padmanee Sharma. . (2016) Immune Checkpoint Therapy and the Search for Predictive Biomarkers. The Cancer Journal 22:2, 68-72.
CrossRef532
Pavlos Msaouel, Erminia Massarelli. . (2016) Immune Checkpoint Therapy in Head and Neck Cancers. The Cancer Journal 22:2, 108-116.
CrossRef533
Reinhard Marks, Roland Mertelsmann. . 2016. Tumor Immunology and Immunotherapy in Cancer Patients. Biochemistry of Oxidative Stress, 425-442.
CrossRef534
K. Dietrich, M. Theobald. . (2016) Immunonkologische Therapiestrategien. Der Onkologe 22:1, 30-39.
CrossRef535
Max Kates, Nikolai A. Sopko, Hotaka Matsui, Charles G. Drake, Noah M. Hahn, Trinity J. Bivalacqua. . (2016) Immune checkpoint inhibitors: a new frontier in bladder cancer. World Journal of Urology 34:1, 49-55.
CrossRef536
Anand Rotte, Madhuri Bhandaru. . 2016. Ipilimumab. Immunotherapy of Melanoma, 275-296.
CrossRef537
Matthew T. Ballo, Bryan Henry Burmeister. . 2016. Malignant Melanoma. Clinical Radiation Oncology, 777-787.e2.
CrossRef538
Demytra Mitsis, Valerie Francescutti, Joseph Skitzki. . (2016) Current Immunotherapies for Sarcoma: Clinical Trials and Rationale. Sarcoma 2016, 1-6.
CrossRef539
Margaret K. Callahan. . (2016) Immune Checkpoint Therapy in Melanoma. The Cancer Journal 22:2, 73-80.
CrossRef540
Amol Mehta, Rahmi Oklu, Rahul A. Sheth. . (2016) Thermal Ablative Therapies and Immune Checkpoint Modulation: Can Locoregional Approaches Effect a Systemic Response?. Gastroenterology Research and Practice 2016, 1-11.
CrossRef541
Philipp Müller, Sacha I. Rothschild, Walter Arnold, Petra Hirschmann, Lukas Horvath, Lukas Bubendorf, Spasenija Savic, Alfred Zippelius. . (2016) Metastatic spread in patients with non-small cell lung cancer is associated with a reduced density of tumor-infiltrating T cells. Cancer Immunology, Immunotherapy 65:1, 1-11.
CrossRef542
Andrzej Świerniak, Marek Kimmel, Jaroslaw Smieja, Krzysztof Puszynski, Krzysztof Psiuk-Maksymowicz. . 2016. Therapy Optimization in Population Dynamics Models. System Engineering Approach to Planning Anticancer Therapies, 55-83.
CrossRef543
Takashi Inozume, Tomonori Yaguchi, Junpei Furuta, Kazutoshi Harada, Yutaka Kawakami, Shinji Shimada. . (2016) Melanoma Cells Control Antimelanoma CTL Responses via Interaction between TIGIT and CD155 in the Effector Phase. Journal of Investigative Dermatology 136:1, 255-263.
CrossRef544
Thomas Wieder, Ellen Brenner, Heidi Braumüller, Martin Röcken. . (2016) Immuntherapie des Melanoms: Wirksamkeit und Wirkungsmechanismen. JDDG: Journal der Deutschen Dermatologischen Gesellschaft 14:1, 28-37.
CrossRef545
Thomas Wieder, Ellen Brenner, Heidi Braumüller, Martin Röcken. . (2016) Immunotherapy of melanoma: efficacy and mode of action. JDDG: Journal der Deutschen Dermatologischen Gesellschaft 14:1, 28-36.
CrossRef546
Lysanne Lievense, Joachim Aerts, Joost Hegmans. . 2016. Immune Therapy. Lung Cancer and Personalized Medicine, 59-90.
CrossRef547
Alexander Roesch, Carola Berking. . 2016. Melanom. Braun-Falco's Dermatologie, Venerologie und Allergologie, 1-17.
CrossRef548
Nagahiro Minato, Tasuku Honjo. . 2016. Cancer Immunotherapy by Checkpoint Blockade. The Vaccine Book, 561-580.
CrossRef549
Jonathan M. Pitt, Dalil Hannani, Marie Vétizou, Laurence Zitvogel. . 2016. Combining Immunotherapies with Standard Therapies in the Treatment of Cancer. Encyclopedia of Immunobiology, 569-580.
CrossRef550
Andrew M. Scott, Marika Ciprotti, Sze-Ting Lee. . 2016. Diagnostic Applications of Nuclear Medicine: Malignant Melanoma. Nuclear Oncology, 1-39.
CrossRef551
Kei ISHIBASHI, Masahiro KITADA, Yoshinari MATSUDA, Satoshi HAYASHI, Satoshi HIRATA, Naoyuki MIYOKAWA. . (2016) Malignant Melanoma at the Dorsal Region Presented with Pleural Dissemination—A Case Report—. Nihon Rinsho Geka Gakkai Zasshi (Journal of Japan Surgical Association) 77:12, 2926-2930.
CrossRef552
Jeffrey E. Gershenwald, Gery P. Guy. . (2016) Stemming the Rising Incidence of Melanoma: Calling Prevention to Action. JNCI: Journal of the National Cancer Institute 108:1.
CrossRef553
Gregory T. Wurz, Chiao-Jung Kao, Michael W. DeGregorio. . (2016) Novel cancer antigens for personalized immunotherapies: latest evidence and clinical potential. Therapeutic Advances in Medical Oncology 8:1, 4-31.
CrossRef554
P. H. Lizotte, A. M. Wen, M. R. Sheen, J. Fields, P. Rojanasopondist, N. F. Steinmetz, S. Fiering. . (2015) In situ vaccination with cowpea mosaic virus nanoparticles suppresses metastatic cancer. Nature Nanotechnology 11:3, 295-303.
CrossRef555
2015. Bibliography. Controlled Release Systems, 449-548.
CrossRef556
Alice Guazzelli, Michelle Hussain, Marija Krstic-Demonacos, Luciano Mutti. . (2015) Tremelimumab for the treatment of malignant mesothelioma. Expert Opinion on Biological Therapy 15:12, 1819-1829.
CrossRef557
Kevin J Harrington, Igor Puzanov, J. Randolph Hecht, F. Stephen Hodi, Zsolt Szabo, Swami Murugappan, Howard L Kaufman. . (2015) Clinical development of talimogene laherparepvec (T-VEC): a modified herpes simplex virus type-1–derived oncolytic immunotherapy. Expert Review of Anticancer Therapy 15:12, 1389-1403.
CrossRef558
Sanjiv S. Agarwala. . (2015) Practical Approaches to Immunotherapy in the Clinic. Seminars in Oncology 42, S20-S27.
CrossRef559
Jungmin Lee, Kofi Clarke. . (2015) Anti-TNF agents in patients with inflammatory bowel disease and malignant melanoma—challenges in management. International Journal of Colorectal Disease 30:12, 1595-1602.
CrossRef560
Matteo S. Carlino, Georgina V. Long, Richard F. Kefford, Helen Rizos. . (2015) Targeting oncogenic BRAF and aberrant MAPK activation in the treatment of cutaneous melanoma. Critical Reviews in Oncology/Hematology 96:3, 385-398.
CrossRef561
Adil Daud. . (2015) Current and Emerging Perspectives on Immunotherapy for Melanoma. Seminars in Oncology 42, S3-S11.
CrossRef562
Michael A. Postow, Manuarii Manuel, Phillip Wong, Jianda Yuan, Zhiwan Dong, Cailian Liu, Solène Perez, Isabelle Tanneau, Marlène Noel, Anaïs Courtier, Nicolas Pasqual, Jedd D. Wolchok. . (2015) Peripheral T cell receptor diversity is associated with clinical outcomes following ipilimumab treatment in metastatic melanoma. Journal for ImmunoTherapy of Cancer 3:1.
CrossRef563
Feifei Teng, Xiangjiao Meng, Li Kong, Dianbin Mu, Hui Zhu, Sujing Liu, Jianbo Zhang, Jinming Yu. . (2015) Tumor-infiltrating lymphocytes, forkhead box P3, programmed death ligand-1, and cytotoxic T lymphocyte–associated antigen-4 expressions before and after neoadjuvant chemoradiation in rectal cancer. Translational Research 166:6, 721-732.e1.
CrossRef564
Martin Lauss, Markus Ringnér, Anna Karlsson, Katja Harbst, Christian Busch, Jürgen Geisler, Per Eystein Lønning, Johan Staaf, Göran Jönsson. . (2015) DNA methylation subgroups in melanoma are associated with proliferative and immunological processes. BMC Medical Genomics 8:1.
CrossRef565
Mostafa Khedri, Houshang Rafatpanah, Khalil Abnous, Pouria Ramezani, Mohammad Ramezani. . (2015) Cancer immunotherapy via nucleic acid aptamers. International Immunopharmacology 29:2, 926-936.
CrossRef566
Paolo A. Ascierto, Michael Atkins, Carlo Bifulco, Gerardo Botti, Alistair Cochran, Michael Davies, Sandra Demaria, Reinhard Dummer, Soldano Ferrone, Silvia Formenti, Thomas F. Gajewski, Claus Garbe, Samir Khleif, Rolf Kiessling, Roger Lo, Paul Lorigan, Grant Mc Arthur, Giuseppe Masucci, Ignacio Melero, Martin Mihm, Giuseppe Palmieri, Giorgio Parmiani, Igor Puzanov, Pedro Romero, Bastian Schilling, Barbara Seliger, David Stroncek, Janis Taube, Sara Tomei, Hassane M. Zarour, Alessandro Testori, Ena Wang, Jérôme Galon, Gennaro Ciliberto, Nicola Mozzillo, Francesco M. Marincola, Magdalena Thurin. . (2015) Future perspectives in melanoma research: meeting report from the “Melanoma Bridge”: Napoli, December 3rd–6th 2014. Journal of Translational Medicine 13:1.
CrossRef567
Liron Zehavi, Hagit Schayek, Jasmine Jacob-Hirsch, Yechezkel Sidi, Raya Leibowitz-Amit, Dror Avni. . (2015) MiR-377 targets E2F3 and alters the NF-kB signaling pathway through MAP3K7 in malignant melanoma. Molecular Cancer 14:1.
CrossRef568
Heinz Läubli, Cathrin Balmelli, Matthias Bossard, Otmar Pfister, Kathrin Glatz, Alfred Zippelius. . (2015) Acute heart failure due to autoimmune myocarditis under pembrolizumab treatment for metastatic melanoma. Journal for ImmunoTherapy of Cancer 3:1.
CrossRef569
, , , , , , . (2015) 2015 Guidance on cancer immunotherapy development in early-phase clinical studies. Cancer Science 106:12, 1761-1771.
CrossRef570
Katy K. Tsai, Adil I. Daud. . (2015) Nivolumab plus ipilimumab in the treatment of advanced melanoma. Journal of Hematology & Oncology 8:1.
CrossRef571
Johan M. van Rooijen, Thijs S. Stutvoet, Carolien P. Schröder, Elisabeth G.E. de Vries. . (2015) Immunotherapeutic options on the horizon in breast cancer treatment. Pharmacology & Therapeutics 156, 90-101.
CrossRef572
Anne Bertrand, Marie Kostine, Thomas Barnetche, Marie-Elise Truchetet, Thierry Schaeverbeke. . (2015) Immune related adverse events associated with anti-CTLA-4 antibodies: systematic review and meta-analysis. BMC Medicine 13:1.
CrossRef573
Michael Atkins. . (2015) Immunotherapy Combinations With Checkpoint Inhibitors in Metastatic Melanoma: Current Approaches and Future Directions. Seminars in Oncology 42, S12-S19.
CrossRef574
Christina Giannopoulou, Eleftherios Sideris, Ros Wade, Thirimon Moe-Byrne, Alison Eastwood, Claire McKenna. . (2015) Ipilimumab for Previously Untreated Unresectable Malignant Melanoma: A Critique of the Evidence. PharmacoEconomics 33:12, 1269-1279.
CrossRef575
Marie R. Webster, Curtis H. Kugel, Ashani T. Weeraratna. . (2015) The Wnts of change: How Wnts regulate phenotype switching in melanoma. Biochimica et Biophysica Acta (BBA) - Reviews on Cancer 1856:2, 244-251.
CrossRef576
Kyriakos Neofytou, Elizabeth C. Smyth, Alexandros Giakoustidis, Aamir Z. Khan, Roger Williams, David Cunningham, Satvinder Mudan. . (2015) The Preoperative Lymphocyte-to-Monocyte Ratio is Prognostic of Clinical Outcomes for Patients with Liver-Only Colorectal Metastases in the Neoadjuvant Setting. Annals of Surgical Oncology 22:13, 4353-4362.
CrossRef577
Jonathan D. Schoenfeld, Anand Mahadevan, Scott R. Floyd, Michael A. Dyer, Paul J. Catalano, Brian M. Alexander, David F. McDermott, Irving D. Kaplan. . (2015) Ipilmumab and cranial radiation in metastatic melanoma patients: a case series and review. Journal for ImmunoTherapy of Cancer 3:1.
CrossRef578
Ulrik Kjerkegaard, Mai Eldon, Pia Sjøgren, Lars Bjørn Stolle. . (2015) A single-center retrospective study on 659 re-excisions of melanoma and 769 sentinel node biopsies in 2008–2012. European Journal of Plastic Surgery 38:6, 471-478.
CrossRef579
Chun-Feng Wu, Hung-Ming Wang, Wen-Kuan Huang, John Wen-Cheng Chang. . (2015) Efficacy and safety of bio-chemotherapy with dacarbazine plus interleukin-2 in patients with unresectable malignant melanoma. Asia-Pacific Journal of Clinical Oncology 11:4, 314-318.
CrossRef580
Paolo A Ascierto, Francesco M Marincola, Michael B Atkins. . (2015) What’s new in melanoma? Combination!. Journal of Translational Medicine 13:1.
CrossRef581
Rita E Morales, Alexander N Shoushtari, Michelle M Walsh, Priya Grewal, Evan J Lipson, Richard D Carvajal. . (2015) Safety and efficacy of ipilimumab to treat advanced melanoma in the setting of liver transplantation. Journal for Immunotherapy of Cancer 3:1.
CrossRef582
A. Berrocal, A. Arance, E. Espinosa, A. G. Castaño, M. G. Cao, J. L. G. Larriba, J. A. L. Martín, I. Márquez, A. Soria, S. M. Algarra. . (2015) SEOM guidelines for the management of Malignant Melanoma 2015. Clinical and Translational Oncology 17:12, 1030-1035.
CrossRef583
Seiji Oguro, Yoshinori Ino, Kazuaki Shimada, Yutaka Hatanaka, Yoshihiro Matsuno, Minoru Esaki, Satoshi Nara, Yoji Kishi, Tomoo Kosuge, Nobuyoshi Hiraoka. . (2015) Clinical significance of tumor-infiltrating immune cells focusing on BTLA and Cbl-b in patients with gallbladder cancer. Cancer Science 106:12, 1750-1760.
CrossRef584
Lisa Zimmer, Thomas K. Eigentler, Felix Kiecker, Jan Simon, Jochen Utikal, Peter Mohr, Carola Berking, Eckhart Kämpgen, Edgar Dippel, Rudolf Stadler, Axel Hauschild, Michael Fluck, Patrick Terheyden, Rainer Rompel, Carmen Loquai, Zeinab Assi, Claus Garbe, Dirk Schadendorf. . (2015) Open-label, multicenter, single-arm phase II DeCOG-study of ipilimumab in pretreated patients with different subtypes of metastatic melanoma. Journal of Translational Medicine 13:1.
CrossRef585
Rebecca Karp Leaf, Hearn Jay Cho, David Avigan. . (2015) Immunotherapy for Multiple Myeloma, Past, Present, and Future: Monoclonal Antibodies, Vaccines, and Cellular Therapies. Current Hematologic Malignancy Reports 10:4, 395-404.
CrossRef586
Brett J. Theeler, Mark R. Gilbert. . (2015) Advances in the treatment of newly diagnosed glioblastoma. BMC Medicine 13:1.
CrossRef587
Stefan Diem, Benjamin Kasenda, Juan Martin-Liberal, Alexander Lee, Dharmisha Chauhan, Martin Gore, James Larkin. . (2015) Prognostic score for patients with advanced melanoma treated with ipilimumab. European Journal of Cancer 51:18, 2785-2791.
CrossRef588
Xiao Ding, He Cao, Xiao Chen, Haofan Jin, Ziling Liu, Guanjun Wang, Lu Cai, Dan Li, Chao Niu, Huimin Tian, Lei Yang, Yuguang Zhao, Wei Li, Jiuwei Cui. . (2015) Cellular immunotherapy as maintenance therapy prolongs the survival of the patients with small cell lung cancer. Journal of Translational Medicine 13:1.
CrossRef589
Reinhard Dummer, Dirk Schadendorf, Paolo A. Ascierto, James Larkin, Celeste Lebbé, Axel Hauschild. . (2015) Integrating first-line treatment options into clinical practice. Melanoma Research 25:6, 461-469.
CrossRef590
Linda Hammerich, Adam Binder, Joshua D. Brody. . (2015) In situ vaccination: Cancer immunotherapy both personalized and off-the-shelf. Molecular Oncology 9:10, 1966-1981.
CrossRef591
Anna Śledzińska, Laurie Menger, Katharina Bergerhoff, Karl S. Peggs, Sergio A. Quezada. . (2015) Negative immune checkpoints on T lymphocytes and their relevance to cancer immunotherapy. Molecular Oncology 9:10, 1936-1965.
CrossRef592
Chunyan Lan, Andreas Heindl, Xin Huang, Shaoyan Xi, Susana Banerjee, Jihong Liu, Yinyin Yuan. . (2015) Quantitative histology analysis of the ovarian tumour microenvironment. Scientific Reports 5:1.
CrossRef593
Jing Lu, Linda Lee-Gabel, Michelle C Nadeau, Thomas M Ferencz, Scott A Soefje. . (2015) Clinical evaluation of compounds targeting PD-1/PD-L1 pathway for cancer immunotherapy. Journal of Oncology Pharmacy Practice 21:6, 451-467.
CrossRef594
Matthew Weinstock, David McDermott. . (2015) Targeting PD-1/PD-L1 in the treatment of metastatic renal cell carcinoma. Therapeutic Advances in Urology 7:6, 365-377.
CrossRef595
Douglas B. Johnson, Vita Saranga-Perry, Patrick J.M. Lavin, W. Bryan Burnette, Stephen W. Clark, David R. Uskavitch, Deborah E. Wallace, Mark A. Dickson, Ragini R. Kudchadkar, Jeffrey A. Sosman. . (2015) Myasthenia Gravis Induced by Ipilimumab in Patients With Metastatic Melanoma. Journal of Clinical Oncology 33:33, e122-e124.
CrossRef596
Michael Hebeisen, Mathilde Allard, Philippe O. Gannon, Julien Schmidt, Daniel E. Speiser, Nathalie Rufer. . (2015) Identifying Individual T Cell Receptors of Optimal Avidity for Tumor Antigens. Frontiers in Immunology 6.
CrossRef597
E Lau, J Sedy, C Sander, M A Shaw, Y Feng, M Scortegagna, G Claps, S Robinson, P Cheng, R Srivas, S Soonthornvacharin, T Ideker, M Bosenberg, R Gonzalez, W Robinson, S K Chanda, C Ware, R Dummer, D Hoon, J M Kirkwood, Z A Ronai. . (2015) Transcriptional repression of IFNβ1 by ATF2 confers melanoma resistance to therapy. Oncogene 34:46, 5739-5748.
CrossRef598
Fabian Echterdiek, Jonas Janikovits, Laura Staffa, Meike Müller, Bernd Lahrmann, Monika Frühschütz, Benjamin Hartog, Nina Nelius, Axel Benner, Mirjam Tariverdian, Magnus von Knebel Doeberitz, Niels Grabe, Matthias Kloor. . (2015) Low density of FOXP3-positive T cells in normal colonic mucosa is related to the presence of beta2-microglobulin mutations in Lynch syndrome-associated colorectal cancer. OncoImmunology, 00-00.
CrossRef599
Ravi A Chandra, Tyler J Wilhite, Tracy A Balboni, Brian M Alexander, Alexander Spektor, Patrick A Ott, Andrea K Ng, F Stephen Hodi, Jonathan D Schoenfeld. . (2015) A systematic evaluation of abscopal responses following radiotherapy in patients with metastatic melanoma treated with ipilimumab. OncoImmunology 4:11, e1046028.
CrossRef600
M. Mailleux, F. Cornélis, G. C. Colin, J. F. Baurain. . (2015) Unusual pulmonary toxicity of ipilimumab treated by macrolides. Acta Clinica Belgica 70:6, 442-444.
CrossRef601
C. Jones, G. Clapton, Z. Zhao, B. Barber, D. Saltman, P. Corrie. . (2015) Unmet clinical needs in the management of advanced melanoma: findings from a survey of oncologists. European Journal of Cancer Care 24:6, 867-872.
CrossRef602
A. Bamias. . (2015) Patterns of practice in oncology: is progress reaching our practice?. European Journal of Cancer Care 24:6, 768-770.
CrossRef603
Rodrigo R Munhoz, Alejandro Falcón González, Vanessa A Reed, Michael A Postow. . (2015) Targeting immune checkpoints in melanoma: an update. Melanoma Management 2:4, 339-352.
CrossRef604
Zeynep Eroglu, Dae Won Kim, Xiaoyan Wang, Luis H. Camacho, Bartosz Chmielowski, Elizabeth Seja, Arturo Villanueva, Kathleen Ruchalski, John A. Glaspy, Kevin B. Kim, Wen-Jen Hwu, Antoni Ribas. . (2015) Long term survival with cytotoxic T lymphocyte-associated antigen 4 blockade using tremelimumab. European Journal of Cancer 51:17, 2689-2697.
CrossRef605
Vittorio Riccio, Simone Carrano, Carlo Buonerba, Giuseppe Di Lorenzo. . (2015) The role of immunotherapy in oncology. Future Oncology 11:21, 2861-2864.
CrossRef606
M. S. Carlino, G. V. Long. . (2015) Is chemotherapy still an option in the treatment of melanoma?: Table 1.. Annals of Oncology 26:11, 2203-2204.
CrossRef607
Alexander Marzuka, Laura Huang, Nicholas Theodosakis, Marcus Bosenberg. . (2015) Melanoma Treatments: Advances and Mechanisms. Journal of Cellular Physiology 230:11, 2626-2633.
CrossRef608
Edjah K. Nduom, Michael Weller, Amy B. Heimberger. . (2015) Immunosuppressive mechanisms in glioblastoma: Fig. 1.. Neuro-Oncology 17:suppl 7, vii9-vii14.
CrossRef609
N. Yamazaki, Y. Kiyohara, H. Uhara, S. Fukushima, H. Uchi, N. Shibagaki, A. Tsutsumida, S. Yoshikawa, R. Okuyama, Y. Ito, T. Tokudome. . (2015) Phase II study of ipilimumab monotherapy in Japanese patients with advanced melanoma. Cancer Chemotherapy and Pharmacology 76:5, 997-1004.
CrossRef610
Matteo Santoni, Alessandro Conti, Kalliopi Andrikou, Alessandro Bittoni, Andrea Lanese, Mirco Pistelli, Francesco Pantano, Bruno Vincenzi, Grazia Armento, Francesco Massari, Giuseppe Tonini, Stefano Cascinu, Daniele Santini. . (2015) Risk of pruritus in cancer patients treated with biological therapies: A systematic review and meta-analysis of clinical trials. Critical Reviews in Oncology/Hematology 96:2, 206-219.
CrossRef611
Ulrike Schick, Joan Kyula, Holly Barker, Radhika Patel, Shane Zaidi, Claire Gregory, Hind Hafsi, Victoria Roulstone, Eric Deutsch, Martin McLaughlin, Kevin Harrington. . (2015) Trametinib radiosensitises RAS- and BRAF-mutated melanoma by perturbing cell cycle and inducing senescence. Radiotherapy and Oncology 117:2, 364-375.
CrossRef612
Shannon K. Quirk, Anna K. Shure, Devendra K. Agrawal. . (2015) Immune-mediated adverse events of anticytotoxic T lymphocyte–associated antigen 4 antibody therapy in metastatic melanoma. Translational Research 166:5, 412-424.
CrossRef613
Martha R. Neagu, David A. Reardon. . (2015) An Update on the Role of Immunotherapy and Vaccine Strategies for Primary Brain Tumors. Current Treatment Options in Oncology 16:11.
CrossRef614
N. Yamazaki, H. Uhara, S. Fukushima, H. Uchi, N. Shibagaki, Y. Kiyohara, A. Tsutsumida, K. Namikawa, R. Okuyama, Y. Otsuka, T. Tokudome. . (2015) Phase II study of the immune-checkpoint inhibitor ipilimumab plus dacarbazine in Japanese patients with previously untreated, unresectable or metastatic melanoma. Cancer Chemotherapy and Pharmacology 76:5, 969-975.
CrossRef615
Aurélien Marabelle, Alexander Eggermont. . (2015) How should we use anti-CTLA-4 antibodies?. European Journal of Cancer 51:17, 2686-2688.
CrossRef616
Omar Abdel-Rahman, Hesham ElHalawani, Mona Fouad. . (2015) Risk of gastrointestinal complications in cancer patients treated with immune checkpoint inhibitors: a meta-analysis. Immunotherapy 7:11, 1213-1227.
CrossRef617
Chad C Cherington, Alan H Bryce. . (2015) The end of the beginning: PD-1 inhibition as the new standard of care first-line immunotherapy in metastatic melanoma. Melanoma Management 2:4, 305-309.
CrossRef618
Lavinia Spain, Eugenie Younger, Emine Hatipoglu, James Larkin. . (2015) Pembrolizumab in the management of metastatic melanoma. Melanoma Management 2:4, 315-325.
CrossRef619
David B Page, Jarushka Naidoo, Heather L McArthur. . (2015) The 2014 San Antonio Breast Cancer Symposium: A successful lift-off for breast immunotherapy?. npj Breast Cancer 1:1.
CrossRef620
Susanne H.C. Baumeister, Glenn Dranoff. . 2015. Principles of Targeted Immunotherapy. Targeted Therapy in Translational Cancer Research, 27-38.
CrossRef621
Keith T. Flaherty. . 2015. Targeted Therapy in Melanoma. Targeted Therapy in Translational Cancer Research, 231-239.
CrossRef622
Parisa Momtaz, Vivian Park, Katherine S. Panageas, Michael A. Postow, Margaret Callahan, Jedd D. Wolchok, Paul B. Chapman. . (2015) Safety of Infusing Ipilimumab Over 30 Minutes. Journal of Clinical Oncology 33:30, 3454-3458.
CrossRef623
E. M. Van Allen, D. Miao, B. Schilling, S. A. Shukla, C. Blank, L. Zimmer, A. Sucker, U. Hillen, M. H. Geukes Foppen, S. M. Goldinger, J. Utikal, J. C. Hassel, B. Weide, K. C. Kaehler, C. Loquai, P. Mohr, R. Gutzmer, R. Dummer, S. Gabriel, C. J. Wu, D. Schadendorf, L. A. Garraway. . (2015) Genomic correlates of response to CTLA-4 blockade in metastatic melanoma. Science 350:6257, 207-211.
CrossRef624
Kelly Kersten, Camilla Salvagno, Karin E. de Visser. . (2015) Exploiting the Immunomodulatory Properties of Chemotherapeutic Drugs to Improve the Success of Cancer Immunotherapy. Frontiers in Immunology 6.
CrossRef625
Rajasekharan Somasundaram, Meenhard Herlyn. . (2015) Nivolumab in combination with ipilimumab for the treatment of melanoma. Expert Review of Anticancer Therapy 15:10, 1135-1141.
CrossRef626
Adrian G Murphy, Lei Zheng. . (2015) Small molecule drugs with immunomodulatory effects in cancer. Human Vaccines & Immunotherapeutics 11:10, 2463-2468.
CrossRef627
Omar Abdel-Rahman, Hesham ElHalawani, Mona Fouad. . (2015) Risk of elevated transaminases in cancer patients treated with immune checkpoint inhibitors: a meta-analysis. Expert Opinion on Drug Safety 14:10, 1507-1518.
CrossRef628
Cesar A Santa-Maria, Sue Jung Park, Sarika Jain, William J Gradishar. . (2015) Breast cancer and immunology: biomarker and therapeutic developments. Expert Review of Anticancer Therapy 15:10, 1215-1222.
CrossRef629
Rajeshwari Sridhara, Kun He, Lei Nie, Yuan-Li Shen, Shenghui Tang. . (2015) Current Statistical Challenges in Oncology Clinical Trials in the Era of Targeted Therapy. Statistics in Biopharmaceutical Research 7:4, 348-356.
CrossRef630
Brendan D. Curti, Walter J. Urba. . (2015) Clinical deployment of antibodies for treatment of melanoma. Molecular Immunology 67:2, 18-27.
CrossRef631
Aljosja Rogiers, Joost J. van den Oord, Marjan Garmyn, Marguerite Stas, Cindy Kenis, Hans Wildiers, Jean-Christophe Marine, Pascal Wolter. . (2015) Novel Therapies for Metastatic Melanoma: An Update on Their Use in Older Patients. Drugs & Aging 32:10, 821-834.
CrossRef632
Cheng Sun, Hao-yu Sun, Wei-hua Xiao, Cai Zhang, Zhi-gang Tian. . (2015) Natural killer cell dysfunction in hepatocellular carcinoma and NK cell-based immunotherapy. Acta Pharmacologica Sinica 36:10, 1191-1199.
CrossRef633
Connull Leslie, Samantha E. Bowyer, Alison White, Fabienne Grieu-Iacopetta, Michelle Trevenen, Barry Iacopetta, Benhur Amanuel, Michael Millward. . (2015) FOXP3+ T regulatory lymphocytes in primary melanoma are associated with BRAF mutation but not with response to BRAF inhibitor. Pathology 47:6, 557-563.
CrossRef634
J.M. Redman, E.M. Hill, D. AlDeghaither, L.M. Weiner. . (2015) Mechanisms of action of therapeutic antibodies for cancer. Molecular Immunology 67:2, 28-45.
CrossRef635
J Gao, Q He, S Subudhi, A Aparicio, A Zurita-Saavedra, D H Lee, C Jimenez, M Suarez-Almazor, P Sharma. . (2015) Review of immune-related adverse events in prostate cancer patients treated with ipilimumab: MD Anderson experience. Oncogene 34:43, 5411-5417.
CrossRef636
Kenji Ishitsuka, Mutsunori Murahashi, Hiroo Katsuya, Ai Mogi, Michio Masaki, Chisato Kawai, Toshitaka Goto, Masanao Ishizu, Yosuke Ikari, Yasushi Takamatsu, Hideki Ishibashi, Satoshi Nimura, Morishige Takeshita, Kazuo Tamura. . (2015) Colitis mimicking graft-versus-host disease during treatment with the anti-CCR4 monoclonal antibody, mogamulizumab. International Journal of Hematology 102:4, 493-497.
CrossRef637
Edward B. Garon. . (2015) Current Perspectives in Immunotherapy for Non-Small Cell Lung Cancer. Seminars in Oncology 42, S11-S18.
CrossRef638
M. R. Middleton, P. Friedlander, O. Hamid, A. Daud, R. Plummer, N. Falotico, B. Chyla, F. Jiang, E. McKeegan, N. M. Mostafa, M. Zhu, J. Qian, M. McKee, Y. Luo, V. L. Giranda, G. A. McArthur. . (2015) Randomized phase II study evaluating veliparib (ABT-888) with temozolomide in patients with metastatic melanoma. Annals of Oncology 26:10, 2173-2179.
CrossRef639
Kirtesh R. Patel, David H. Lawson, Ragini R. Kudchadkar, Bradley C. Carthon, Daniel E. Oliver, Derick Okwan-Duodu, Rafi Ahmed, Mohammad K. Khan. . (2015) Two heads better than one? Ipilimumab immunotherapy and radiation therapy for melanoma brain metastases. Neuro-Oncology 17:10, 1312-1321.
CrossRef640
Joanna Mangana, Phil F. Cheng, Katja Schindler, Benjamin Weide, Ulrike Held, Anna L. Frauchiger, Emanuella Romano, Katharina C. Kähler, Sima Rozati, Markus Rechsteiner, Holger Moch, Olivier Michielin, Claus Garbe, Axel Hauschild, Christoph Hoeller, Reinhard Dummer, Simone M. Goldinger, Jian Jian Li. . (2015) Analysis of BRAF and NRAS Mutation Status in Advanced Melanoma Patients Treated with Anti-CTLA-4 Antibodies: Association with Overall Survival?. PLOS ONE 10:10, e0139438.
CrossRef641
Pei He, Zheng Su. . (2015) A novel design for randomized immuno-oncology clinical trials with potentially delayed treatment effects. Contemporary Clinical Trials Communications 1, 28-31.
CrossRef642
Ingrid Allix, Vincent Rohmer. . (2015) Hypophysitis in 2014. Annales d'Endocrinologie 76:5, 585-594.
CrossRef643
Saif S. Ahmad, Wendi Qian, Sarah Ellis, Elaine Mason, Muhammad A. Khattak, Avinash Gupta, Heather Shaw, Amy Quinton, Jarmila Kovarikova, Kiruthikah Thillai, Ankit Rao, Ruth Board, Jenny Nobes, Angus Dalgleish, Simon Grumett, Anthony Maraveyas, Sarah Danson, Toby Talbot, Mark Harries, Maria Marples, Ruth Plummer, Satish Kumar, Paul Nathan, Mark R. Middleton, James Larkin, Paul Lorigan, Matthew Wheater, Christian H. Ottensmeier, Pippa G. Corrie. . (2015) Ipilimumab in the real world. Melanoma Research 25:5, 432-442.
CrossRef644
Tasha Hughes, Matthew Klairmont, William H. Sharfman, Howard L. Kaufman. . (2015) Interleukin-2, Ipilimumab, and Anti-PD-1: Clinical Management and the Evolving Role of Immunotherapy for the Treatment of Patients With Metastatic Melanoma. Cancer Biology & Therapy, 00-00.
CrossRef645
Alison M. Paterson, Scott B. Lovitch, Peter T. Sage, Vikram R. Juneja, Youjin Lee, Justin D. Trombley, Carolina V. Arancibia-Cárcamo, Raymond A. Sobel, Alexander Y. Rudensky, Vijay K. Kuchroo, Gordon J. Freeman, Arlene H. Sharpe. . (2015) Deletion of CTLA-4 on regulatory T cells during adulthood leads to resistance to autoimmunity. The Journal of Experimental Medicine 212:10, 1603-1621.
CrossRef646
J. Naidoo, D. B. Page, B. T. Li, L. C. Connell, K. Schindler, M. E. Lacouture, M. A. Postow, J. D. Wolchok. . (2015) Toxicities of the anti-PD-1 and anti-PD-L1 immune checkpoint antibodies. Annals of Oncology, mdv383.
CrossRef647
Pedro Iglesias, Ainara Soria, Juan José Díez. . (2015) Endocrinopatías autoinmunitarias inducidas por anticuerpos inmunomoduladores en el tratamiento del cáncer. Medicina Clínica 145:6, 264-268.
CrossRef648
Pedro Iglesias, Ainara Soria, Juan José Díez. . (2015) Autoimmune endocrinopathies induced by immunomodulating antibodies in the treatment of cancer. Medicina Clínica (English Edition) 145:6, 264-268.
CrossRef649
Benjamin Weide, Nicolas Allgaier, Andreas Hector, Andrea Forschner, Ulrike Leiter, Thomas K. Eigentler, Claus Garbe, Dominik Hartl. . (2015) Increased CCL17 serum levels are associated with improved survival in advanced melanoma. Cancer Immunology, Immunotherapy 64:9, 1075-1082.
CrossRef650
Antonio Tejera-Vaquerizo, Eduardo Nagore, Susana Puig, Caroline Robert, Philippe Saiag, Paula Martín-Cuevas, Elena Gallego, Enrique Herrera-Acosta, José Aguilera, Josep Malvehy, Cristina Carrera, Andrea Cavalcanti, Ramón Rull, Antonio Vilalta-Solsona, Emilie Lannoy, Celine Boutros, Naima Benannoune, Gorana Tomasic, Philippe Aegerte, Sergi Vidal-Sicart, Josep Palou, LLúcia Alos, Celia Requena, Víctor Traves, Ángel Pla, Isidro Bolumar, Virtudes Soriano, Carlos Guillén, Enrique Herrera-Ceballos. . (2015) Effect of time to sentinel-node biopsy on the prognosis of cutaneous melanoma. European Journal of Cancer 51:13, 1780-1793.
CrossRef651
Terry R. Medler, Tiziana Cotechini, Lisa M. Coussens. . (2015) Immune Response to Cancer Therapy: Mounting an Effective Antitumor Response and Mechanisms of Resistance. Trends in Cancer 1:1, 66-75.
CrossRef652
Olivier Michielin, Christoph Hoeller. . (2015) Gaining momentum: New options and opportunities for the treatment of advanced melanoma. Cancer Treatment Reviews 41:8, 660-670.
CrossRef653
Emmanuel Gabriel, Joseph Skitzki. . (2015) The Role of Regional Therapies for in-Transit Melanoma in the Era of Improved Systemic Options. Cancers 7:3, 1154-1177.
CrossRef654
Jordan M. Chinai, Murali Janakiram, Fuxiang Chen, Wantao Chen, Mark Kaplan, Xingxing Zang. . (2015) New immunotherapies targeting the PD-1 pathway. Trends in Pharmacological Sciences 36:9, 587-595.
CrossRef655
Elizabeth Buchbinder, F. Stephen Hodi. . (2015) Cytotoxic T lymphocyte antigen-4 and immune checkpoint blockade. Journal of Clinical Investigation 125:9, 3377-3383.
CrossRef656
Lijo John, C. Lance Cowey. . (2015) The Rapid Emergence of Novel Therapeutics in Advanced Malignant Melanoma. Dermatology and Therapy 5:3, 151-169.
CrossRef657
John K. Bui, John W. Mellors. . (2015) Reversal of T-cell exhaustion as a strategy to improve immune control of HIV-1. AIDS 29:15, 1911-1915.
CrossRef658
Michele W.L. Teng, Jerome Galon, Wolf-Herman Fridman, Mark J. Smyth. . (2015) From mice to humans: developments in cancer immunoediting. Journal of Clinical Investigation 125:9, 3338-3346.
CrossRef659
R. Dummer, A. Hauschild, N. Lindenblatt, G. Pentheroudakis, U. Keilholz. . (2015) Cutaneous melanoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Annals of Oncology 26:suppl 5, v126-v132.
CrossRef660
L. Apetoh, S. Ladoire, G. Coukos, F. Ghiringhelli. . (2015) Combining immunotherapy and anticancer agents: the right path to achieve cancer cure?. Annals of Oncology 26:9, 1813-1823.
CrossRef661
Natascha Hermann-Kleiter, Victoria Klepsch, Stephanie Wallner, Kerstin Siegmund, Sebastian Klepsch, Selma Tuzlak, Andreas Villunger, Sandra Kaminski, Christa Pfeifhofer-Obermair, Thomas Gruber, Dominik Wolf, Gottfried Baier. . (2015) The Nuclear Orphan Receptor NR2F6 Is a Central Checkpoint for Cancer Immune Surveillance. Cell Reports 12:12, 2072-2085.
CrossRef662
Omar Abdel-Rahman, Hesham ElHalawani, Mona Fouad. . (2015) Risk of cutaneous toxicities in patients with solid tumors treated with immune checkpoint inhibitors: a meta-analysis. Future Oncology 11:17, 2471-2484.
CrossRef663
Rhiannon Koirala, David Gyorki. . (2015) Targeting the Immune System for Cancer Therapy: Lessons for Perioperative Management?. Current Anesthesiology Reports 5:3, 257-267.
CrossRef664
Tai-Tsang Chen. . (2015) Milestone Survival: A Potential Intermediate Endpoint for Immune Checkpoint Inhibitors. Journal of the National Cancer Institute 107:9, djv156.
CrossRef665
Roberta Zappasodi, Taha Merghoub. . (2015) Alphavirus-based vaccines in melanoma: rationale and potential improvements in immunotherapeutic combinations. Immunotherapy 7:9, 981-997.
CrossRef666
Yanxia Guo, Adele Y. Wang. . (2015) Novel Immune Check-Point Regulators in Tolerance Maintenance. Frontiers in Immunology 6.
CrossRef667
Simon Ville, Nicolas Poirier, Gilles Blancho, Bernard Vanhove. . (2015) Co-Stimulatory Blockade of the CD28/CD80-86/CTLA-4 Balance in Transplantation: Impact on Memory T Cells?. Frontiers in Immunology 6.
CrossRef668
Travis E Grotz, James W Jakub, Aaron S Mansfield, Rachel Goldenstein, Elizabeth Ann L Enninga, Wendy K Nevala, Alexey A Leontovich, Svetomir N Markovic. . (2015) Evidence of Th2 polarization of the sentinel lymph node (SLN) in melanoma. OncoImmunology 4:8, e1026504.
CrossRef669
Edmond L. Toy, Francis Vekeman, Michael C. Lewis, Alan K. Oglesby, Mei Sheng Duh. . (2015) Costs, resource utilization, and treatment patterns for patients with metastatic melanoma in a commercially insured setting. Current Medical Research and Opinion 31:8, 1561-1572.
CrossRef670
Robert H Pierce, Jean S Campbell, Sara I Pai, Joshua D Brody, Holbrook EK Kohrt. . (2015) In-situ tumor vaccination: Bringing the fight to the tumor. Human Vaccines & Immunotherapeutics 11:8, 1901-1909.
CrossRef671
Anthony M. Joshua, Jose G. Monzon, Catalin Mihalcioiu, David Hogg, Michael Smylie, Tina Cheng. . (2015) A phase 2 study of tremelimumab in patients with advanced uveal melanoma. Melanoma Research 25:4, 342-347.
CrossRef672
Powell Perng, Charles Marcus, Rathan M. Subramaniam. . (2015) 18 F-FDG PET/CT and Melanoma: Staging, Immune Modulation and Mutation-Targeted Therapy Assessment, and Prognosis. American Journal of Roentgenology 205:2, 259-270.
CrossRef673
Aurélien Marabelle, Juliet Gray. . (2015) Tumor-targeted and immune-targeted monoclonal antibodies: Going from passive to active immunotherapy. Pediatric Blood & Cancer 62:8, 1317-1325.
CrossRef674
Margaret K. Callahan, Jedd D. Wolchok. . (2015) Clinical Activity, Toxicity, Biomarkers, and Future Development of CTLA-4 Checkpoint Antagonists. Seminars in Oncology 42:4, 573-586.
CrossRef675
Toby A. Eyre, Graham P. Collins. . (2015) Immune checkpoint inhibition in lymphoid disease. British Journal of Haematology 170:3, 291-304.
CrossRef676
Peter E Hall, James Spicer, Sanjay Popat. . (2015) Rationale for targeting the ErbB family of receptors in patients with advanced squamous cell carcinoma of the lung. Future Oncology 11:15, 2175-2191.
CrossRef677
Srinath Sundararajan, Nicholas J Vogelzang. . (2015) Anti-PD-1 and PD-L1 therapy for bladder cancer: what is on the horizon?. Future Oncology 11:16, 2299-2306.
CrossRef678
Corey J. Langer. . (2015) Emerging Immunotherapies in the Treatment of Non–small Cell Lung Cancer (NSCLC). American Journal of Clinical Oncology 38:4, 422-430.
CrossRef679
C. Pföhler, T. Vogt, C.S.L. Müller. . (2015) Maligne Melanome im Kopf-Hals-Bereich. HNO 63:8, 593-604.
CrossRef680
A. Gupta, K. M. De Felice, E. V. Loftus, S. Khanna. . (2015) Systematic review: colitis associated with anti-CTLA-4 therapy. Alimentary Pharmacology & Therapeutics 42:4, 406-417.
CrossRef681
Yago Pico de Coaña, Aniruddha Choudhury, Rolf Kiessling. . (2015) Checkpoint blockade for cancer therapy: revitalizing a suppressed immune system. Trends in Molecular Medicine 21:8, 482-491.
CrossRef682
N. I. Cherny, R. Sullivan, U. Dafni, J. M. Kerst, A. Sobrero, C. Zielinski, E. G. E. de Vries, M. J. Piccart. . (2015) A standardised, generic, validated approach to stratify the magnitude of clinical benefit that can be anticipated from anti-cancer therapies: the European Society for Medical Oncology Magnitude of Clinical Benefit Scale (ESMO-MCBS). Annals of Oncology 26:8, 1547-1573.
CrossRef683
Jennifer A. Wargo, Alexandre Reuben, Zachary A. Cooper, Kevin S. Oh, Ryan J. Sullivan. . (2015) Immune Effects of Chemotherapy, Radiation, and Targeted Therapy and Opportunities for Combination With Immunotherapy. Seminars in Oncology 42:4, 601-616.
CrossRef684
Haydn T Kissick, Martin G Sanda. . (2015) The role of active vaccination in cancer immunotherapy: lessons from clinical trials. Current Opinion in Immunology 35, 15-22.
CrossRef685
Oriol Yélamos, Pedram Gerami. . (2015) Predicting the outcome of melanoma: can we tell the future of a patient’s melanoma?. Melanoma Management 2:3, 217-224.
CrossRef686
Antoni Ribas, Igor Puzanov, Reinhard Dummer, Dirk Schadendorf, Omid Hamid, Caroline Robert, F Stephen Hodi, Jacob Schachter, Anna C Pavlick, Karl D Lewis, Lee D Cranmer, Christian U Blank, Steven J O'Day, Paolo A Ascierto, April K S Salama, Kim A Margolin, Carmen Loquai, Thomas K Eigentler, Tara C Gangadhar, Matteo S Carlino, Sanjiv S Agarwala, Stergios J Moschos, Jeffrey A Sosman, Simone M Goldinger, Ronnie Shapira-Frommer, Rene Gonzalez, John M Kirkwood, Jedd D Wolchok, Alexander Eggermont, Xiaoyun Nicole Li, Wei Zhou, Adriane M Zernhelt, Joy Lis, Scot Ebbinghaus, S Peter Kang, Adil Daud. . (2015) Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial. The Lancet Oncology 16:8, 908-918.
CrossRef687
Adam J Cooper, Matteo S Carlino, Richard F Kefford. . (2015) Immune checkpoint inhibitors in melanoma. Melanoma Management 2:3, 267-284.
CrossRef688
Maria Teresa P. de Aquino, Anshu Malhotra, Manoj K. Mishra, Anil Shanker. . (2015) Challenges and future perspectives of T cell immunotherapy in cancer. Immunology Letters 166:2, 117-133.
CrossRef689
Meagan S. Barbee, Adebayo Ogunniyi, Troy Z. Horvat, Thu-Oanh Dang. . (2015) Current Status and Future Directions of the Immune Checkpoint Inhibitors Ipilimumab, Pembrolizumab, and Nivolumab in Oncology. Annals of Pharmacotherapy 49:8, 907-937.
CrossRef690
Kathleen M. Mahoney, Paul D. Rennert, Gordon J. Freeman. . (2015) Combination cancer immunotherapy and new immunomodulatory targets. Nature Reviews Drug Discovery 14:8, 561-584.
CrossRef691
Ignacio Melero, David M. Berman, M. Angela Aznar, Alan J. Korman, José Luis Pérez Gracia, John Haanen. . (2015) Evolving synergistic combinations of targeted immunotherapies to combat cancer. Nature Reviews Cancer 15:8, 457-472.
CrossRef692
Michael Allen, Louise Jones. . (2015) The role of inflammation in progression of breast cancer: Friend or foe? (Review). International Journal of Oncology.
CrossRef693
Yan Ye, Xiao-Juan Chao, Jin-Feng Wu, Brian Cheng, Tao Su, Xiu-Qiong Fu, Ting Li, Hui Guo, Anfernee Tse, Hiu-Yee Kwan, Juan Du, Gui-Xin Chou, Zhi-Ling Yu. . (2015) ERK/GSK3β signaling is involved in atractylenolide I-induced apoptosis and cell cycle arrest in melanoma cells. Oncology Reports.
CrossRef694
Neha Chopra, Paul D Nathan. . (2015) Trametinib in metastatic melanoma. Expert Review of Anticancer Therapy 15:7, 749-760.
CrossRef695
Larkin, James, Chiarion-Sileni, Vanna, Gonzalez, Rene, Grob, Jean Jacques, Cowey, C. Lance, Lao, Christopher D., Schadendorf, Dirk, Dummer, Reinhard, Smylie, Michael, Rutkowski, Piotr, Ferrucci, Pier F., Hill, Andrew, Wagstaff, John, Carlino, Matteo S., Haanen, John B., Maio, Michele, Marquez-Rodas, Ivan, McArthur, Grant A., Ascierto, Paolo A., Long, Georgina V., Callahan, Margaret K., Postow, Michael A., Grossmann, Kenneth, Sznol, Mario, Dreno, Brigitte, Bastholt, Lars, Yang, Arvin, Rollin, Linda M., Horak, Christine, Hodi, F. Stephen, Wolchok, Jedd D., . . (2015) Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma. New England Journal of Medicine 373:1, 23-34.
Free Full Text696
Shiao-Pei Weathers, Mark R. Gilbert. . (2015) Current challenges in designing GBM trials for immunotherapy. Journal of Neuro-Oncology 123:3, 331-337.
CrossRef697
John F. Thompson, Sanjiv S. Agarwala, B. Mark Smithers, Merrick I. Ross, Charles R. Scoggins, Brendon J. Coventry, Susan J. Neuhaus, David R. Minor, Jamie M. Singer, Eric A. Wachter. . (2015) Phase 2 Study of Intralesional PV-10 in Refractory Metastatic Melanoma. Annals of Surgical Oncology 22:7, 2135-2142.
CrossRef698
C. Gedye, A. van der Westhuizen, T. John. . (2015) Checkpoint immunotherapy for cancer: superior survival, unaccustomed toxicities. Internal Medicine Journal 45:7, 696-701.
CrossRef699
Moniek A. de Witte, Guido J. J. Kierkels, Trudy Straetemans, Cedrik M. Britten, Jürgen Kuball. . (2015) Orchestrating an immune response against cancer with engineered immune cells expressing αβTCRs, CARs, and innate immune receptors: an immunological and regulatory challenge. Cancer Immunology, Immunotherapy 64:7, 893-902.
CrossRef700
Loretta J. Nastoupil, Sattva S. Neelapu. . (2015) Novel Immunologic Approaches in Lymphoma: Unleashing the Brakes on the Immune System. Current Oncology Reports 17:7.
CrossRef701
Joanna Y. Wang, Chetan Bettegowda. . (2015) Genetics and immunotherapy: using the genetic landscape of gliomas to inform management strategies. Journal of Neuro-Oncology 123:3, 373-383.
CrossRef702
Mira A. Patel, Drew M. Pardoll. . (2015) Concepts of immunotherapy for glioma. Journal of Neuro-Oncology 123:3, 323-330.
CrossRef703
Meghan E. Turnis, Lawrence P. Andrews, Dario A. A. Vignali. . (2015) Inhibitory receptors as targets for cancer immunotherapy. European Journal of Immunology 45:7, 1892-1905.
CrossRef704
David A. Reardon, Hideho Okada. . (2015) Re-defining response and treatment effects for neuro-oncology immunotherapy clinical trials. Journal of Neuro-Oncology 123:3, 339-346.
CrossRef705
Robert, Caroline, Schachter, Jacob, Long, Georgina V., Arance, Ana, Grob, Jean Jacques, Mortier, Laurent, Daud, Adil, Carlino, Matteo S., McNeil, Catriona, Lotem, Michal, Larkin, James, Lorigan, Paul, Neyns, Bart, Blank, Christian U., Hamid, Omid, Mateus, Christine, Shapira-Frommer, Ronnie, Kosh, Michele, Zhou, Honghong, Ibrahim, Nageatte, Ebbinghaus, Scot, Ribas, Antoni, . . (2015) Pembrolizumab versus Ipilimumab in Advanced Melanoma. New England Journal of Medicine 372:26, 2521-2532.
Free Full Text706
Holly E. Barker, James T. E. Paget, Aadil A. Khan, Kevin J. Harrington. . (2015) The tumour microenvironment after radiotherapy: mechanisms of resistance and recurrence. Nature Reviews Cancer 15:7, 409-425.
CrossRef707
Axel Hauschild, Claus Garbe. . (2015) Immunotherapy: Combined immunotherapy—a new standard in metastatic melanoma?. Nature Reviews Clinical Oncology 12:8, 439-440.
CrossRef708
Jeffrey S. Weber, James C. Yang, Michael B. Atkins, Mary L. Disis. . (2015) Toxicities of Immunotherapy for the Practitioner. Journal of Clinical Oncology 33:18, 2092-2099.
CrossRef709
Lina Chakrabarti, Clifford Morgan, Anthony D. Sandler, Xue-feng Bai. . (2015) Combination of Id2 Knockdown Whole Tumor Cells and Checkpoint Blockade: A Potent Vaccine Strategy in a Mouse Neuroblastoma Model. PLOS ONE 10:6, e0129237.
CrossRef710
Antoni Ribas, Keith T. Flaherty. . (2015) Gauging the Long-Term Benefits of Ipilimumab in Melanoma. Journal of Clinical Oncology 33:17, 1865-1866.
CrossRef711
Geoffrey T. Gibney, Michael B. Atkins. . (2015) Swinging for the Fences: Long-Term Survival With Ipilimumab in Metastatic Melanoma. Journal of Clinical Oncology 33:17, 1873-1877.
CrossRef712
Dirk Schadendorf, F. Stephen Hodi, Caroline Robert, Jeffrey S. Weber, Kim Margolin, Omid Hamid, Debra Patt, Tai-Tsang Chen, David M. Berman, Jedd D. Wolchok. . (2015) Pooled Analysis of Long-Term Survival Data From Phase II and Phase III Trials of Ipilimumab in Unresectable or Metastatic Melanoma. Journal of Clinical Oncology 33:17, 1889-1894.
CrossRef713
Michael A. Postow, Margaret K. Callahan, Jedd D. Wolchok. . (2015) Immune Checkpoint Blockade in Cancer Therapy. Journal of Clinical Oncology 33:17, 1974-1982.
CrossRef714
Jamie Honeychurch, Eleanor J Cheadle, Simon J Dovedi, Timothy M Illidge. . (2015) Immuno-regulatory antibodies for the treatment of cancer. Expert Opinion on Biological Therapy 15:6, 787-801.
CrossRef715
Juan Martin-Liberal, Tiana Kordbacheh, James Larkin. . (2015) Safety of pembrolizumab for the treatment of melanoma. Expert Opinion on Drug Safety 14:6, 957-964.
CrossRef716
Nicola Mozzillo, Ester Simeone, Lucia Benedetto, Marcello Curvietto, Diana Giannarelli, Giusy Gentilcore, Rosa Camerlingo, Mariaelena Capone, Gabriele Madonna, Lucia Festino, Corrado Caracò, Gianluca Di Monta, Ugo Marone, Massimiliano Di Marzo, Antonio M Grimaldi, Stefano Mori, Gennaro Ciliberto, Paolo A Ascierto. . (2015) Assessing a novel immuno-oncology-based combination therapy: Ipilimumab plus electrochemotherapy. OncoImmunology 4:6, e1008842.
CrossRef717
Nadia Yousaf, Michael Davidson, Emily Goode, Charlotte Thomas, Rachel Hung, Martin Gore, James Larkin. . (2015) The cost of ipilimumab toxicity. Melanoma Research 25:3, 259-264.
CrossRef718
Alexandre Doussot, Charlée Nardin, Haruyuki Takaki, Tess D. Litchman, Michael I. D'Angelica, William R. Jarnagin, Michael A. Postow, Joseph P. Erinjeri, T. Peter Kingham. . (2015) Liver resection and ablation for metastatic melanoma: A single center experience. Journal of Surgical Oncology 111:8, 962-968.
CrossRef719
G.V. Scagliotti, P. Bironzo, J.F. Vansteenkiste. . (2015) Addressing the unmet need in lung cancer: The potential of immuno-oncology. Cancer Treatment Reviews 41:6, 465-475.
CrossRef720
Imran Rafique, John M. Kirkwood, Ahmad A. Tarhini. . (2015) Immune Checkpoint Blockade and Interferon-α in Melanoma. Seminars in Oncology 42:3, 436-447.
CrossRef721
Benjamin Weide, Anna Maria Di Giacomo, Ester Fonsatti, Laurence Zitvogel. . (2015) Immunologic Correlates in the Course of Treatment With Immunomodulating Antibodies. Seminars in Oncology 42:3, 448-458.
CrossRef722
Yarne Klaver, Andre Kunert, Stefan Sleijfer, Reno Debets, Cor HJ Lamers. . (2015) Adoptive T-cell therapy: a need for standard immune monitoring. Immunotherapy 7:5, 513-533.
CrossRef723
John B.A.G. Haanen, Hans van Thienen, Christian U. Blank. . (2015) Toxicity Patterns With Immunomodulating Antibodies and Their Combinations. Seminars in Oncology 42:3, 423-428.
CrossRef724
Jonathan Crews, Aniruddha Agarwal, Loren Jack, Ding Xu, Diana V. Do, Quan Dong Nguyen. . (2015) Ipilimumab-Associated Retinopathy. Ophthalmic Surgery, Lasers and Imaging Retina 46:6, 658-660.
CrossRef725
Pier-Luigi Lollini, Federica Cavallo, Patrizia Nanni, Elena Quaglino. . (2015) The Promise of Preventive Cancer Vaccines. Vaccines 3:2, 467-489.
CrossRef726
Dmitriy Zamarin, Michael A. Postow. . (2015) Immune checkpoint modulation: Rational design of combination strategies. Pharmacology & Therapeutics 150, 23-32.
CrossRef727
Julie Delyon, Michele Maio, Celeste Lebbé. . (2015) The Ipilimumab Lesson in Melanoma: Achieving Long-Term Survival. Seminars in Oncology 42:3, 387-401.
CrossRef728
Ana P. Kiess, Jedd D. Wolchok, Christopher A. Barker, Michael A. Postow, Viviane Tabar, Jason T. Huse, Timothy A. Chan, Yoshiya Yamada, Kathryn Beal. . (2015) Stereotactic Radiosurgery for Melanoma Brain Metastases in Patients Receiving Ipilimumab: Safety Profile and Efficacy of Combined Treatment. International Journal of Radiation Oncology*Biology*Physics 92:2, 368-375.
CrossRef729
Martin Reck, Luis Paz-Ares. . (2015) Immunologic Checkpoint Blockade in Lung Cancer. Seminars in Oncology 42:3, 402-417.
CrossRef730
Ding Zhang, Zhihong Chen, Diane C. Wang, Xiangdong Wang. . (2015) Regulatory T cells and potential inmmunotherapeutic targets in lung cancer. Cancer and Metastasis Reviews 34:2, 277-290.
CrossRef731
N Lendvai, A D Cohen, H J Cho. . (2015) Beyond consolidation: auto-SCT and immunotherapy for plasma cell myeloma. Bone Marrow Transplantation 50:6, 770-780.
CrossRef732
Paola Queirolo, Virginia Picasso, Francesco Spagnolo. . (2015) Combined BRAF and MEK inhibition for the treatment of BRAF-mutated metastatic melanoma. Cancer Treatment Reviews 41:6, 519-526.
CrossRef733
Edward Cha, Jeffrey Wallin, Marcin Kowanetz. . (2015) PD-L1 Inhibition With MPDL3280A for Solid Tumors. Seminars in Oncology 42:3, 484-487.
CrossRef734
Alexander M.M. Eggermont, Michele Maio, Caroline Robert. . (2015) Immune Checkpoint Inhibitors in Melanoma Provide the Cornerstones for Curative Therapies. Seminars in Oncology 42:3, 429-435.
CrossRef735
Valentina A. Zavala, Alexis M. Kalergis. . (2015) New clinical advances in immunotherapy for the treatment of solid tumours. Immunology 145:2, 182-201.
CrossRef736
Ashlyn R. Seeley, Jennifer F. De Los Santos, Robert M. Conry. . (2015) Induction vemurafenib followed by consolidative radiation therapy for surgically incurable melanoma. Melanoma Research 25:3, 246-251.
CrossRef737
Pier F. Ferrucci, Ida Minchella, Massimo Mosconi, Sara Gandini, Francesco Verrecchia, Emilia Cocorocchio, Claudia Passoni, Chiara Pari, Alessandro Testori, Paola Coco, Elisabetta Munzone. . (2015) Dacarbazine in combination with bevacizumab for the treatment of unresectable/metastatic melanoma. Melanoma Research 25:3, 239-245.
CrossRef738
Falk Nimmerjahn, Sina Gordan, Anja Lux. . (2015) FcγR dependent mechanisms of cytotoxic, agonistic, and neutralizing antibody activities. Trends in Immunology 36:6, 325-336.
CrossRef739
George J. Weiner. . (2015) Building better monoclonal antibody-based therapeutics. Nature Reviews Cancer 15:6, 361-370.
CrossRef740
Postow, Michael A., Chesney, Jason, Pavlick, Anna C., Robert, Caroline, Grossmann, Kenneth, McDermott, David, Linette, Gerald P., Meyer, Nicolas, Giguere, Jeffrey K., Agarwala, Sanjiv S., Shaheen, Montaser, Ernstoff, Marc S., Minor, David, Salama, April K., Taylor, Matthew, Ott, Patrick A., Rollin, Linda M., Horak, Christine, Gagnier, Paul, Wolchok, Jedd D., Hodi, F. Stephen, . . (2015) Nivolumab and Ipilimumab versus Ipilimumab in Untreated Melanoma. New England Journal of Medicine 372:21, 2006-2017.
Free Full Text741
Emanuela Romano, Monika Kusio-Kobialka, Periklis G. Foukas, Petra Baumgaertner, Christiane Meyer, Pierluigi Ballabeni, Olivier Michielin, Benjamin Weide, Pedro Romero, Daniel E. Speiser. . (2015) Ipilimumab-dependent cell-mediated cytotoxicity of regulatory T cells ex vivo by nonclassical monocytes in melanoma patients. Proceedings of the National Academy of Sciences 112:19, 6140-6145.
CrossRef742
Norma Bloy, Aitziber Buqué, Fernando Aranda, Francesca Castoldi, Alexander Eggermont, Isabelle Cremer, Catherine Sautès-Fridman, Jitka Fucikova, Jérôme Galon, Radek Spisek, Eric Tartour, Laurence Zitvogel, Guido Kroemer, Lorenzo Galluzzi. . (2015) Trial watch: Naked and vectored DNA-based anticancer vaccines. OncoImmunology 4:5, e1026531.
CrossRef743
Jens Bedke, Stephan Kruck, Georgios Gakis, Arnulf Stenzl, Peter J Goebell. . (2015) Checkpoint modulation - A new way to direct the immune system against renal cell carcinoma. Human Vaccines & Immunotherapeutics 11:5, 1201-1208.
CrossRef744
Edward J Wyluda, Jihua Cheng, Todd D Schell, Jeremy S Haley, Carol Mallon, Rogerio I Neves, Gavin Robertson, Jeffrey Sivik, Heath Mackley, Giampaolo Talamo, Joseph J Drabick. . (2015) Durable complete responses off all treatment in patients with metastatic malignant melanoma after sequential immunotherapy followed by a finite course of BRAF inhibitor therapy. Cancer Biology & Therapy 16:5, 662-670.
CrossRef745
Luis H. Camacho. . (2015) CTLA-4 blockade with ipilimumab: biology, safety, efficacy, and future considerations. Cancer Medicine 4:5, 661-672.
CrossRef746
Fred Saad, Kurt Miller. . (2015) Current and Emerging Immunotherapies for Castration-resistant Prostate Cancer. Urology 85:5, 976-986.
CrossRef747
Julie R Brahmer, Hans Hammers, Evan J Lipson. . (2015) Nivolumab: targeting PD-1 to bolster antitumor immunity. Future Oncology 11:9, 1307-1326.
CrossRef748
Alexander M M Eggermont, Vanna Chiarion-Sileni, Jean-Jacques Grob, Reinhard Dummer, Jedd D Wolchok, Henrik Schmidt, Omid Hamid, Caroline Robert, Paolo A Ascierto, Jon M Richards, Céleste Lebbé, Virginia Ferraresi, Michael Smylie, Jeffrey S Weber, Michele Maio, Cyril Konto, Axel Hoos, Veerle de Pril, Ravichandra Karra Gurunath, Gaetan de Schaetzen, Stefan Suciu, Alessandro Testori. . (2015) Adjuvant ipilimumab versus placebo after complete resection of high-risk stage III melanoma (EORTC 18071): a randomised, double-blind, phase 3 trial. The Lancet Oncology 16:5, 522-530.
CrossRef749
Dirk Schadendorf, Mayur M. Amonkar, Daniil Stroyakovskiy, Evgeny Levchenko, Helen Gogas, Filippo de Braud, Jean-Jacques Grob, Igor Bondarenko, Claus Garbe, Celeste Lebbe, James Larkin, Vanna Chiarion-Sileni, Michael Millward, Ana Arance, Mario Mandalà, Keith T. Flaherty, Paul Nathan, Antoni Ribas, Caroline Robert, Michelle Casey, Douglas J. DeMarini, Jhangir G. Irani, Gursel Aktan, Georgina V. Long. . (2015) Health-related quality of life impact in a randomised phase III study of the combination of dabrafenib and trametinib versus dabrafenib monotherapy in patients with BRAF V600 metastatic melanoma. European Journal of Cancer 51:7, 833-840.
CrossRef750
Matthew Howell, Rebecca Lee, Samantha Bowyer, Alberto Fusi, Paul Lorigan. . (2015) Optimal management of immune-related toxicities associated with checkpoint inhibitors in lung cancer. Lung Cancer 88:2, 117-123.
CrossRef751
Daniel A. Wattson, Ryan J. Sullivan, Andrzej Niemierko, Ryan M. Merritt, Donald P. Lawrence, Kevin S. Oh, Keith T. Flaherty, Helen A. Shih. . (2015) Survival patterns following brain metastases for patients with melanoma in the MAP-kinase inhibitor era. Journal of Neuro-Oncology 123:1, 75-84.
CrossRef752
Laetitia E. Lamberts, Simon P. Williams, Anton G.T. Terwisscha van Scheltinga, Marjolijn N. Lub-de Hooge, Carolien P. Schröder, Jourik A. Gietema, Adrienne H. Brouwers, Elisabeth G.E. de Vries. . (2015) Antibody Positron Emission Tomography Imaging in Anticancer Drug Development. Journal of Clinical Oncology 33:13, 1491-1504.
CrossRef753
Kenneth F. Grossmann, Kim Margolin. . (2015) Long-term survival as a treatment benchmark in melanoma: latest results and clinical implications. Therapeutic Advances in Medical Oncology 7:3, 181-191.
CrossRef754
B Homet Moreno, A Ribas. . (2015) Anti-programmed cell death protein-1/ligand-1 therapy in different cancers. British Journal of Cancer 112:9, 1421-1427.
CrossRef755
J. Cuende, S. Lienart, O. Dedobbeleer, B. van der Woning, G. De Boeck, J. Stockis, C. Huygens, D. Colau, J. Somja, P. Delvenne, M. Hannon, F. Baron, L. Dumoutier, J.-C. Renauld, H. De Haard, M. Saunders, P. G. Coulie, S. Lucas. . (2015) Monoclonal antibodies against GARP/TGF- 1 complexes inhibit the immunosuppressive activity of human regulatory T cells in vivo. Science Translational Medicine 7:284, 284ra56-284ra56.
CrossRef756
Wiebke Sondermann, Klaus G. Griewank, Bastian Schilling, Elisabeth Livingstone, Julia C. Leyh, Natalia Rompoti, Ioana Cosgarea, Tobias Schimming, Dirk Schadendorf, Lisa Zimmer, Uwe Hillen, Nikolas K. Haass. . (2015) Corticosteroids Augment BRAF Inhibitor Vemurafenib Induced Lymphopenia and Risk of Infection. PLOS ONE 10:4, e0124590.
CrossRef757
A P Algazi, E Cha, S M Ortiz-Urda, T McCalmont, B C Bastian, J Hwang, M H Pampaloni, S Behr, K Chong, B Cortez, A Quiroz, F Coakley, S Liu, A I Daud. . (2015) The combination of axitinib followed by paclitaxel/carboplatin yields extended survival in advanced BRAF wild-type melanoma: results of a clinical/correlative prospective phase II clinical trial. British Journal of Cancer 112:8, 1326-1331.
CrossRef758
Li X Zhu, Michael Davoodi, Minu K Srivastava, Puja Kachroo, Jay M Lee, Maie St. John, Marni Harris-White, Min Huang, Robert M Strieter, Steven Dubinett, Sherven Sharma. . (2015) GITR agonist enhances vaccination responses in lung cancer. OncoImmunology 4:4, e992237.
CrossRef759
Lesly A Dossett, Ragini R Kudchadkar, Jonathan S Zager. . (2015) BRAF and MEK inhibition in melanoma. Expert Opinion on Drug Safety 14:4, 559-570.
CrossRef760
P. Sharma, J. P. Allison. . (2015) The future of immune checkpoint therapy. Science 348:6230, 56-61.
CrossRef761
Takanobu Motoshima, Yoshihiro Komohara, Hasita Horlad, Ario Takeuchi, Yoshihiro Maeda, Kenichiro Tanoue, Yoshiaki Kawano, Mamoru Harada, Motohiro Takeya, Masatoshi Eto. . (2015) Sorafenib enhances the antitumor effects of anti-CTLA-4 antibody in a murine cancer model by inhibiting myeloid-derived suppressor cells. Oncology Reports.
CrossRef762
Seth B. Coffelt, Karin E. de Visser. . (2015) Immune-mediated mechanisms influencing the efficacy of anticancer therapies. Trends in Immunology 36:4, 198-216.
CrossRef763
Nicole J. Look Hong, Teresa Petrella, Kelvin Chan. . (2015) Cost-effectiveness analysis of staging strategies in patients with regionally metastatic melanoma. Journal of Surgical Oncology 111:4, 423-430.
CrossRef764
Max Schnurr, Peter Duewell, Christian Bauer, Simon Rothenfusser, Kirsten Lauber, Stefan Endres, Sebastian Kobold. . (2015) Strategies to relieve immunosuppression in pancreatic cancer. Immunotherapy 7:4, 363-376.
CrossRef765
Akihisa Matsuda, Masao Miyashita, Satoshi Matsumoto, Goro Takahashi, Takeshi Matsutani, Takeshi Yamada, Taro Kishi, Eiji Uchida. . (2015) Abdominoperineal Resection Provides Better Local Control But Equivalent Overall Survival to Local Excision of Anorectal Malignant Melanoma. Annals of Surgery 261:4, 670-677.
CrossRef766
Jun Li, Yujue Wang, Ruijing Liang, Xiangjie An, Ke Wang, Guanxin Shen, Yating Tu, Jintao Zhu, Juan Tao. . (2015) Recent advances in targeted nanoparticles drug delivery to melanoma. Nanomedicine: Nanotechnology, Biology and Medicine 11:3, 769-794.
CrossRef767
Padmanee Sharma, James P. Allison. . (2015) Immune Checkpoint Targeting in Cancer Therapy: Toward Combination Strategies with Curative Potential. Cell 161:2, 205-214.
CrossRef768
A. M. Di Giacomo, P. A. Ascierto, P. Queirolo, L. Pilla, R. Ridolfi, M. Santinami, A. Testori, E. Simeone, M. Guidoboni, A. Maurichi, L. Orgiano, G. Spadola, M. Del Vecchio, R. Danielli, L. Calabro, D. Annesi, D. Giannarelli, C. Maccalli, E. Fonsatti, G. Parmiani, M. Maio. . (2015) Three-year follow-up of advanced melanoma patients who received ipilimumab plus fotemustine in the Italian Network for Tumor Biotherapy (NIBIT)-M1 phase II study. Annals of Oncology 26:4, 798-803.
CrossRef769
David Berman, Alan Korman, Ronald Peck, David Feltquate, Nils Lonberg, Renzo Canetta. . (2015) The development of immunomodulatory monoclonal antibodies as a new therapeutic modality for cancer: The Bristol-Myers Squibb experience. Pharmacology & Therapeutics 148, 132-153.
CrossRef770
Sue S. Yom, Maximilian Diehn, David Raben. . (2015) Molecular Determinants of Radiation Response in Non–Small Cell Lung Cancer. Seminars in Radiation Oncology 25:2, 67-77.
CrossRef771
Douglas B. Johnson, Igor Puzanov. . (2015) Treatment of NRAS-Mutant Melanoma. Current Treatment Options in Oncology 16:4.
CrossRef772
Wenyin Shi. . (2015) Role for Radiation Therapy in Melanoma. Surgical Oncology Clinics of North America 24:2, 323-335.
CrossRef773
Elizabeth I. Buchbinder, David F. McDermott. . (2015) Cytotoxic T-Lymphocyte Antigen-4 Blockade in Melanoma. Clinical Therapeutics 37:4, 755-763.
CrossRef774
Robert Cheng, Adam Cooper, James Kench, Geoff Watson, William Bye, Catriona McNeil, Nicholas Shackel. . (2015) Ipilimumab-induced toxicities and the gastroenterologist. Journal of Gastroenterology and Hepatology 30:4, 657-666.
CrossRef775
Thomas John. . (2015) Role of immunotherapy in lung cancer: Preliminary results of new vaccines and immune checkpoint inhibitors. Asia-Pacific Journal of Clinical Oncology 11, 2-8.
CrossRef776
J. Kopecky, P. Trojanova, O. Kube ek, O. Kopecky. . (2015) Treatment possibilities of ipilimumab-induced thrombocytopenia--case study and literature review. Japanese Journal of Clinical Oncology 45:4, 381-384.
CrossRef777
Mengze Hao, Fengju Song, Xiaoling Du, Guowen Wang, Yun Yang, Kexin Chen, Jilong Yang. . (2015) Advances in targeted therapy for unresectable melanoma: New drugs and combinations. Cancer Letters 359:1, 1-8.
CrossRef778
Jamie Green, Charlotte Ariyan. . (2015) Update on Immunotherapy in Melanoma. Surgical Oncology Clinics of North America 24:2, 337-346.
CrossRef779
Lili Yue, Zhi-Ming Huang, Stephen Fong, Stanley Leong, James G. Jakowatz, Alex Charruyer-Reinwald, Maria Wei, Ruby Ghadially. . (2015) Targeting ALDH1 to decrease tumorigenicity, growth and metastasis of human melanoma. Melanoma Research 25:2, 138-148.
CrossRef780
Daniel Sanghoon Shin, Antoni Ribas. . (2015) The evolution of checkpoint blockade as a cancer therapy: what's here, what's next?. Current Opinion in Immunology 33, 23-35.
CrossRef781
Suzanne L. Topalian, Charles G. Drake, Drew M. Pardoll. . (2015) Immune Checkpoint Blockade: A Common Denominator Approach to Cancer Therapy. Cancer Cell 27:4, 450-461.
CrossRef782
Michele Maio, Jean-Jacques Grob, Steinar Aamdal, Igor Bondarenko, Caroline Robert, Luc Thomas, Claus Garbe, Vanna Chiarion-Sileni, Alessandro Testori, Tai-Tsang Chen, Marina Tschaika, Jedd D. Wolchok. . (2015) Five-Year Survival Rates for Treatment-Naive Patients With Advanced Melanoma Who Received Ipilimumab Plus Dacarbazine in a Phase III Trial. Journal of Clinical Oncology 33:10, 1191-1196.
CrossRef783
Megan M. Saraceni, Nikhil I. Khushalani, Anthony Jarkowski. . (2015) Immunotherapy in Melanoma. Journal of Pharmacy Practice 28:2, 193-203.
CrossRef784
Florencia Paula Madorsky Rowdo, Antonela Baron, Mariela Urrutia, José Mordoh. . (2015) Immunotherapy in Cancer: A Combat between Tumors and the Immune System; You Win Some, You Lose Some. Frontiers in Immunology 6.
CrossRef785
A. M. Lesokhin, M. K. Callahan, M. A. Postow, J. D. Wolchok. . (2015) On being less tolerant: Enhanced cancer immunosurveillance enabled by targeting checkpoints and agonists of T cell activation. Science Translational Medicine 7:280, 280sr1-280sr1.
CrossRef786
S. Hu-Lieskovan, S. Mok, B. Homet Moreno, J. Tsoi, L. Robert, L. Goedert, E. M. Pinheiro, R. C. Koya, T. G. Graeber, B. Comin-Anduix, A. Ribas. . (2015) Improved antitumor activity of immunotherapy with BRAF and MEK inhibitors in BRAFV600E melanoma. Science Translational Medicine 7:279, 279ra41-279ra41.
CrossRef787
Lisa Zimmer, Julia Vaubel, Peter Mohr, Axel Hauschild, Jochen Utikal, Jan Simon, Claus Garbe, Rudolf Herbst, Alexander Enk, Eckhart Kämpgen, Elisabeth Livingstone, Leonie Bluhm, Rainer Rompel, Klaus G. Griewank, Michael Fluck, Bastian Schilling, Dirk Schadendorf, Jose Luis Perez-Gracia. . (2015) Phase II DeCOG-Study of Ipilimumab in Pretreated and Treatment-Naïve Patients with Metastatic Uveal Melanoma. PLOS ONE 10:3, e0118564.
CrossRef788
Manik Amin, Albert Craig Lockhart. . (2015) The potential role of immunotherapy to treat colorectal cancer. Expert Opinion on Investigational Drugs 24:3, 329-344.
CrossRef789
Karissa M Johnston, Emily McPherson, Katherine Osenenko, Joanna Vergidis, Adrian R Levy, Stuart Peacock. . (2015) Cost–effectiveness of therapies for melanoma. Expert Review of Pharmacoeconomics & Outcomes Research 15:2, 229-242.
CrossRef790
Camillo Porta, Laura Cosmai, Maurizio Gallieni, Paolo Pedrazzoli, Fabio Malberti. . (2015) Renal effects of targeted anticancer therapies. Nature Reviews Nephrology 11:6, 354-370.
CrossRef791
Christos Sachpekidis, Lionel Larribere, Leyun Pan, Uwe Haberkorn, Antonia Dimitrakopoulou-Strauss, Jessica C. Hassel. . (2015) Predictive value of early 18F-FDG PET/CT studies for treatment response evaluation to ipilimumab in metastatic melanoma: preliminary results of an ongoing study. European Journal of Nuclear Medicine and Molecular Imaging 42:3, 386-396.
CrossRef792
Heinz Läubli, Alfred Zippelius. . (2015) Immunstimulation durch Checkpoint-inhibition. Info Onkologie 18:2, 31-34.
CrossRef793
Omgo E. Nieweg, José Francisco Gallegos-Hernández. . (2015) La cirugía en melanoma cutáneo maligno y las nuevas drogas. Cirugía y Cirujanos 83:2, 175-180.
CrossRef794
Andrea K. Miyahira, Haydn T. Kissick, Jennifer L. Bishop, David Y. Takeda, Christopher E. Barbieri, Jonathan W. Simons, Kenneth J. Pienta, Howard R. Soule. . (2015) Beyond immune checkpoint blockade: New approaches to targeting host-tumor interactions in prostate cancer: Report from the 2014 Coffey-Holden prostate cancer Academy meeting. The Prostate 75:4, 337-347.
CrossRef795
Omgo E. Nieweg, José Francisco Gallegos-Hernández. . (2015) Cutaneous melanoma and the new drugs. Cirugía y Cirujanos (English Edition) 83:2, 175-180.
CrossRef796
Alexios Matikas, Dimitrios Mavroudis. . (2015) Beyond CTLA-4: novel immunotherapy strategies for metastatic melanoma. Future Oncology 11:6, 997-1009.
CrossRef797
K. M. Joyce, N. M. McInerney, C. W. Joyce, D. M. Jones, A. J. Hussey, P. Donnellan, M. J. Kerin, J. L. Kelly, P. J. Regan. . (2015) A review of sentinel lymph node biopsy for thin melanoma. Irish Journal of Medical Science (1971 -) 184:1, 119-123.
CrossRef798
Anand Rotte, Madhuri Bhandaru, Youwen Zhou, Kevin J. McElwee. . (2015) Immunotherapy of melanoma: Present options and future promises. Cancer and Metastasis Reviews 34:1, 115-128.
CrossRef799
Sofie Wilgenhof, Jurgen Corthals, An M. T. Van Nuffel, Daphné Benteyn, Carlo Heirman, Aude Bonehill, Kris Thielemans, Bart Neyns. . (2015) Long-term clinical outcome of melanoma patients treated with messenger RNA-electroporated dendritic cell therapy following complete resection of metastases. Cancer Immunology, Immunotherapy 64:3, 381-388.
CrossRef800
Carlos Kamiya-Matsuoka, Mark R Gilbert. . (2015) Treating recurrent glioblastoma: an update. CNS Oncology 4:2, 91-104.
CrossRef801
Danka J. F. Stuijver, Erica Romualdi, Bregje van Zaane, Leon Bax, Harry R. Büller, Victor E. A. Gerdes, Alessandro Squizzato. . (2015) Under-reporting of venous and arterial thrombotic events in randomized clinical trials: a meta-analysis. Internal and Emergency Medicine 10:2, 219-246.
CrossRef802
R. Sousa, P. Cortes, M. Harries, S. Papa. . (2015) Treatment for metastatic melanoma: a new and evolving era. International Journal of Clinical Practice 69:3, 273-280.
CrossRef803
Angus G Dalgleish. . (2015) Rationale for combining immunotherapy with chemotherapy. Immunotherapy 7:3, 309-316.
CrossRef804
Yawen Zheng, Yan Dou, Lili Duan, Changsheng Cong, Aiqin Gao, Qinghua Lai, Yuping Sun. . (2015) Using chemo-drugs or irradiation to break immune tolerance and facilitate immunotherapy in solid cancer. Cellular Immunology 294:1, 54-59.
CrossRef805
Alexios Matikas, Natalia Asimakopoulou, Vassilis Georgoulias, John Souglakos. . (2015) The Place of Targeted Agents in the Treatment of Elderly Patients with Metastatic Colorectal Cancer. Cancers 7:1, 439-449.
CrossRef806
R. E. Gardiner, S. Jahangeer, P. Forde, A. B. Ariffin, B. Bird, D. Soden, J. Hinchion. . (2015) Low immunogenicity in non-small cell lung cancer; do new developments and novel treatments have a role?. Cancer and Metastasis Reviews 34:1, 129-144.
CrossRef807
Roy A. Raad, Anna Pavlick, Rajni Kannan, Kent P. Friedman. . (2015) Ipilimumab-Induced Hepatitis on 18F-FDG PET/CT in a Patient With Malignant Melanoma. Clinical Nuclear Medicine 40:3, 258-259.
CrossRef808
S. Ugurel, C. Loquai, K. Kähler, J. Hassel, C. Berking, L. Zimmer, I. Haubitz, I. Satzger, T. Müller-Brenne, N. C. Mikhaimer, J. C. Becker, K. J. Kilian, D. Schadendorf, L. Heinzerling, M. Kaatz, J. Utikal, D. Göppner, C. Pföhler, A. Pflugfelder, R. Mössner, R. Gutzmer. . (2015) A multicenter DeCOG study on predictors of vemurafenib therapy outcome in melanoma: pretreatment impacts survival. Annals of Oncology 26:3, 573-582.
CrossRef809
Douglas B. Johnson, Chengwei Peng, Jeffrey A. Sosman. . (2015) Nivolumab in melanoma: latest evidence and clinical potential. Therapeutic Advances in Medical Oncology 7:2, 97-106.
CrossRef810
Colin R. Lindsay, Pavlina Spiliopoulou, Ashita Waterston. . (2015) Blinded by the light: why the treatment of metastatic melanoma has created a new paradigm for the management of cancer. Therapeutic Advances in Medical Oncology 7:2, 107-121.
CrossRef811
Takeshi Ishikawa, Satoko Adachi, Tetsuya Okayama, Satoshi Kokura, Katsura Mizushima, Toshifumi Doi, Tatsuzo Matsuyama, Naoyuki Sakamoto, Kazuhiro Katada, Kazuhiro Kamada, Kazuhiko Uchiyama, Osamu Handa, Tomohisa Takagi, Yuji Naito, Yoshito Itoh, Toshikazu Yoshikawa. . (2015) Cytotoxic T lymphocyte-associated antigen 4 inhibition increases the antitumor activity of adoptive T-cell therapy when carried out with na�ve rather than differentiated T cells. Oncology Reports.
CrossRef812
Dalil Hannani, Marie Vétizou, David Enot, Sylvie Rusakiewicz, Nathalie Chaput, David Klatzmann, Melanie Desbois, Nicolas Jacquelot, Nadège Vimond, Salem Chouaib, Christine Mateus, James P Allison, Antoni Ribas, Jedd D Wolchok, Jianda Yuan, Philip Wong, Michael Postow, Andrzej Mackiewicz, Jacek Mackiewicz, Dirk Schadendorff, Dirk Jaeger, Alan J Korman, Keith Bahjat, Michele Maio, Luana Calabro, Michele WL Teng, Mark J Smyth, Alexander Eggermont, Caroline Robert, Guido Kroemer, Laurence Zitvogel. . (2015) Anticancer immunotherapy by CTLA-4 blockade: obligatory contribution of IL-2 receptors and negative prognostic impact of soluble CD25. Cell Research 25:2, 208-224.
CrossRef813
Max S. Schreuer, Ines L. Chevolet, Yanina J. Jansen, Teofila C. Seremet, Sofie Wilgenhof, Danielle Liénard, Veronique del Marmol, Bart Neyns. . (2015) Objective responses can be obtained by CTLA-4 inhibition in metastatic melanoma after BRAF inhibitor failure. Melanoma Research 25:1, 68-74.
CrossRef814
Shikha Jain, Joseph I Clark. . (2015) Ipilimumab for the treatment of melanoma. Melanoma Management 2:1, 33-39.
CrossRef815
Naoya Yamazaki, Ryota Tanaka, Arata Tsutsumida, Kenjiro Namikawa, Hironobu Eguchi, Wataru Omata, Kohei Oashi, Toru Ogawa, Amiko Hayashi, Noriyuki Nakamura, Koji Tsuta. . (2015) BRAF V600 mutations and pathological features in Japanese melanoma patients. Melanoma Research 25:1, 9-14.
CrossRef816
C. Rodríguez-Antona, M. Taron. . (2015) Pharmacogenomic biomarkers for personalized cancer treatment. Journal of Internal Medicine 277:2, 201-217.
CrossRef817
Georgia Beasley, Douglas Tyler. . (2015) In-transit Melanoma Metastases: Incidence, Prognosis, and the Role of Lymphadenectomy. Annals of Surgical Oncology 22:2, 358-360.
CrossRef818
E. Dabrowski, E. Dippel. . (2015) Systemische Therapie des fernmetastasierten malignen Melanoms. Der Radiologe 55:2, 99-104.
CrossRef819
Jan Bogaerts, Matthew R. Sydes, Nicola Keat, Andrea McConnell, Al Benson, Alan Ho, Arnaud Roth, Catherine Fortpied, Cathy Eng, Clare Peckitt, Corneel Coens, Curtis Pettaway, Dirk Arnold, Emma Hall, Ernie Marshall, Francesco Sclafani, Helen Hatcher, Helena Earl, Isabelle Ray-Coquard, James Paul, Jean-Yves Blay, Jeremy Whelan, Kathy Panageas, Keith Wheatley, Kevin Harrington, Lisa Licitra, Lucinda Billingham, Martee Hensley, Martin McCabe, Poulam M. Patel, Richard Carvajal, Richard Wilson, Rob Glynne-Jones, Rob McWilliams, Serge Leyvraz, Sheela Rao, Steve Nicholson, Virginia Filiaci, Anastassia Negrouk, Denis Lacombe, Elisabeth Dupont, Iris Pauporté, John J. Welch, Kate Law, Ted Trimble, Matthew Seymour. . (2015) Clinical trial designs for rare diseases: Studies developed and discussed by the International Rare Cancers Initiative. European Journal of Cancer 51:3, 271-281.
CrossRef820
Lynn E. Spitler, Peter Boasberg, Steven O’ Day, Omid Hamid, Scott Cruickshank, Shane Mesko, Robert W. Weber. . (2015) Phase II Study of Nab-Paclitaxel and Bevacizumab as First-line Therapy for Patients with Unresectable Stage III and IV Melanoma. American Journal of Clinical Oncology 38:1, 61-67.
CrossRef821
Derick Okwan-Duodu, Brian P. Pollack, David Lawson, Mohammad K. Khan. . (2015) Role of Radiation Therapy as Immune Activator in the Era of Modern Immunotherapy for Metastatic Malignant Melanoma. American Journal of Clinical Oncology 38:1, 119-125.
CrossRef822
D. Peter O’Leary, Kevin G. Byrnes, Derek G. Power, H. Paul Redmond. . (2015) Surgical management of metastatic melanoma in the era of targeted systemic therapies. Melanoma Research 25:1, 1-8.
CrossRef823
Christine Yu, Inder J Chopra, Edward Ha. . (2015) A novel melanoma therapy stirs up a storm: ipilimumab-induced thyrotoxicosis. Endocrinology, Diabetes & Metabolism Case Reports.
CrossRef824
Harry C. Brastianos, Daniel P. Cahill, Priscilla K. Brastianos. . (2015) Systemic Therapy of Brain Metastases. Current Neurology and Neuroscience Reports 15:2.
CrossRef825
Vafa Shahabi, Michael A. Postow, David Tuck, Jedd D. Wolchok. . (2015) Immune-priming of the Tumor Microenvironment by Radiotherapy. American Journal of Clinical Oncology 38:1, 90-97.
CrossRef826
Juan Martin-Liberal, James Larkin. . (2015) Vemurafenib for the treatment of BRAF mutant metastatic melanoma. Future Oncology 11:4, 579-589.
CrossRef827
Geoffrey Kozak, Fernando F. Blanco, Jonathan R. Brody. . (2015) Novel Targets in Pancreatic Cancer Research. Seminars in Oncology 42:1, 177-187.
CrossRef828
Antoine Hollebecque, David Malka, Charles Ferté, Michel Ducreux, Valérie Boige. . (2015) Systemic treatment of advanced hepatocellular carcinoma: From disillusions to new horizons. European Journal of Cancer 51:3, 327-339.
CrossRef829
James B. Macdonald, Brooke Macdonald, Loren E. Golitz, Patricia LoRusso, Aleksandar Sekulic. . (2015) Cutaneous adverse effects of targeted therapies. Journal of the American Academy of Dermatology 72:2, 221-236.
CrossRef830
Robert , Caroline , Long , Georgina V. , Brady , Benjamin , Dutriaux , Caroline , Maio , Michele , Mortier , Laurent , Hassel , Jessica C. , Rutkowski , Piotr , McNeil , Catriona , Kalinka-Warzocha , Ewa , Savage , Kerry J. , Hernberg , Micaela M. , Lebbé , Celeste , Charles , Julie , Mihalcioiu , Catalin , Chiarion-Sileni , Vanna , Mauch , Cornelia , Cognetti , Francesco , Arance , Ana , Schmidt , Henrik , Schadendorf , Dirk , Gogas , Helen , Lundgren-Eriksson , Lotta , Horak , Christine , Sharkey , Brian , Waxman , Ian M. , Atkinson , Victoria , Ascierto , Paolo A. , . . (2015) Nivolumab in Previously Untreated Melanoma without BRAF Mutation. New England Journal of Medicine 372:4, 320-330.
Free Full Text831
Margaret K. Callahan, Michael A. Postow, Jedd D. Wolchok. . (2015) CTLA-4 and PD-1 Pathway Blockade: Combinations in the Clinic. Frontiers in Oncology 4.
CrossRef832
F. Albarel, C. Gaudy, F. Castinetti, T. Carre, I. Morange, B. Conte-Devolx, J.-J. Grob, T. Brue. . (2015) Long-term follow-up of ipilimumab-induced hypophysitis, a common adverse event of the anti-CTLA-4 antibody in melanoma. European Journal of Endocrinology 172:2, 195-204.
CrossRef833
Giuseppe Bronte, Giovanni Sortino, Francesco Passiglia, Sergio Rizzo, Francesca Lo Vullo, Antonio Galvano, Viviana Bazan, Christian Rolfo, Antonio Russo. . (2015) Monoclonal antibodies for the treatment of non-haematological tumours: update of an expanding scenario. Expert Opinion on Biological Therapy 15:1, 45-59.
CrossRef834
Alessia E Russo, Francesco Ferraù, Giovanna Antonelli, Domenico Priolo, James A McCubrey, Massimo Libra. . (2015) Malignant melanoma in elderly patients: biological, surgical and medical issues. Expert Review of Anticancer Therapy 15:1, 101-108.
CrossRef835
Robert, Caroline, Karaszewska, Boguslawa, Schachter, Jacob, Rutkowski, Piotr, Mackiewicz, Andrzej, Stroiakovski, Daniil, Lichinitser, Michael, Dummer, Reinhard, Grange, Florent, Mortier, Laurent, Chiarion-Sileni, Vanna, Drucis, Kamil, Krajsova, Ivana, Hauschild, Axel, Lorigan, Paul, Wolter, Pascal, Long, Georgina V., Flaherty, Keith, Nathan, Paul, Ribas, Antoni, Martin, Anne-Marie, Sun, Peng, Crist, Wendy, Legos, Jeff, Rubin, Stephen D., Little, Shonda M., Schadendorf, Dirk, . . (2015) Improved Overall Survival in Melanoma with Combined Dabrafenib and Trametinib. New England Journal of Medicine 372:1, 30-39.
Free Full Text836
Emmanouil Fokas. . 2015. New Targeted Therapies for Brain Metastases from Breast and Lung Cancer and Melanoma. Brain Metastases from Primary Tumors, 105-112.
CrossRef837
Carmen Avendaño, J. Carlos Menéndez. . 2015. Biological Therapy of Cancer. Medicinal Chemistry of Anticancer Drugs, 561-593.
CrossRef838
Seongseok Yun, Nicole D. Vincelette, Iyad Mansour, Dana Hariri, Sara Motamed. . (2015) Late Onset Ipilimumab-Induced Pericarditis and Pericardial Effusion: A Rare but Life Threatening Complication. Case Reports in Oncological Medicine 2015, 1-5.
CrossRef839
Nathalie Vigneron. . (2015) Human Tumor Antigens and Cancer Immunotherapy. BioMed Research International 2015, 1-17.
CrossRef840
Anna Niezgoda, Piotr Niezgoda, Rafał Czajkowski. . (2015) Novel Approaches to Treatment of Advanced Melanoma: A Review on Targeted Therapy and Immunotherapy. BioMed Research International 2015, 1-16.
CrossRef841
Manzoor Ahmad Mir. . 2015. T-Cell Costimulation and Its Applications in Diseases. Developing Costimulatory Molecules for Immunotherapy of Diseases, 255-292.
CrossRef842
Davide Bedognetti, Sara Tomei, Wouter Hendrickx, Francesco M. Marincola, Ena Wang. . 2015. Toward the Identification of Genetic Determinants of Responsiveness to Cancer Immunotherapy. Developments in T Cell Based Cancer Immunotherapies, 99-127.
CrossRef843
Gaetano Bertino, Shirin Demma, Annalisa Ardiri, Maria Proiti, Alessandra Mangia, Salvatore Gruttadauria, Adriana Toro, Isidoro Di Carlo, Giulia Malaguarnera, Nicoletta Bertino, Mariano Malaguarnera, Michele Malaguarnera. . (2015) The Immune System in Hepatocellular Carcinoma and Potential New Immunotherapeutic Strategies. BioMed Research International 2015, 1-12.
CrossRef844
Ayumu Ito, Shunsuke Kondo, Kohei Tada, Shigehisa Kitano. . (2015) Clinical Development of Immune Checkpoint Inhibitors. BioMed Research International 2015, 1-12.
CrossRef845
Paolo A. Ascierto, Lars Bastholt, Peter Hersey, Gabriela Cinat, Alexander M. M. Eggermont, Axel Hauschild, Enrique Espinosa, Caroline Robert. . (2015) Side Effects and Toxicities of Targeted Therapies in Stage IV Melanoma. American Journal of Therapeutics 22:1, 44-53.
CrossRef846
Riccardo Danielli, Roberto Patuzzo, Pier Adelchi Ruffini, Andrea Maurichi, Leonardo Giovannoni, Giuliano Elia, Dario Neri, Mario Santinami. . (2015) Armed antibodies for cancer treatment: a promising tool in a changing era. Cancer Immunology, Immunotherapy 64:1, 113-121.
CrossRef847
Patrick A. Ott, F. Stephen Hodi. . 2015. T Cell Modulation: Anti-PD-1 Antibodies for the Treatment of Cancer. Developments in T Cell Based Cancer Immunotherapies, 231-244.
CrossRef848
C. U. Blank, A. Enk. . (2015) Therapeutic use of anti-CTLA-4 antibodies. International Immunology 27:1, 3-10.
CrossRef849
Peter Hersey, Kavitha Gowrishankar. . (2015) Pembrolizumab joins the anti-PD-1 armamentarium in the treatment of melanoma. Future Oncology 11:1, 133-140.
CrossRef850
Jay A. Berzofsky, Lauren V. Wood, Masaki Terabe. . 2015. Strategies for Improving Vaccines to Elicit T Cells to Treat Cancer. Developments in T Cell Based Cancer Immunotherapies, 29-52.
CrossRef851
Ramsey Asmar, Naiyer A. Rizvi. . (2015) Immunotherapy for Advanced Lung Cancer. The Cancer Journal 21:5, 383-391.
CrossRef852
Mara Giavina-Bianchi, Pedro Giavina-Bianchi, Mirian Nacagami Sotto, Alona Muzikansky, Jorge Kalil, Cyro Festa-Neto, Lyn M. Duncan. . (2015) Increased NY-ESO-1 Expression and Reduced Infiltrating CD3+ T Cells in Cutaneous Melanoma. Journal of Immunology Research 2015, 1-8.
CrossRef853
Mark S. Swanson, Uttam K. Sinha. . (2015) Rationale for combined blockade of PD-1 and CTLA-4 in advanced head and neck squamous cell cancer – Review of current data. Oral Oncology 51:1, 12-15.
CrossRef854
Francesca De Felice, Claudia Marchetti, Innocenza Palaia, Daniela Musio, Ludovico Muzii, Vincenzo Tombolini, Pierluigi Benedetti Panici. . (2015) Immunotherapy of Ovarian Cancer: The Role of Checkpoint Inhibitors. Journal of Immunology Research 2015, 1-7.
CrossRef855
William W. Tseng, Shruti Malu, Minying Zhang, Jieqing Chen, Geok Choo Sim, Wei Wei, Davis Ingram, Neeta Somaiah, Dina C. Lev, Raphael E. Pollock, Gregory Lizée, Laszlo Radvanyi, Patrick Hwu. . (2015) Analysis of the Intratumoral Adaptive Immune Response in Well Differentiated and Dedifferentiated Retroperitoneal Liposarcoma. Sarcoma 2015, 1-9.
CrossRef856
Julija Mozūraitienė, Kristina Bielskienė, Vydmantas Atkočius, Danutė Labeikytė. . (2015) Molecular alterations in signal pathways of melanoma and new personalized treatment strategies: Targeting of Notch. Medicina 51:3, 133-145.
CrossRef857
Maria M. Choudhary, Pierre L. Triozzi, Arun D. Singh. . (2015) Uveal Melanoma. International Ophthalmology Clinics 55:1, 45-51.
CrossRef858
(2015) Nippon Jibiinkoka Gakkai Kaiho 118:11, 1366-1367.
CrossRef859
Naamit K. Gerber, Robert J. Young, Christopher A. Barker, Jedd D. Wolchok, Timothy A. Chan, Yoshiya Yamada, Leigh Friguglietti, Kathryn Beal. . (2015) Ipilimumab and whole brain radiation therapy for melanoma brain metastases. Journal of Neuro-Oncology 121:1, 159-165.
CrossRef860
Hina Khan, Rasim Gucalp, Iuliana Shapira. . (2015) Evolving Concepts: Immunity in Oncology from Targets to Treatments. Journal of Oncology 2015, 1-15.
CrossRef861
Takashi Yokoi. . (2015) The Actual State and Potential of Immunotherapy for Lung Cancer. Haigan 55:6, 991-994.
CrossRef862
Manzoor Ahmad Mir. . 2015. Costimulation in Lymphomas and Cancers. Developing Costimulatory Molecules for Immunotherapy of Diseases, 185-254.
CrossRef863
Karim Tazi, Amanda Hathaway, Cody Chiuzan, Keisuke Shirai. . (2015) Survival of melanoma patients with brain metastases treated with ipilimumab and stereotactic radiosurgery. Cancer Medicine 4:1, 1-6.
CrossRef864
Tamar Plitt, Dmitriy Zamarin. . (2015) Cancer therapy with Newcastle disease virus: rationale for new immunotherapeutic combinations. Clinical Investigation 5:1, 75-87.
CrossRef865
Anna Sophie Berghoff, Gerda Ricken, Georg Widhalm, Orsolya Rajky, Karin Dieckmann, Peter Birner, Rupert Bartsch, Christoph Höller, Matthias Preusser. . (2015) Tumour-infiltrating lymphocytes and expression of programmed death ligand 1 (PD-L1) in melanoma brain metastases. Histopathology 66:2, 289-299.
CrossRef866
Vincent C. Lombardi, Svetlana F. Khaiboullina, Albert A. Rizvanov. . (2015) Plasmacytoid dendritic cells, a role in neoplastic prevention and progression. European Journal of Clinical Investigation 45, 1-8.
CrossRef867
Carmen Avendaño, J. Carlos Menéndez. . 2015. General Aspects of Cancer Chemotherapy. Medicinal Chemistry of Anticancer Drugs, 1-22.
CrossRef868
E. M. Hersh, M. Del Vecchio, M. P. Brown, R. Kefford, C. Loquai, A. Testori, S. Bhatia, R. Gutzmer, R. Conry, A. Haydon, C. Robert, S. Ernst, J. Homsi, J. J. Grob, K. Kendra, S. S. Agarwala, M. Li, A. Clawson, C. Brachmann, M. Karnoub, I. Elias, M. F. Renschler, A. Hauschild. . (2015) A randomized, controlled phase III trial of nab -Paclitaxel versus dacarbazine in chemotherapy-naïve patients with metastatic melanoma. Annals of Oncology 26:11, 2267.
CrossRef869
Marco Ranzani, Constantine Alifrangis, Daniele Perna, Ken Dutton-Regester, Antonia Pritchard, Kim Wong, Mamunur Rashid, Carla Daniela Robles-Espinoza, Nicholas K. Hayward, Ultan McDermott, Mathew Garnett, David J. Adams. . (2015) BRAF / NRAS wild-type melanoma, NF1 status and sensitivity to trametinib. Pigment Cell & Melanoma Research 28:1, 117-119.
CrossRef870
Alexander B. Dillon, Kevin Lin, Andrew Kwong, Susana Ortiz, . . (2015) Immunotherapy in Melanoma, Gastrointestinal (GI), and Pulmonary Malignancies. AIMS Public Health 2:1, 86-114.
CrossRef871
Robert D. Leone, Ying-Chun Lo, Jonathan D. Powell. . (2015) A2aR antagonists: Next generation checkpoint blockade for cancer immunotherapy. Computational and Structural Biotechnology Journal 13, 265-272.
CrossRef872
2015. E28 Literaturhinweise und Internetadressen. Facharzt H?matologie Onkologie, e1-e79.
CrossRef873
Paul A. Oakley. . (2015) Is Use of Radiation Hormesis the Missing Link to a Better Cancer Treatment?. Journal of Cancer Therapy 06:07, 601-605.
CrossRef874
Douglas Zippel, Hani Barlev, Rona Ortenberg, Iris Barshack, Jacob Schachter, Gal Markel. . (2014) A longitudinal study of CEACAM1 expression in melanoma disease progression. Oncology Reports.
CrossRef875
Guan Jiang, Rong-Hua Li, Chao Sun, Yan-Qun Liu, Jun-Nian Zheng, Jian-Xin Gao. . (2014) Dacarbazine Combined Targeted Therapy versus Dacarbazine Alone in Patients with Malignant Melanoma: A Meta-Analysis. PLoS ONE 9:12, e111920.
CrossRef876
Y. Yuan. . (2014) Modelling the spatial heterogeneity and molecular correlates of lymphocytic infiltration in triple-negative breast cancer. Journal of The Royal Society Interface 12:103, 20141153-20141153.
CrossRef877
J Naidoo, D B Page, J D Wolchok. . (2014) Immune modulation for cancer therapy. British Journal of Cancer 111:12, 2214-2219.
CrossRef878
Eric E. Schadt, Sean Buchanan, Kristen J. Brennand, Kalpana M. Merchant. . (2014) Evolving toward a human-cell based and multiscale approach to drug discovery for CNS disorders. Frontiers in Pharmacology 5.
CrossRef879
David M. Marcus, Michael Lowe, Mohammad K. Khan, David H. Lawson, Ian R. Crocker, Joseph W. Shelton, Alisa Melton, Necia Maynard, Keith A. Delman, Grant W. Carlson, Monica Rizzo. . (2014) Prognostic Factors for Overall Survival After Radiosurgery for Brain Metastases From Melanoma. American Journal of Clinical Oncology 37:6, 580-584.
CrossRef880
Carminia Della Corte, Morena Fasano, Federica Papaccio, Fortunato Ciardiello, Floriana Morgillo. . (2014) Role of HGF–MET Signaling in Primary and Acquired Resistance to Targeted Therapies in Cancer. Biomedicines 2:4, 345-358.
CrossRef881
Morgan A. O'Brien, Derek G. Power, A. James P. Clover, Brian Bird, Declan M. Soden, Patrick F. Forde. . (2014) Local tumour ablative therapies: Opportunities for maximising immune engagement and activation. Biochimica et Biophysica Acta (BBA) - Reviews on Cancer 1846:2, 510-523.
CrossRef882
Ester Simeone, Antonio Maria Grimaldi, Assunta Esposito, Marcello Curvietto, Marco Palla, Miriam Paone, Nicola Mozzillo, Paolo Antonio Ascierto. . (2014) Serious haematological toxicity during and after ipilimumab treatment: a case series. Journal of Medical Case Reports 8:1.
CrossRef883
Mingjun Wang, Bingnan Yin, Helen Y Wang, Rong-Fu Wang. . (2014) Current advances in T-cell-based cancer immunotherapy. Immunotherapy 6:12, 1265-1278.
CrossRef884
I. Tromme, B. Devleesschauwer, P. Beutels, P. Richez, A. Leroy, J.-F. Baurain, F. Cornelis, C. Bertrand, N. Legrand, J. Degueldre, L. Thomas, C. Legrand, J. Lambert, J. Haagsma, N. Speybroeck. . (2014) Health-related quality of life in patients with melanoma expressed as utilities and disability weights. British Journal of Dermatology 171:6, 1443-1450.
CrossRef885
Alan D Smith, Desam Roda, Timothy A Yap. . (2014) Strategies for modern biomarker and drug development in oncology. Journal of Hematology & Oncology 7:1.
CrossRef886
Sowmya Ravi, Kristen Spencer, Mary Ruisi, Nageatte Ibrahim, Jason J Luke, John A Thompson, Keisuke Shirai, David Lawson, Heddy Bartell, Ragini Kudchadkar, Ngoc Thi Gunter, Janice M Mehnert, Evan J Lipson. . (2014) Ipilimumab administration for advanced melanoma in patients with pre-existing Hepatitis B or C infection: a multicenter, retrospective case series. Journal for ImmunoTherapy of Cancer 2:1.
CrossRef887
Th. Jouary. . (2014) Quoi de neuf en cancérologie cutanée ?. Annales de Dermatologie et de Vénéréologie 141, S630-S642.
CrossRef888
Alfonso Berrocal, Ana Arance, Jose Antonio Lopez Martin, Virtudes Soriano, Eva Muñoz, Lorenzo Alonso, Enrique Espinosa, Pilar Lopez Criado, Javier Valdivia, Salvador Martin Algarra. . (2014) Ipilimumab for advanced melanoma. Melanoma Research 24:6, 577-583.
CrossRef889
Paolo A Ascierto, Raffaele Addeo, Giacomo Cartenì, Bruno Daniele, Michele De Laurentis, Giovanni Pietro Ianniello, Alessandro Morabito, Giovannella Palmieri, Stefano Pepe, Francesco Perrone, Sandro Pignata, Vincenzo Montesarchio. . (2014) The role of immunotherapy in solid tumors: report from the Campania Society of Oncology Immunotherapy (SCITO) meeting, Naples 2014. Journal of Translational Medicine 12:1.
CrossRef890
Scott A Fisher, Amanda Cleaver, Devina D Lakhiani, Andrea Khong, Theresa Connor, Ben Wylie, W Joost Lesterhuis, Bruce WS Robinson, Richard A Lake. . (2014) Neoadjuvant anti-tumor vaccination prior to surgery enhances survival. Journal of Translational Medicine 12:1.
CrossRef891
Chrisann Kyi, Richard D Carvajal, Jedd D Wolchok, Michael A Postow. . (2014) Ipilimumab in patients with melanoma and autoimmune disease. Journal for ImmunoTherapy of Cancer 2:1.
CrossRef892
Demetris Christou, Nicos Katodritis, Marios P. Decatris, Angela Katodritou, Ioannis Michaelides, Nicolaos Nicolaou, Michalis Kounoushis, Panayiotis Hadjicostas. . (2014) Melanoma of the gallbladder: appropriate surgical management and review of the literature. Clinical Case Reports 2:6, 313-318.
CrossRef893
Uwe Trefzer, Ralf Gutzmer, Tabea Wilhelm, Florian Schenck, Katharina C Kähler, Volkmar Jacobi, Klaus Witthohn, Hans Lentzen, Peter Mohr. . (2014) Treatment of unresectable stage IV metastatic melanoma with aviscumine after anti-neoplastic treatment failure: a phase II, multi-centre study. Journal for ImmunoTherapy of Cancer 2:1.
CrossRef894
Vito Michele Garrisi, Sabino Strippoli, Simona De Summa, Rosamaria Pinto, Antonella Perrone, Gabriella Guida, Amalia Azzariti, Michele Guida, Tommasi Stefania, Roger Chammas. . (2014) Proteomic Profile and In Silico Analysis in Metastatic Melanoma with and without BRAF Mutation. PLoS ONE 9:12, e112025.
CrossRef895
Ralph E. Vatner, Benjamin T. Cooper, Claire Vanpouille-Box, Sandra Demaria, Silvia C. Formenti. . (2014) Combinations of Immunotherapy and Radiation in Cancer Therapy. Frontiers in Oncology 4.
CrossRef896
Makoto Wada, Mano Horinaka, Toshikazu Yamazaki, Norito Katoh, Toshiyuki Sakai, Nikolas K. Haass. . (2014) The Dual RAF/MEK Inhibitor CH5126766/RO5126766 May Be a Potential Therapy for RAS-Mutated Tumor Cells. PLoS ONE 9:11, e113217.
CrossRef897
Lawrence E. Flaherty, Megan Othus, Michael B. Atkins, Ralph J. Tuthill, John A. Thompson, John T. Vetto, Frank G. Haluska, Alberto S. Pappo, Jeffrey A. Sosman, Bruce G. Redman, James Moon, Antoni Ribas, John M. Kirkwood, Vernon K. Sondak. . (2014) Southwest Oncology Group S0008: A Phase III Trial of High-Dose Interferon Alfa-2b Versus Cisplatin, Vinblastine, and Dacarbazine, Plus Interleukin-2 and Interferon in Patients With High-Risk Melanoma—An Intergroup Study of Cancer and Leukemia Group B, Children's Oncology Group, Eastern Cooperative Oncology Group, and Southwest Oncology Group. Journal of Clinical Oncology 32:33, 3771-3778.
CrossRef898
Long , Georgina V. , Stroyakovskiy , Daniil , Gogas , Helen , Levchenko , Evgeny , de Braud , Filippo , Larkin , James , Garbe , Claus , Jouary , Thomas , Hauschild , Axel , Grob , Jean Jacques , Chiarion Sileni , Vanna , Lebbe , Celeste , Mandalà , Mario , Millward , Michael , Arance , Ana , Bondarenko , Igor , Haanen , John B.A.G. , Hansson , Johan , Utikal , Jochen , Ferraresi , Virginia , Kovalenko , Nadezhda , Mohr , Peter , Probachai , Volodymyr , Schadendorf , Dirk , Nathan , Paul , Robert , Caroline , Ribas , Antoni , DeMarini , Douglas J. , Irani , Jhangir G. , Casey , Michelle , Ouellet , Daniele , Martin , Anne-Marie , Le , Ngocdiep , Patel , Kiran , Flaherty , Keith , . . (2014) Combined BRAF and MEK Inhibition versus BRAF Inhibition Alone in Melanoma. New England Journal of Medicine 371:20, 1877-1888.
Free Full Text899
Patrick A. Ott, Omid Hamid, Anna C. Pavlick, Harriet Kluger, Kevin B. Kim, Peter D. Boasberg, Ronit Simantov, Elizabeth Crowley, Jennifer A. Green, Thomas Hawthorne, Thomas A. Davis, Mario Sznol, Patrick Hwu. . (2014) Phase I/II Study of the Antibody-Drug Conjugate Glembatumumab Vedotin in Patients With Advanced Melanoma. Journal of Clinical Oncology 32:32, 3659-3666.
CrossRef900
Ramona Krammer, Lucie Heinzerling, Andrzej T. Slominski. . (2014) Therapy Preferences in Melanoma Treatment - Willingness to Pay and Preference of Quality versus Length of Life of Patients, Physicians and Healthy Controls. PLoS ONE 9:11, e111237.
CrossRef901
Angus G Dalgleish. . (2014) Vaccines versus immunotherapy: Overview of approaches in deciding between options. Human Vaccines & Immunotherapeutics 10:11, 3369-3374.
CrossRef902
Katy K Tsai, Inés Zarzoso, Adil I Daud. . (2014) PD-1 and PD-L1 antibodies for melanoma. Human Vaccines & Immunotherapeutics 10:11, 3111-3116.
CrossRef903
Erika J Schneble, Xianzhong Yu, TE Wagner, George E Peoples. . (2014) Novel dendritic cell-based vaccination in late stage melanoma. Human Vaccines & Immunotherapeutics 10:11, 3132-3138.
CrossRef904
William W Tseng, Neeta Somaiah, Edgar G Engleman. . (2014) Potential for immunotherapy in soft tissue sarcoma. Human Vaccines & Immunotherapeutics 10:11, 3117-3124.
CrossRef905
Lawrence Steinman. . (2014) Conflicting consequences of immunity to cancer versus autoimmunity to neurons: Insights from paraneoplastic disease. European Journal of Immunology 44:11, 3201-3205.
CrossRef906
Kent Shih, Hendrik-Tobias Arkenau, Jeffrey R. Infante. . (2014) Clinical Impact of Checkpoint Inhibitors as Novel Cancer Therapies. Drugs 74:17, 1993-2013.
CrossRef907
Dae Won Kim, Van Anh Trinh, Wen-Jen Hwu. . (2014) Ipilimumab in the treatment of advanced melanoma – a clinical update. Expert Opinion on Biological Therapy 14:11, 1709-1718.
CrossRef908
C. Lebbe, J. S. Weber, M. Maio, B. Neyns, K. Harmankaya, O. Hamid, S. J. O'Day, C. Konto, L. Cykowski, M. B. McHenry, J. D. Wolchok. . (2014) Survival follow-up and ipilimumab retreatment of patients with advanced melanoma who received ipilimumab in prior phase II studies. Annals of Oncology 25:11, 2277-2284.
CrossRef909
Gaetano Finocchiaro, Serena Pellegatta. . (2014) Perspectives for immunotherapy in glioblastoma treatment. Current Opinion in Oncology 26:6, 608-614.
CrossRef910
Duarte Domingues, Alice Turner, Maria Dília Silva, Dânia Sofia Marques, Juan Carlos Mellidez, Luciano Wannesson, Giannis Mountzios, Ramon Andrade de Mello. . (2014) Immunotherapy and lung cancer: current developments and novel targeted therapies. Immunotherapy 6:11, 1221-1235.
CrossRef911
Peter Hersey, Hojabr Kakavand, James Wilmott, Andre van der Westhuizen, Stuart Gallagher, Kavitha Gowrishankar, Richard Scolyer. . (2014) How anti-PD1 treatments are changing the management of melanoma. Melanoma Management 1:2, 165-172.
CrossRef912
Laura Gilardi, Chiara Maria Grana, Giovanni Paganelli. . (2014) Evaluation of response to immunotherapy: new challenges and opportunities for PET imaging. European Journal of Nuclear Medicine and Molecular Imaging 41:11, 2090-2092.
CrossRef913
Eric L. Smith, Dmitriy Zamarin, Alexander M. Lesokhin. . (2014) Harnessing the immune system for cancer therapy. Current Opinion in Oncology 26:6, 600-607.
CrossRef914
Rebecca Jane Lee, Noor Ul-Ain-Tariq, Alberto Fusi, Samantha Bowyer, Paul Lorigan. . (2014) The role of chemotherapy in the modern management of melanoma. Melanoma Management 1:2, 173-184.
CrossRef915
Tai Hato, Lipika Goyal, Tim F. Greten, Dan G. Duda, Andrew X. Zhu. . (2014) Immune checkpoint blockade in hepatocellular carcinoma: Current progress and future directions. Hepatology 60:5, 1776-1782.
CrossRef916
Baijun Dong, Laurie J Minze, Wei Xue, Wenhao Chen. . (2014) Molecular insights into the development of T cell-based immunotherapy for prostate cancer. Expert Review of Clinical Immunology 10:11, 1547-1557.
CrossRef917
Mario M. Leitao, Xi Cheng, Anne L. Hamilton, Nadeem A. Siddiqui, Ina Jurgenliemk-Schulz, Sven Mahner, Elisabeth Åvall-Lundqvist, Kidong Kim, Gilles Freyer. . (2014) Gynecologic Cancer InterGroup (GCIG) Consensus Review for Vulvovaginal Melanomas. International Journal of Gynecological Cancer 24, S117-S122.
CrossRef918
Mark S. Walker, Carolina Reyes, Jiandong Kerr, Sacha Satram-Hoang, Edward J. Stepanski. . (2014) Treatment patterns and outcomes among patients with metastatic melanoma treated in community practice. International Journal of Dermatology 53:11, e499-e506.
CrossRef919
D. A. Reardon, G. Freeman, C. Wu, E. A. Chiocca, K. W. Wucherpfennig, P. Y. Wen, E. F. Fritsch, W. T. Curry, J. H. Sampson, G. Dranoff. . (2014) Immunotherapy advances for glioblastoma. Neuro-Oncology 16:11, 1441-1458.
CrossRef920
Christine E Engeland, Christian Grossardt, Rūta Veinalde, Sascha Bossow, Diana Lutz, Johanna K Kaufmann, Ivan Shevchenko, Viktor Umansky, Dirk M Nettelbeck, Wilko Weichert, Dirk Jäger, Christof von Kalle, Guy Ungerechts. . (2014) CTLA-4 and PD-L1 Checkpoint Blockade Enhances Oncolytic Measles Virus Therapy. Molecular Therapy 22:11, 1949-1959.
CrossRef921
Anthony Jarkowski, LeAnn Norris, Van Anh Trinh. . (2014) Controversies in the Management of Advanced Melanoma. Annals of Pharmacotherapy 48:11, 1456-1468.
CrossRef922
2014. Skin and Soft Tissue Lesions. Key Notes on Plastic Surgery, 80-132.
CrossRef923
C G Drake, P Sharma, W Gerritsen. . (2014) Metastatic castration-resistant prostate cancer: new therapies, novel combination strategies and implications for immunotherapy. Oncogene 33:43, 5053-5064.
CrossRef924
Brian S Henick, Roy S Herbst, Sarah B Goldberg. . (2014) The PD-1 pathway as a therapeutic target to overcome immune escape mechanisms in cancer. Expert Opinion on Therapeutic Targets, 1-14.
CrossRef925
James H. Doroshow, Shivaani Kummar. . (2014) Translational research in oncology—10 years of progress and future prospects. Nature Reviews Clinical Oncology 11:11, 649-662.
CrossRef926
Péter Kovács, Gitta Pánczél, Kinga Borbola, Gabriella Juhász, Gabriella Liszkay. . (2014) Psychological Changes in Melanoma Patients During Ipilimumab Treatment Compared to Low-Dose Interferon Alpha Therapy—A Follow-Up Study of First Experiences. Pathology & Oncology Research 20:4, 939-944.
CrossRef927
Géraldine Lescaille, Juliette Rochefort, Rodney Macedo, Aline Le Moignic, Claude Baillou, Véronique Mateo, Chloé Bertolus, François M. Lemoine. . (2014) Immunité et cancers des voies aéro-digestives supérieures 2 e partie. Immunothérapies des cancers des VADS. Médecine Buccale Chirurgie Buccale 20:4, 245-252.
CrossRef928
Iris H. Wei, Mark A. Healy, Sandra L. Wong. . (2014) Surgical Treatment Options for Stage IV Melanoma. Surgical Clinics of North America 94:5, 1075-1089.
CrossRef929
R Donald Harvey, E T Morgan. . (2014) Cancer, Inflammation, and Therapy: Effects on Cytochrome P450–Mediated Drug Metabolism and Implications for Novel Immunotherapeutic Agents. Clinical Pharmacology & Therapeutics 96:4, 449-457.
CrossRef930
April KS Salama, Kevin B Kim. . (2014) Advances in targeted therapy for melanoma: a focus on MEK inhibition. Clinical Investigation 4:10, 903-913.
CrossRef931
N.H. Rekers, E.G.C. Troost, C.M.L. Zegers, W.T.V. Germeraad, L.J. Dubois, P. Lambin. . (2014) Stereotactic ablative body radiotherapy combined with immunotherapy: Present status and future perspectives. Cancer/Radiothérapie 18:5-6, 391-395.
CrossRef932
Dionysios Papadatos-Pastos, Kiruthikah Thillai, Roy Rabbie, Paul Ross, Debashis Sarker. . (2014) FOLFIRINOX – a new paradigm in the treatment of pancreatic cancer. Expert Review of Anticancer Therapy 14:10, 1115-1125.
CrossRef933
Jeffrey S. Weber. . (2014) Current Perspectives on Immunotherapy. Seminars in Oncology 41, S14-S29.
CrossRef934
E. R. Plimack, J. R. Desai, J. P. Issa, J. Jelinek, P. Sharma, L. M. Vence, R. L. Bassett, J. L. Ilagan, N. E. Papadopoulos, W. J. Hwu. . (2014) A phase I study of decitabine with pegylated interferon α-2b in advanced melanoma: impact on DNA methylation and lymphocyte populations. Investigational New Drugs 32:5, 969-975.
CrossRef935
Franziska Roth-Walter, Anna Moskovskich, Cristina Gomez-Casado, Araceli Diaz-Perales, Kumiko Oida, Josef Singer, Tamar Kinaciyan, Heidemarie C. Fuchs, Erika Jensen-Jarolim, Stephen J. Polyak. . (2014) Immune Suppressive Effect of Cinnamaldehyde Due to Inhibition of Proliferation and Induction of Apoptosis in Immune Cells: Implications in Cancer. PLoS ONE 9:10, e108402.
CrossRef936
Christian Rolfo, Giovanni Sortino, Evelien Smits, Francesco Passiglia, Giuseppe Bronte, Marta Castiglia, Antonio Russo, Edgardo S Santos, Annelies Janssens, Patrick Pauwels, Luis Raez. . (2014) Immunotherapy: is a minor god yet in the pantheon of treatments for lung cancer?. Expert Review of Anticancer Therapy 14:10, 1173-1187.
CrossRef937
S. Di Franco, M. Todaro, F. Dieli, G. Stassi. . (2014) Colorectal cancer defeating? Challenge accepted!. Molecular Aspects of Medicine 39, 61-81.
CrossRef938
David McDermott, Celeste Lebbé, F. Stephen Hodi, Michele Maio, Jeffrey S. Weber, Jedd D. Wolchok, John A. Thompson, Charles M. Balch. . (2014) Durable benefit and the potential for long-term survival with immunotherapy in advanced melanoma. Cancer Treatment Reviews 40:9, 1056-1064.
CrossRef939
Maria Chiara Zatelli, Maria Rosaria Ambrosio, Marta Bondanelli, Ettore degli Uberti. . (2014) Pituitary side effects of old and new drugs. Journal of Endocrinological Investigation 37:10, 917-923.
CrossRef940
Christophe Perrin, Marc Pracht, Karen Talour, Henri Adamski, Isabelle Cumin, Marc Porneuf, Marie Talarmin, Habiba Mesbah, Odile Audrain, Aline Moignet, Claudia Lefeuvre-Plesse, Thierry Lesimple. . (2014) Metastatic melanoma: results of ‘classical' second-line treatment with cytotoxic chemotherapies. Journal of Dermatological Treatment 25:5, 396-400.
CrossRef941
Erjian Wang, Dongwoo Kang, Kyun-Seop Bae, Margaret A. Marshall, Dmitri Pavlov, Kourosh Parivar. . (2014) Population pharmacokinetic and pharmacodynamic analysis of tremelimumab in patients with metastatic melanoma. The Journal of Clinical Pharmacology 54:10, 1108-1116.
CrossRef942
P. Kvistborg, D. Philips, S. Kelderman, L. Hageman, C. Ottensmeier, D. Joseph-Pietras, M. J. P. Welters, S. van der Burg, E. Kapiteijn, O. Michielin, E. Romano, C. Linnemann, D. Speiser, C. Blank, J. B. Haanen, T. N. Schumacher. . (2014) Anti-CTLA-4 therapy broadens the melanoma-reactive CD8+ T cell response. Science Translational Medicine 6:254, 254ra128-254ra128.
CrossRef943
Patti Curl, Igor Vujic, Laura J. van ‘t Veer, Susana Ortiz-Urda, James G. Kahn, Andrzej T. Slominski. . (2014) Cost-Effectiveness of Treatment Strategies for BRAF-Mutated Metastatic Melanoma. PLoS ONE 9:9, e107255.
CrossRef944
J. Wang, Z.-Z. Guo, Y.-J. Wang, S.-G. Zhang, D.-G. Xing. . (2014) Microsurgery for the treatment of primary malignant intracranial melanoma: A surgical series and literature review. European Journal of Surgical Oncology (EJSO) 40:9, 1062-1071.
CrossRef945
David E. Gyorki, John Spillane, David Speakman, Mark Shackleton, Michael A. Henderson. . (2014) Current management of advanced melanoma: a transformed landscape. ANZ Journal of Surgery 84:9, 612-617.
CrossRef946
P. Corrie, M. Hategan, K. Fife, C. Parkinson. . (2014) Management of melanoma. British Medical Bulletin 111:1, 149-162.
CrossRef947
Eli T. Sayegh, Taemin Oh, Shayan Fakurnejad, Orin Bloch, Andrew T. Parsa. . (2014) Vaccine therapies for patients with glioblastoma. Journal of Neuro-Oncology 119:3, 531-546.
CrossRef948
Jonathan B. Wallach, Petra Rietschel, Shalom Kalnicki, Jana L. Fox. . (2014) BRAF inhibitor (vemurafenib) concurrent with radiation therapy for metastatic melanoma producing severe skin and oral cavity reactions. Practical Radiation Oncology 4:5, e213-e216.
CrossRef949
Michael T. Schweizer, Charles G. Drake. . (2014) Immunotherapy for prostate cancer: recent developments and future challenges. Cancer and Metastasis Reviews 33:2-3, 641-655.
CrossRef950
Zhi-Hua Huang, Zhan-Yi Sun, Yue Gao, Pu-Guang Chen, Yan-Fang Liu, Yong-Xiang Chen, Yan-Mei Li. . (2014) Strategy for Designing a Synthetic Tumor Vaccine: Multi-Component, Multivalency and Antigen Modification. Vaccines 2:3, 549-562.
CrossRef951
Marielle A.E. Nobbenhuis, Susan Lalondrelle, James Larkin, Susana Banerjee. . (2014) Management of melanomas of the gynaecological tract. Current Opinion in Oncology 26:5, 508-513.
CrossRef952
Marcela S. Villaverde, Kristell Combe, Adriana G. Duchene, Ming X. Wei, Gerardo C. Glikin, Liliana M.E. Finocchiaro. . (2014) Suicide plus immune gene therapy prevents post-surgical local relapse and increases overall survival in an aggressive mouse melanoma setting. International Immunopharmacology 22:1, 167-175.
CrossRef953
Alfonso Berrocal, Luis Cabañas, Enrique Espinosa, Ricardo Fernández-de-Misa, Salvador Martín-Algarra, José Carlos Martínez-Cedres, Luis Ríos-Buceta, José Luis Rodríguez-Peralto. . (2014) Melanoma: Diagnosis, Staging, and Treatment. Consensus group recommendations. Advances in Therapy 31:9, 945-960.
CrossRef954
Giuseppe Lombardi, Anna Luisa Di Stefano, Patrizia Farina, Vittorina Zagonel, Emeline Tabouret. . (2014) Systemic treatments for brain metastases from breast cancer, non-small cell lung cancer, melanoma and renal cell carcinoma: An overview of the literature. Cancer Treatment Reviews 40:8, 951-959.
CrossRef955
Cathrin Balmelli, Michael Mark, Christian Spirig, Vito Spataro, Stefanie Pederiva, Christian Monnerat, Alfred Zippelius, Andreas Wicki. . (2014) Long-term tolerability of the BRAF inhibitor vemurafenib in patients with metastatic melanoma: current study data and real-life observations. memo - Magazine of European Medical Oncology 7:3, 181-186.
CrossRef956
Hans-Joachim Schmoll, Burghardt Wittig, Dirk Arnold, Jorge Riera-Knorrenschild, Dieter Nitsche, Hendrik Kroening, Frank Mayer, Johannes Andel, Reinhard Ziebermayr, Werner Scheithauer. . (2014) Maintenance treatment with the immunomodulator MGN1703, a Toll-like receptor 9 (TLR9) agonist, in patients with metastatic colorectal carcinoma and disease control after chemotherapy: a randomised, double-blind, placebo-controlled trial. Journal of Cancer Research and Clinical Oncology 140:9, 1615-1624.
CrossRef957
Darren M. Palathinkal, Timmie R. Sharma, Henry B. Koon, Jeremy S. Bordeaux. . (2014) Current Systemic Therapies for Melanoma. Dermatologic Surgery 40:9, 948-963.
CrossRef958
Hans Anton Schlößer, Sebastian Theurich, Alexander Shimabukuro-Vornhagen, Udo Holtick, Dirk Ludger Stippel, Michael von Bergwelt-Baildon. . (2014) Overcoming tumor-mediated immunosuppression. Immunotherapy 6:9, 973-988.
CrossRef959
Kea Martin, Philipp Müller, Jens Schreiner, Spasenija Savic Prince, Didier Lardinois, Viola A. Heinzelmann-Schwarz, Daniela S. Thommen, Alfred Zippelius. . (2014) The microtubule-depolymerizing agent ansamitocin P3 programs dendritic cells toward enhanced anti-tumor immunity. Cancer Immunology, Immunotherapy 63:9, 925-938.
CrossRef960
Maria Romina Girotti, Grazia Saturno, Paul Lorigan, Richard Marais. . (2014) No longer an untreatable disease: How targeted and immunotherapies have changed the management of melanoma patients. Molecular Oncology 8:6, 1140-1158.
CrossRef961
Sander Kelderman, Ton N.M. Schumacher, John B.A.G. Haanen. . (2014) Acquired and intrinsic resistance in cancer immunotherapy. Molecular Oncology 8:6, 1132-1139.
CrossRef962
Kue Peng Lim, Nicole Ai Leng Chun, Siti Mazlipah Ismail, Mannil Thomas Abraham, Mohd Nury Yusoff, Rosnah Binti Zain, Wei Cheong Ngeow, Sathibalan Ponniah, Sok Ching Cheong, Frederic Rieux-Laucat. . (2014) CD4+CD25hiCD127low Regulatory T Cells Are Increased in Oral Squamous Cell Carcinoma Patients. PLoS ONE 9:8, e103975.
CrossRef963
Teresa Alonso Gordoa, Javier Puente Vázquez, Eduardo Díaz-Rubio. . 2014. Ipilimumab (Yervoy®). Handbook of Therapeutic Antibodies, 1619-1644.
CrossRef964
Ulf Petrausch, Peter Markus Deckert. . 2014. Monoclonal Antibody Cancer Treatments in Phase III Clinical Trials. Handbook of Therapeutic Antibodies, 735-786.
CrossRef965
Mikiya Ishihara, Naohiro Seo, Jun Mitsui, Daisuke Muraoka, Maki Tanaka, Junichi Mineno, Hiroaki Ikeda, Hiroshi Shiku, Claude Krummenacher. . (2014) Systemic CD8+ T Cell-Mediated Tumoricidal Effects by Intratumoral Treatment of Oncolytic Herpes Simplex Virus with the Agonistic Monoclonal Antibody for Murine Glucocorticoid-Induced Tumor Necrosis Factor Receptor. PLoS ONE 9:8, e104669.
CrossRef966
David A. Smith, Paul Conkling, Donald A. Richards, John J. Nemunaitis, Thomas E. Boyd, Alain C. Mita, Guillaume de La Bourdonnaye, David Wages, Alice S. Bexon. . (2014) Antitumor activity and safety of combination therapy with the Toll-like receptor 9 agonist IMO-2055, erlotinib, and bevacizumab in advanced or metastatic non-small cell lung cancer patients who have progressed following chemotherapy. Cancer Immunology, Immunotherapy 63:8, 787-796.
CrossRef967
Philine Schneider, Margarete Schön, Nadin Pletz, Cornelia S. Seitz, Ningshu Liu, Karl Ziegelbauer, Karolin Zachmann, Steffen Emmert, Michael P. Schön. . (2014) The novel PI3 kinase inhibitor, BAY 80-6946, impairs melanoma growth in vivo and in vitro. Experimental Dermatology 23:8, 579-584.
CrossRef968
Thomas D. Szucs, Daniele Puri, Patricia R. Blank. . (2014) The use of the EVITA algorithm for clinical assessment of novel agents used in prostate cancer, metastatic melanoma, and systemic lupus erythematosus. European Journal of Clinical Pharmacology 70:8, 983-990.
CrossRef969
Steven C. Almo, Chandan Guha. . (2014) Considerations for Combined Immune Checkpoint Modulation and Radiation Treatment. Radiation Research 182:2, 230-238.
CrossRef970
Chante Karimkhani, Rene Gonzalez, Robert P. Dellavalle. . (2014) A Review of Novel Therapies for Melanoma. American Journal of Clinical Dermatology 15:4, 323-337.
CrossRef971
Michael Davidson, Paul Lorigan, James Larkin. . (2014) High-risk cutaneous melanoma follow-up: time for more intensive surveillance?. Melanoma Management 1:1, 7-10.
CrossRef972
A. Paolo, Vanna Chiarion-Sileni, Antonio Muggiano, Mario Mandalà, Nicola Pimpinelli, Michele Del Vecchio, Gaetana Rinaldi, Ester Simeone, Paola Queirolo. . (2014) Interferon alpha for the adjuvant treatment of melanoma: review of international literature and practical recommendations from an expert panel on the use of interferon. Journal of Chemotherapy 26:4, 193-201.
CrossRef973
Paolo A Ascierto. . (2014) Combination therapies in advanced melanoma. Melanoma Management 1:1, 47-56.
CrossRef974
Siwen Hu-Lieskovan, Lidia Robert, Blanca Homet Moreno, Antoni Ribas. . (2014) Combining Targeted Therapy With Immunotherapy in BRAF -Mutant Melanoma: Promise and Challenges. Journal of Clinical Oncology 32:21, 2248-2254.
CrossRef975
Zineb Belcaid, Jillian A. Phallen, Jing Zeng, Alfred P. See, Dimitrios Mathios, Chelsea Gottschalk, Sarah Nicholas, Meghan Kellett, Jacob Ruzevick, Christopher Jackson, Emilia Albesiano, Nicholas M. Durham, Xiaobu Ye, Phuoc T. Tran, Betty Tyler, John W. Wong, Henry Brem, Drew M. Pardoll, Charles G. Drake, Michael Lim, Mike Chen. . (2014) Focal Radiation Therapy Combined with 4-1BB Activation and CTLA-4 Blockade Yields Long-Term Survival and a Protective Antigen-Specific Memory Response in a Murine Glioma Model. PLoS ONE 9:7, e101764.
CrossRef976
Ignacio Melero, Gustav Gaudernack, Winald Gerritsen, Christoph Huber, Giorgio Parmiani, Suzy Scholl, Nicholas Thatcher, John Wagstaff, Christoph Zielinski, Ian Faulkner, Håkan Mellstedt. . (2014) Therapeutic vaccines for cancer: an overview of clinical trials. Nature Reviews Clinical Oncology 11:9, 509-524.
CrossRef977
Ghaith Bakdash, Inge Schreurs, Gerty Schreibelt, Jurjen Tel. . (2014) Crosstalk between dendritic cell subsets and implications for dendritic cell-based anticancer immunotherapy. Expert Review of Clinical Immunology 10:7, 915-926.
CrossRef978
U. Urner-Bloch, M. Urner, P. Stieger, N. Galliker, N. Winterton, A. Zubel, L. Moutouh-de Parseval, R. Dummer, S. M. Goldinger. . (2014) Transient MEK inhibitor-associated retinopathy in metastatic melanoma. Annals of Oncology 25:7, 1437-1441.
CrossRef979
Jean A. Klastersky. . (2014) Adverse events of targeted therapies. Current Opinion in Oncology 26:4, 395-402.
CrossRef980
Mario E. Lacouture, Jedd D. Wolchok, Gil Yosipovitch, Katharina C. Kähler, Klaus J. Busam, Axel Hauschild. . (2014) Ipilimumab in patients with cancer and the management of dermatologic adverse events. Journal of the American Academy of Dermatology 71:1, 161-169.
CrossRef981
U. Leiter, F. Meier, C. Garbe. . (2014) Zielgerichtete und immunologische Therapieansätze beim malignen Melanom. Der Hautarzt 65:7, 600-606.
CrossRef982
Giulio Tosti, Emilia Cocorocchio, Elisabetta Pennacchioli, Pier Francesco Ferrucci, Alessandro Testori, Chiara Martinoli. . (2014) Heat-shock proteins-based immunotherapy for advanced melanoma in the era of target therapies and immunomodulating agents. Expert Opinion on Biological Therapy 14:7, 955-967.
CrossRef983
Yan Feng, Eric Masson, David Dai, Susan M. Parker, David Berman, Amit Roy. . (2014) Model-based clinical pharmacology profiling of ipilimumab in patients with advanced melanoma. British Journal of Clinical Pharmacology 78:1, 106-117.
CrossRef984
Andrew J.S. Furness, Frederick Arce Vargas, Karl S. Peggs, Sergio A. Quezada. . (2014) Impact of tumour microenvironment and Fc receptors on the activity of immunomodulatory antibodies. Trends in Immunology 35:7, 290-298.
CrossRef985
Evan J. Lipson, Mabel A. Bodell, Edward S. Kraus, William H. Sharfman. . (2014) Successful Administration of Ipilimumab to Two Kidney Transplantation Patients With Metastatic Melanoma. Journal of Clinical Oncology 32:19, e69-e71.
CrossRef986
E. Greenberg, S. Hajdu, Y. Nemlich, R. Cohen, O. Itzhaki, J. Jacob-Hirsch, M. J. Besser, J. Schachter, G. Markel. . (2014) Differential regulation of aggressive features in melanoma cells by members of the miR-17-92 complex. Open Biology 4:6, 140030-140030.
CrossRef987
Mary Ann N. Johnson, April W. Armstrong. . 2014. Treatment of Cutaneous Melanoma. Evidence-Based Dermatology, 231-240.
CrossRef988
James R Wong, Afshan A Nanji, Anat Galor, Carol L Karp. . (2014) Management of conjunctival malignant melanoma: a review and update. Expert Review of Ophthalmology 9:3, 185-204.
CrossRef989
A. Moya-Plana, C. Robert, O. Laccourreye, F. Janot. . (2014) Métastase sous-cutanée jugale de mélanome malin. Annales françaises d'Oto-rhino-laryngologie et de Pathologie Cervico-faciale 131:3, 176-178.
CrossRef990
Vernon K. Sondak, Geoffrey T. Gibney. . (2014) Surgical Management of Melanoma. Hematology/Oncology Clinics of North America 28:3, 455-470.
CrossRef991
Martina Sanlorenzo, Igor Vujic, Christian Posch, Akshay Dajee, Adam Yen, Sarasa Kim, Michelle Ashworth, Michael D Rosenblum, Alain Algazi, Simona Osella-Abate, Pietro Quaglino, Adil Daud, Susanna Ortiz-Urda. . (2014) Melanoma immunotherapy. Cancer Biology & Therapy 15:6, 665-674.
CrossRef992
Ahmed I. Megahed, Henry B. Koon. . (2014) What Is the Role of Chemotherapy in the Treatment of Melanoma?. Current Treatment Options in Oncology 15:2, 321-335.
CrossRef993
Damien Kee, Grant McArthur. . (2014) Targeted Therapies for Cutaneous Melanoma. Hematology/Oncology Clinics of North America 28:3, 491-505.
CrossRef994
A. Moya-Plana, C. Robert, O. Laccourreye, F. Janot. . (2014) Hypodermal metastasis of malignant melanoma to the cheek. European Annals of Otorhinolaryngology, Head and Neck Diseases 131:3, 189-191.
CrossRef995
Erika Vacchelli, Fernando Aranda, Florine Obrist, Alexander Eggermont, Jérôme Galon, Isabelle Cremer, Laurence Zitvogel, Guido Kroemer, Lorenzo Galluzzi. . (2014) Trial watch. OncoImmunology 3:6, e29030.
CrossRef996
Eugene D Kwon, Charles G Drake, Howard I Scher, Karim Fizazi, Alberto Bossi, Alfons J M van den Eertwegh, Michael Krainer, Nadine Houede, Ricardo Santos, Hakim Mahammedi, Siobhan Ng, Michele Maio, Fabio A Franke, Santhanam Sundar, Neeraj Agarwal, Andries M Bergman, Tudor E Ciuleanu, Ernesto Korbenfeld, Lisa Sengeløv, Steinbjorn Hansen, Christopher Logothetis, Tomasz M Beer, M Brent McHenry, Paul Gagnier, David Liu, Winald R Gerritsen. . (2014) Ipilimumab versus placebo after radiotherapy in patients with metastatic castration-resistant prostate cancer that had progressed after docetaxel chemotherapy (CA184-043): a multicentre, randomised, double-blind, phase 3 trial. The Lancet Oncology 15:7, 700-712.
CrossRef997
Danielle M. Bello, Ronald P. DeMatteo, Charlotte E. Ariyan. . (2014) The GIST of Targeted Therapy for Malignant Melanoma. Annals of Surgical Oncology 21:6, 2059-2067.
CrossRef998
Berna C. Özdemir, Tsvetelina Pentcheva-Hoang, Julienne L. Carstens, Xiaofeng Zheng, Chia-Chin Wu, Tyler R. Simpson, Hanane Laklai, Hikaru Sugimoto, Christoph Kahlert, Sergey V. Novitskiy, Ana De Jesus-Acosta, Padmanee Sharma, Pedram Heidari, Umar Mahmood, Lynda Chin, Harold L. Moses, Valerie M. Weaver, Anirban Maitra, James P. Allison, Valerie S. LeBleu, Raghu Kalluri. . (2014) Depletion of Carcinoma-Associated Fibroblasts and Fibrosis Induces Immunosuppression and Accelerates Pancreas Cancer with Reduced Survival. Cancer Cell 25:6, 719-734.
CrossRef999
Michelle T. Ashworth, Adil I. Daud. . (2014) Combinatorial Approach to Treatment of Melanoma. Hematology/Oncology Clinics of North America 28:3, 601-612.
CrossRef1000
Allison Ackerman, Oliver Klein, David F. McDermott, Wei Wang, Nageatte Ibrahim, Donald P. Lawrence, Anasuya Gunturi, Keith T. Flaherty, F. Stephen Hodi, Richard Kefford, Alexander M. Menzies, Michael B. Atkins, Georgina V. Long, Ryan J. Sullivan. . (2014) Outcomes of patients with metastatic melanoma treated with immunotherapy prior to or after BRAF inhibitors. Cancer 120:11, 1695-1701.
CrossRef
- Letters
- Metrics
Social Media statistics are not yet available.